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Abstract 
During recent years, the use of functional ingredients in aquaculture industry 
has increased dramatically. Accordingly, there are a broad range of 
functional feeds available for use in fish farming. As a result, there is ongoing 
research which focuses on developing oral delivery systems for fish. Variety 
of products can be incorporated into alginate matrices to avoid damage from 
the low pH and proteolytic enzymes encountered in the digestive tract of fish. 
However, there has been very little research reported on the effectiveness of 
those oral delivery systems with respect to performance within fish feed and 
fish. Furthermore, the reported particle sizes used within alginate delivery 
systems require further reduction to be suitable for effective association 
within feed pellets. Additionally, it is essential that active compounds are 
released at the right place in fish.  
In this study, encapsulation technology capable of providing an economical 
and high throughput method for producing fine alginate beads (≤10 µm) was 
assessed. Post-coating examination with the micro-tomography (micro-CT) 
equipment confirmed the presence of alginate particles inside the pellet in 
large numbers. According to our observations in an enzyme assay, the active 
compounds are released at the most favourable site in Atlantic salmon which 
is the distal intestine. There is also evidence to suggest that alginate-
encapsulated protein antigens when released in the intestine are capable of 
crossing the intestinal epithelial layer. Similarly, in the assessment of 
intraperitoneal priming/oral boosting strategy against infectious pancreatic 
necrosis (IPN), alginate-encapsulated IPN antigens boosted immune 
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response in salmon. This could be seen in significant up-regulation of 
relevant genes measured by quantitative PCR and specific antibody 
response detected in an ELISA assay.   
The results of these investigative studies significantly improve understanding 
of the issues regarding incorporation of delivery systems into fish feed in the 
current manufacturing process leading to a novel approach for functionalizing 
fish feed.  
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Chapter One: General Introduction 
1.1  Lay summary 
Intensification of aquaculture has led to an increasing frequency of outbreaks 
of infectious viral disease, resulting in high economic losses and fish 
mortality. Infectious Pancreatic Necrosis (IPN) emerged as a very important 
disease with large impact on salmon production in the European Union and 
Norway. It is primarily an acute, clinical disease in young salmonid fish. The 
IPN virus is a good model virus to work with because of being very well 
characterised and understood while other viruses are less well documented. 
Equally, the experience and technology acquired working with IPN could 
easily be applied to other viral disease.  
The common scientific view in aquaculture is that some viral vaccines are not 
effective enough in the field and may not exert sufficient long-lasting 
protective effects. For this reason, there is a growing demand from fish 
farmers for an effective oral vaccine against the viral diseases. At present 
there are few, if any, effective oral vaccines in the market.  
For sensitive antigens, various delivery options involving polymeric coatings 
and encapsulation are being evaluated and tested. These various options 
involve synthetic and naturally occurring polymers such as alginate. The 
advantages of using natural polymers include their low cost, biocompatibility 
and aqueous solubility.  
Despite the fact that an extensive research on alginate is going on, there are 
several factors that remain to be explored before adopting alginates as an 
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oral delivery system for viral antigens to salmonid fish. For instance, many 
oral vaccines have been found ineffective as a result of insufficient uptake of 
antigen due to degradation in the digestive tract. Furthermore, size of 
alginate beads needs further reduction in order to be suitable for an effective 
incorporation into fish feed pellets. At the same time, there are no scientific 
reports about assessing in vitro release of macromolecular drugs from 
alginates at test conditions relevant for A. salmon. Similarly, very few studies 
provide evidence of macromolecular drug release in the intestinal region of 
salmonid fish. Currently unexplored as well is the ability of alginate to protect 
protein antigens throughout the entire fish feed production process.  
The aforementioned issues are addressed in four chapters (Ch. 3, 4, 5 and 6) 
of this thesis. Thus, Chapter 3 deals with the uptake of IPNV antigen and the 
ability of antigen to immunise salmon. Chapter 4 addresses issues related to 
the release from alginate matrices. Size of alginate microbeads was adapted 
for better integration with fish feed in Chapter 5. Ultimately, stability of 
antigens in fish feed production process was assessed in Chapter 6.    
Before modifying and improving, exploring the full potential of IPNV antigen 
with frequently tested alginate technology was the most sensible assessment 
to start with. Hence, the assessment of uptake and immunogenicity of IPNV 
antigen were selected as the initial trails (Chapter 3). Previous to these trails, 
adverse effects and efficiency of the encapsulation method were studied 
(Section 3.2). It was necessary to check whether the encapsulation process 
(electrospraying) was damaging to the antigen. Additionally, the 
encapsulation efficiency of IPNV antigen in alginate matrix/microbeads had to 
be determined. This was necessary to know for determining the 
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concentration of antigen in microbeads as accurately as possible. These two 
experiments are described in Section 3.2.1 while Section 3.2.2 presents the 
results and Section 3.5 discusses them. In fact, all results obtained in 
Chapter 3 are discussed in Section 3.5.    
In the next instance, the uptake of free antigen was compared to the uptake 
of encapsulated antigen (Section 3.3). The encapsulated antigen was 
entrapped in calcium alginate matrix. The uptake study, which was carried 
out by oral intubation, is described in Section 3.3.1 while Section 3.3.2 
presents the results. 
In the final instance, the ability of both encapsulated and free antigen to 
immunise A. salmon was investigated in a feeding study (Section 3.4). In this 
study, ethylenediammonium alginate was introduced as a novel oral delivery 
system for fish. The immune response study by feeding is described in 
Section 3.4.1 while Section 3.4.2 presents the results.  
To develop a fast-dissolving and temperature-independent oral delivery 
system within the temperature range of seawater in which A. salmon 
habituate, a series of dissolution tests were conducted. Firstly, it was 
necessary to determine encapsulation efficiency of blue dextran which 
served as a model compound in the dissolution testing. Secondly, it was also 
necessary to develop a new dissolution test. The new test was required to be 
more representative for the mechanisms of alginate disintegration in the 
gastrointestinal tract of A. salmon. Dissolution testing is described and the 
results are discussed in Section 4.2. 
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To check whether the in vitro dissolution tests are consistent with the actual 
release from alginate matrices in fish, two in vivo tests were carried out. The 
first in vivo experiment was performed with the aim of visualising dissolution 
of alginate microbeads loaded with cardiogreen by an in vivo imagining 
technique. The second in vivo experiment was conducted with the purpose of 
localising the site where most of the release from alginate matrices occurred. 
The first trial is detailed in Section 4.3 while the second trial is elaborated in 
Section 4.4.    
After all, the main vehicle for an oral delivery system intended for farmed fish 
is the feed pellet. Fish feed pellets are extruded in a process which involves 
high temperature, pressure and shear force. Optionally, alginate microbeads 
can be incorporated into feed pellets before extrusion in a vacuum coater and 
after extrusion in a meal mixer. Thus, Chapter 5 deals with the issues related 
to the post-extrusion addition, while the pre-extrusion addition is addressed in 
Chapter 6. The main problem related to the post-extrusion addition is the low 
ability of microbeads to fuse with the feed pellets. This issue is linked to the 
size of pellet pores along with the size of microbeads.    
For this reason, the feed pellet pores were characterised by mercury 
intrusion porosimetry and scanning electron microscopy. In addition, feed 
pellets, which were infused with alginate microbeads in a vacuum coater, 
were scanned by micro–computed tomography. These experiments are 
described in Section 5.2 while Section 5.2.2 presents and discuss the results.  
Nevertheless, it was preferred to further reduce the size of microbeads. 
Therefore, the encapsulation process, namely air pressure-assisted 
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energised jetting (APAEJ) was optimised to produce the smallest attainable 
alginate microbeads. This experiment is described in Section 5.3 while the 
results are presented and discussed in its subsections.  
Finally, the morphology of the obtained alginate microbeads were 
characterised by using an imaging particle analysis system in Section 5.4. 
The results were discussed as they were presented in Section 5.4.2. At the 
end, an overall conclusion for Chapter 5 was drawn in Section 5.5.   
The major issue related to the pre-extrusion addition is the survival of protein 
antigens throughout the fish feed production process. In order to learn 
whether IPNV antigen is able to get undamaged through an entire feed 
production process, a stability test was performed in Chapter 6. The test is 
described in Section 6.2 while the results are discussed in Section 6.3. 
Chapter 7 concludes the thesis. It discusses the major findings, provides 
guidelines for future directions and draws a general conclusion 
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1.2 General overview 
In the mid-60s Norwegian fish farmers started cultivating Atlantic salmon 
(Salmo salar) (Tilseth et al., 1991). The growth of the industry has been 
particularly rapid from 1980 onwards (Liu et al., 2011). Since then, salmon 
aquaculture has experienced remarkable growth. In slightly less than 30 
years, global salmon production increased from 5,288 tonnes in 1980 to 
more than 1.7 million tonnes in 2012 with a farm gate value of over $ 7 
billion. Norway dominates this production, accounting for 60% by volume and 
50% by value (FAO, 2012).  
Intensification of aquaculture has led to an increasing number and frequency 
of infectious viral disease outbreaks, resulting in high economic losses and 
fish mortality. The most important contagious and loss-making viral diseases 
are infectious pancreatic necrosis (IPN) (Cepeda et al., 2011), infectious 
salmon anemia (ISA) (Toennessen et al., 2010), pancreas disease (PD) 
(Jansen et al., 2014), cardiomyopathy syndrome (CMS) (Haugland et al., 
2011) and heart and skeleton muscle inflammation (HSMI) (Kristoffersen et 
al., 2013).  
IPN is very important disease with large impact on salmon production in the 
European Union and Norway (Skjelstad et al., 2003). It is primarily an acute, 
clinical disease in young freshwater salmonids (Pedersen, 2007). For that 
reason, IPN is a cause of high morality in first feeding fry (Roberts and 
Pearson, 2005). However, the number of outbreaks is also high during the 
first months after transferring salmon smolt to seawater (Jarp et al., 1995; 
Smail et al., 1995). Generally, IPN virus attacks salmon in its very critical 
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stages of development. It is usually the first viral infection affecting these fish. 
Consequently, the disease can influence the outcome of the secondary 
infections as well (Johansen and Sommer, 2001; Johansen et al., 2009). 
Therefore, there is a common wish in aquaculture industry to gain control of 
the disease. By doing so, vulnerable smolts would become more resistant to 
the other diseases.  
From the Figure 1.1 it can be seen that fish mostly at risk of succumbing to 
PD in early summer (May and June) or early autumn (September and 
October) (Rodger and Mitchell, 2007). The observed period of clinical HSMI 
and mortality was from June to August (Kongtorp et al., 2006). HSMI is 
normally observed five to nine months after transfer to sea water while 
clinical CMS first occurs after 12 to 18 months (Palacios et al., 2010). The 
ISA outbreaks occur in all seasons with a peak during spring (April–June) 
and autumn (October–December) (Lyngstad et al., 2008). 
IPN virus belongs to the genus Aquabirnavirus within the family Birnaviridae. 
A brinavirus has double stranded RNA which codes for the five viral proteins 
VP1-VP5 (Bain et al., 2008). The proteins are arranged into a non-enveloped 
T=13 icosahedral structure with an average diameter of 70 nm. The capsid is 
composed of 260 trimeric spikes formed by VP2 (Coulibaly et al., 2010). In 
particular, VP2 is assumed to be major carriers of IPN virus virulence 
properties (Song et al., 2005). IPNV is a good model virus to work with 
because of being well characterised and VP2 being very well understood 
while other viruses are less well documented (Rodrguez Saint-Jean et al., 
2010). 
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Development of an effective IPN vaccine is important as well for a sustained 
control of the disease in salmon farming. There are three major modes for 
the application of vaccines: injection, immersion and oral. According to the 
Norwegian Medicines Agency, there are currently four commercial injection 
vaccines (Pentium Forte Plus vet, Novartis; Norvax Minova 6 vet, Intervet; 
Alpha Ject 6-2 and Alpha Ject Micro 6, Pharmaq). These vaccines are based 
on both killed virus particles and recombinant VP2 capsid protein.  
Good protective effect of the IPN vaccine based on recombinant VP2 has 
been obtained in laboratory and field experiments (Ramstad et al., 2007). 
Although the number of IPN outbreaks in Norway shows a decreasing trend 
from 2010 (198 outbreaks) to 2012 (119 outbreaks), it is still very high 
(Johansen, 2013). However, the actual losses due to IPN appear to have 
declined in recent years. This decline could be attributed to the extensive 
vaccination programme (Munang’andu et al., 2014; Robertsen, 2011), 
improved husbandry and gene typing by quantitative trait loci (QTL) 
technique for resistant individuals (Moen et al., 2009).  
Accidentally, salmon, which have pulled through an IPNV infection, may 
become an asymptomatic carrier of the virus for a long time. As a 
consequence, production of the virus may resume in the stressed carriers 
anytime in the future. In that case, the re-infected fish can spread the virus to 
the surrounding fish and thus cause a new outbreak (Gadan et al., 2013; 
Skjesol et al., 2011). There are indications that the effect of IPN is pro-
inflammatory and may lead to some immune suppression in the carriers 
(Collet, 2014; Ellis et al., 2010). This may increase risk from subsequent 
diseases such as HSMI (Kongtorp et al., 2006).  
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The common scientific view in aquaculture is that some viral vaccines are not 
effective enough in the field and may not exert sufficient long-lasting 
protective effects (Robertsen, 2011). Generally, viral vaccines are short lived. 
For this reason, there is a growing demand from fish farmers for an effective 
oral vaccine against the viral diseases. Delivery of oral vaccines would allow 
a booster immunisation to occur after some months in seawater (Villumsen et 
al., 2014).  
According to current practice, after injection with oil based vaccines, 
subsequent vaccinations are not usually carried out. The only known 
exception is the vaccination against piscirickettsiosis in Chile where injection 
is followed by oral booster vaccination (Brudeseth et al., 2013). The reason 
for this is the lack of effective oral vaccines in the market although the oral 
vaccination is the most feasible method from the perspective of a fish farmer.     
Some of the beneficial characteristics assigned to the oral vaccination are 
described as labour-saving, non-stressful and large-scale applicable to fish in 
the seawater cages (Adelmann et al., 2008). There are also some negative 
characteristics related to the oral vaccination. For example, administration of 
an exact antigen dose is challenging due to variable feed consumption 
among fish. Moreover, delivery of intact antigens through the acidic part of 
the gut is problematic in gastric fish (Dhar, 2013; Quentel and Vigneulle, 
1997). All this leads to another issue with the oral vaccination which is the 
high dosage requirement. Consequently, the economic viability of an oral 
vaccine project is always challenged. Additionally, ineffective uptake, short 
term protection and high dosage requirement are factors that prevent oral 
vaccines from being favoured as the primary choice in treating diseased fish. 
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It has always been a challenge to deliver medicines and functional 
ingredients to farmed fish. The only available oral delivery system to farmed 
salmon is the fish feed pellet produced by extrusion cooking. The extrusion 
cooking is often called the high temperature short time (HTST) process. This 
kind of processes tends to maximise the beneficial effects of heating feeds 
while minimising the detrimental effects (Harper, 1978).  
According to current knowledge, most biological proteins will lose their 
higher-order structure after being exposed to heat treatment. As a result, they 
become denatured and may coagulate. Loss of three-dimensional structure 
usually produces a loss of biological activity (Privalle et al., 2011).  
For sensitive antigens, various approaches involving polymeric coatings or 
encapsulation are being evaluated and tested (Bruno et al., 2013; Pinto Reis 
et al., 2013; Singh and O’Hagan, 1998). These various approaches include 
naturally occurring polymers: starch, gelatine, alginates and synthetic 
polymers: polylactide-co-glycolide (PLG), proteinoid microspheres, cellulose 
acetate phthalates (CAP), methacrylates (MAA), methyl methacrylates 
(MMA), polyanhydrides (Singh and O’Hagan, 1998). Furthermore, 
mesoporous silica nanoparticles (MSN) are another synthetic approach. This 
material have recently been investigated for its potential as drug delivery 
system (Urabe et al., 2007).  
The advantages of using natural polymers include their low cost, 
biocompatibility and aqueous solubility. In contrast, synthetic polymers can 
be prepared with a desired degradation rate.  
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With annual production of 6,700 tonnes, Norway is the world's leading 
producer of alginate. This ensures good availability and makes this raw 
material very interesting in this context (Bixler and Porse, 2011). Marine 
alginate is an ideal polymer for oral delivery systems exhibiting protective 
features (Augst et al., 2006). Alginate encapsulation may protect bioactive 
compounds from acidic and proteolytic degradation in the gastrointestinal 
tract of the fish. Cross-linked alginate is characterised by being stable at low 
pH and soluble in the alkaline environment (Maurice et al., 2004; Tian et al., 
2008). As a result, antigens entrapped in an alginate matrix are protected 
throughout the stomach, and then released in the intestinal region of the gut 
where their chances for uptake are maximized (Rombout et al., 2011). 
Despite the fact that extensive research on alginate is going on, there are 
several factors that remain to be explored before adopting alginates as an 
oral delivery system for salmonid fish. For instance, particle size of the 
delivery systems based on alginates needs further reduction in order to be 
suitable for an effective incorporation into fish feed pellets. At the same time, 
there are no scientific reports about assessing release of macromolecular 
drugs from alginates at test conditions relevant for A. salmon. Similarly, very 
few studies provide evidence of macromolecular drug release in the intestinal 
region of salmonid fish. In addition, ability of alginate to protect protein 
antigens throughout fish feed production process and fish itself is currently 
unexplored.   
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Figure 1.1: Life cycle of farmed A. salmon with potential outbreaks of viral 
diseases. Orange arrow represents autumn smolt cycle while green arrow 
represents spring smolt. The most important contagious and loss-making 
viral diseases are mapped: infectious pancreatic necrosis (IPN), infectious 
salmon anaemia (ISA), pancreas disease (PD), cardiomyopathy syndrome 
(CMS) and heart and skeleton muscle inflammation (HSMI). 
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1.3 Immune response 
From the previous section it becomes evident that the ability to help antigens 
immunise the host is one of the key criteria for a promising oral delivery 
system to A. salmon. In order to be able to measure the effects of 
immunisation, it is important to understand how the immune system can 
respond to a delivered antigen. This understanding is crucial for selecting 
useful markers that can reveal which immune pathways are induced by the 
ingested antigen.  
For clarity reasons, only the basic immune factors, which are relevant for the 
immune response study described in Chapter 3, are reviewed in this Section. 
Since immunology is a complex matter, the immune system here is depicted 
as simply as possible.  
Firstly, the ingested antigens are processed by antigen presenting cells 
(APC). After processing antigens, APCs present their fragments to T cells, 
particularly naïve CD4+ T cells (Th0 cells). From this point, immune response 
can go in at least two main directions (Figure 1.2). One direction is the Th1 
response which induces the cell-mediated immune system. Second direction 
is the Th2 response which induces the humoral immunity (Collet, 2014; 
Romagnani, 2000). Furthermore, there is a third response (Th3) which is 
balancing Th1 and Th2 cytokines to prevent serious cell-mediated 
inflammatory reactions. This mechanism mainly acts in mucosal tissue 
(Strober et al., 1997). However, T cells can also differentiate into regulatory T 
cells (Treg). As a result, immune functions can be suppressed by induced Treg 
(Kumari et al., 2013). Consequently, fish may develop immune tolerance 
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(Sakaguchi et al., 2008). It is considered that both very high and very low 
dose of the same antigen may induce immune tolerance (Möbs et al., 2008; 
Zouali, 2014). 
In the cell-mediated immune response, Th0 cells are activated and developed 
into effector Th1 cells against intracellular bacteria, virus and protozoa. The 
major effectors of the cellular immunity are macrophages and cytotoxic T 
cells. The differentiation into Th1 cells is activated by IL-12 and INF-γ 
cytokines (Wang and Husain, 2014). The rate of transcription is controlled by 
T-bet and STAT4 transcription factors (Whitmire, 2014). 
In the humoral immune response, the naïve T cells develop into effector T 
cells against extracellular microorganisms including helminths. This 
development is activated by IL-4 and IL-10 among others interleukins 
(McKenzie et al., 1998). On the other hand, transcription is controlled by 
GATA-3 and STAT6 transcription factors (Kumari et al., 2009; Urban et al., 
1998). The major effector cells of the humoral immunity are eosinophils 
(Damask, 2015), basophils (Schwartz et al., 2015), mast cells (Gregory et al., 
2005) and B cells. Eventually, B cells are transformed into immunoglobulins 
(Ig) or antibodies (Marrella et al., 2015). According to the present knowledge, 
there are only three major Ig isotypes in A. salmon. These are: IgM that is 
systemic antibody and IgD along with IgT that are mucosal antibodies 
(Hordvik, 2015; Rombout et al., 2011). 
Unlike Th cells, Treg cells generally suppress induction and proliferation of 
effector T cells (Möbs et al., 2008). This is an important feature of the 
immune system when an infection is eliminated. In addition, Tregs can limit 
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inflammatory responses and prevent autoimmunity (Gol-Ara et al., 2012).  
Production of Treg cells is triggered by TGF-β and IL-6 cytokines (Li and 
Flavell, 2008). Factors such as FoxP3 and STAT5 control the rate of 
transcription (Chen et al., 2003; Hori et al., 2003). 
In this thesis, IPNV antigen was used with the purpose of inducing the 
humoral or adaptive immunity. Adaptive immunity involves activation of T 
cells and B cells that can initiate a tailored immune response to a specific 
pathogen (Rote, 2007). For this reason, gene expression of IgM, IgT, CD4, 
GATA-3 and IL-10 was of special interest. The cytokine IL-10 was selected 
because of its ability to both activate Th2  and inhibit the Th1 pathway (Tec 
and Morita, 2015; Zhou et al., 2007). IL-10 has a potent immunosuppressive 
capacity towards Th1 route (Akdis and Akdis, 2014; Weiner et al., 2011). It 
also enhances B cell survival and antibody production (Trifunović et al., 
2015). In addition, it is common that IL-10 along with IL-4 act together with 
TGF-β in down-regulating inflammatory Th responses (Gonnella et al., 1998; 
Skugor et al., 2008). The status of Treg cells is interested due to possible 
development of immune tolerance against the oral antigen (Chen et al., 
1996). For that purpose, level of the IL-10 and FoxP3 (Treg markers) 
expression is important to determine.  
An interesting subset of Treg cells is Th3 cells. Although Th3 cells are 
considered as antigen non-specific, their response is associated with 
microbial antigens (Belkaid, 2007; Weiner et al., 2011). These cells can 
differentiate from Th0 cells under influence of IL-10 and TGF-β. Therefore, 
these two cytokines are good markers for Th3 response (Sonmez et al., 
2004). It is also suggested that orally ingested antigen can initiate the Th3 
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response with the oral tolerance as an outcome (Castro-Sánchez and Martín-
Villa, 2013; Wan and Flavell, 2008). In fact, the oral tolerance is mediated by 
TGF-β which is produced by Th3 cells (Carrier et al., 2007; Letterio and 
Roberts, 1998). However, all details related to the mechanisms of Th3 action 
are unexplored.  
Finally, Th17-cells act at epithelial barrier driving pro-inflammatory responses. 
Development of autoimmunity is also attributed to induction of Th17 pathway. 
Differentiation from Th0 cells is initiated by activators such as RORγ and 
STAT3. This transcription factors induce the expression of TGF-β, IL-17, IL-6 
among other cytokines (Wilson et al., 2009). 
In summary, induced INF-γ, and STAT4 together with IL-12 refers to the Th1 
immune response. On the other hand, the induced GATA3, STAT6, IL-4 
along with IL-10 witnesses of Th2 response. Furthermore, the up-regulated 
IL-10 together with FoxP3 indicates that the Th1 related immunity is in the 
process of being down-regulated. However, the up-regulated IL-10 together 
with TGF-β is a sign of suppression of both Th1 and Th2 immunity (Cecere et 
al., 2012). This condition is linked to immune tolerance (Th3 response). 
Finally, pro-inflammatory pathway, Th17 is recognised by IL-17, RORγ and 
STAT3 among other markers. 
There are many more markers and pathways than those mentioned here. 
The reason these markers were selected is that they are very well 
documented and understood.     
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Figure 1.2: An overview of the most likely immune responses to the ingested 
antigen. Immune system can respond to an ingested antigen in two different 
ways: 1) cellular immune response (Th1 cells) activated by IFN-γ and IL-12 
cytokines in combination with T-bet and STAT4 transcription factors and 2) 
humoral immune response (Th2 cells) triggered by IL-4 and IL-10 among 
others cytokines with support of GATA-3 and STAT6 transcription factors. 
These two responses are balanced by Th3 cells secreting IL-10 and TGF-β 
cytokines. As a consequence, immune system can start self-limiting its own 
response. This is done by inducing Treg cells with the aid of TGF-β & IL-6 
activator cytokines and FoxP3 & STAT5 transcription factors. In addition, 
immune system can also overreact and cause sustained inflammation which 
can turn into autoimmune disease. This reaction is a main characteristic of 
Th17 response.   
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1.4  Alginate encapsulation 
The most likely immune responses of A. salmon to ingested antigens were 
reviewed in the preceding section. Some useful markers for different immune 
pathways were highlighted. To generate an effective oral delivery system 
based on alginate, it is important to get an overview of encapsulation 
methods and their capabilities as well. Equally important, it is to gain an 
insight into the relations between crosslinking properties and chemical 
composition of alginate. The mentioned overview and insight are also 
essential for the reason that the alginate encapsulation is the key element in 
all experiments conducted in this thesis.     
Alginates are polysaccharides isolated from brown algae such as 
Ascophyllum nodosum, Durvillaea sp., Ecklonia sp., Laminaria sp., Lessonia 
sp., Sargassum sp. and Macrocystis pyrifera found in coastal waters around 
the globe. Laminaria digitata and Laminaria hyperborea are the major raw 
materials for Norwegian alginate industry (McHugh et al., 2003). The first 
characterisation of alginic acid was carried out by Stanford  who extracted it 
with sodium carbonate and then precipitated the alginate out of solution at 
low pH (Stanford, 1886). 
Marine alginates are composed of two forms of uronic acid: mannuronic (M) 
and guluronic (G) (Figure 1.3). Some of the first analytical methods applied to 
obtain the M/G ratio included partial acid hydrolysis of the alginates followed 
by separation and detection using paper chromatography. It was shown that 
the M/G ratio varies between sources and that alginates are block polymers 
(Haug et al., 1966). Nowadays, more advance analytical methods such as 
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Nuclear magnetic resonance (NMR) are used to study that matter 
(Salomonsen et al., 2009; Sperger et al., 2011). Two blocks of adjacent 
polymer chains can be cross-linked with multivalent cations (e.g., Ca2+,  Ba2+, 
etc.) through interactions with the carboxylic groups in the uronic acid, which 
leads to the formation of a gel network as shown in the Figure 1.4 (Augst et 
al., 2006). From light-scattering and viscosity experiments, it was found that 
stiffness of the chain blocks increased in order MG<MM<GG (Smidsrød et 
al., 1973). The arrangement of M and G bocks in a polymer chain is the 
major differences between alginate products (Minghou et al., 1984). 
In this thesis, two very different cations were used to crosslink sodium 
alginate, namely calcium cation (Ca2+) and ethylenediammonium dication 
(EDA2+ or C2H4(NH3)2
2+). The former (Ca2+) is most commonly used to 
crosslink sodium alginates, and therefore, it is a good benchmark for every 
new cross-linker (Lee et al., 2012; Pathak et al., 2010). However, it seems 
that the letter (EDA2+) has been very rarely studied in combination with 
alginates since Cooper et al. described it in 1962. Consequently, the 
application of EDA-alginate as an oral delivery system for protein antigens to 
animals and humans is currently unexplored and novel.  
According to Cooper et al., (1962) EDA-alginate is superior to Ca-alginate in 
the rate of dissolution under alkaline conditions. For this reason, EDA-
alginate was compared to Ca-alginate in terms of encapsulation efficiency 
and immune response in Chapter 3. Thus, the encapsulation efficiency was 
assessed in Section 3.2. The ability of EDA-alginate to improve the specific 
immune response to IPNV antigen in salmon was investigated in Section 3.4.  
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These two alginate matrices were also compared to each other in terms of 
the in vitro and in vivo dissolution in Chapter 4. The need for a fast-dissolving 
alginate matrix is pointed out in Section 4.1. The performed experiments are 
described in Sections 4.2.1 and 4.4.1. On the other hand, the results are 
presented in Sections 4.2.2 and 4.4.2 while Section 4.5 discusses them. 
Finally, the major implications regarding EDA-alginate are stressed again in 
the concluding chapter, namely Chapter 7 (Section 7.1.2).     
 
Figure 1.3: Monomer molecules of the alginate building blocks: β-D-
mannuronate (M) and α-L-guluronate (G). 1) M and 2) G residues are 
covalently (1-4)-linked together in consecutive M-blocks, G-blocks and 
alternating MG-blocks forming a linear copolymer called alginate. 
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Figure 1.4: Crosslinking pattern of M and G blocks in the presence of 
calcium cations. 
 
The crosslinking properties of alginate form the basis for various 
encapsulation techniques including both electrostatic driven and non-electric 
driven methods. For instance, aerodynamically assisted bio-jetting/-threading 
is a good representative for non-electric driven methods (Arumuganathar and 
Jayasinghe, 2008; Jayasinghe, 2011). On the other hand, electrospraying is 
a typical example of an electrostatic driven process. Electrospraying was 
conceived through the theory established by Lord Rayleigh. He anticipated 
that droplets would disrupt and throw out fine jets of liquid if the total charge 
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on the droplet surface would reach a limiting value. This limiting value is now 
known as the "Rayleigh limit" (Rayleigh, 1882). This theory has been 
confirmed experimentally by many researchers since that time (Gomez and 
Tang, 1994). 
As a result, there are various electrostatic microbead generators in the 
market today. These generators use an electric potential to pull the droplets 
from a needle tip (Moyer et al., 2010). Consequently, motion and size of the 
droplets can be controlled by the electrostatic potential. The electrostatic 
potential is established between the needle feeding the mixture of alginate 
and hardening solution. Spherical microbeads are formed by electrostatic 
extrusion of the alginate solution through a needle using a syringe pump and 
a plastic syringe. The generated droplets fall into a hardening solution 
through the centre of a ring electrode. The ring electrode is grounded while 
the needle is charged. The opposite is possible as well. Potential difference 
is controlled by a high voltage DC unit. Droplet size may be controlled by 
adjusting the magnitude of the voltage. Size of the microbeads depends on 
the distance between the needle tip and the hardening solution. Diameter of 
the needle and flow rate of the alginate solution along with the viscosity are 
important factors as well (Figure 1.5) (Jaworek and Sobczyk, 2008). 
The generated droplets are rather uniform in size. Compared to the other 
encapsulation techniques, electrospraying allows for better regulation of 
morphology and particle size distribution (Bock et al., 2012). Moreover, 
electrospraying is frequently used technique and very well documented in the 
scientific literature (Bock et al., 2014; Jaworek, 2007). The advantages of 
using electrospraying are: monodispersed particles, even morphology, high 
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encapsulation efficiencies and undamaged bioactive compounds. On the 
other hand, disadvantageous aspects are: low throughput and high sensitivity 
to the viscosity of polymer solutions. Since electrospraying offers high control 
over the generation of microbeads, it is an obvious first choice for 
encapsulating protein antigens. However, an area that electrospraying could 
be improved in is the particle size. Generally, size of the alginate microbeads 
needs further reduction to be suitable for incorporation into feed pellets.   
For this reason, another encapsulation technique, namely aerodynamically 
assisted jetting (AAJ) was modified in this thesis. The new technique was 
named air pressure-assisted energised jetting (APAEJ). APAEJ is a further 
development of AAJ and it is basically fusion of AAJ with electrospraying 
(Figure 1.6). AAJ offers relatively high throughput and the possibility of 
producing very small microbeads (Jayasinghe and Suter, 2006). For this 
reason, the focus was eventually directed towards this encapsulation 
process. 
In this process, a jet of alginate microdroplets is generated by extruding 
alginate solution through a nozzle into an air-pressurised chamber. The 
chamber is fitted with a narrow exit orifice. Through the orifice, the expanding 
air is dispersing the incoming solution into a jet of fine alginate micro-
droplets. Hovering aerosols and very fine micro-droplets are attracted to 
cross-linking solution by creating electric potential difference between the 
jetting head and the solution. Along the way, a high precision syringe pump 
regulates the flow rate of alginate solution while a pressure regulator controls 
the air flow (Griessinger et al., 2012). This encapsulation process is further 
explained and discussed in details in Chapter 5. 
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For the reason that encapsulation herein is based on the entrapment of a 
bioactive compound in an alginate matrix, the term “encapsulation” is 
interchangeable with the term “entrapment”. However, the word 
“encapsulation” is most commonly used of the two in the scientific literature. 
Therefore, “encapsulation” meaning “entrapment” will be mostly used in this 
thesis as well.  
 
Figure 1.5: Architecture of the electrospraying apparatus. The apparatus 
consist of a needle (1), syringe (2), syringe pump (3), high voltage DC power 
supply (4) and a vessel (7). Needle (1) is wired to positive voltage (5) while 
vessel is grounded (6). 
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Figure 1.6: Architecture of the air pressure-assisted energised jetting 
apparatus. The apparatus consists of a jetting head (1), pressure regulator 
(2), syringe (5), syringe pump (8), air filter (6), high voltage DC power supply 
(7) and a vessel (9). Jetting head is wired to positive voltage (3) while vessel 
is grounded (4). Air filter connects to a source of compressed air. 
 
Reported average size of alginate particle using aforementioned methods 
and other available methods varies a lot. For instance, Park et al., 2012 
demonstrate that the encapsulation of adenovirus in alginate beads smaller 
than 150 µm using electrospraying is feasible. Though the alginate beads 
with davg = 170 ±100 μm (Bugarski et al., 1994) and 50 > davg < 200 μm 
(Sugiura et al., 2005) were reported successfully fabricated, generation of 
smaller beads than 200 μm with an electrostatic droplet generator has been 
rather impractical to date. In a study by Arumuganathar et al., 2007, the 
average droplets size observed in the jet formed by an aerodynamically 
assisted jetting device were between 55 and 87μm. 
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When it comes to other methods, Sahu and Prusty (2010) provide evidence 
for successful generations of polymeric (alginate and chitosan) nanoparticles 
by a complex coacervation process. In his study, the minimum achieved 
average size (davg ±SD) of empty and bovine serum albumin (BSA) loaded 
nanoparticles were davg = 339.8 ±0.2 nm and davg = 474 ±19 nm respectively. 
On the other hand, Shinde and Nagarsenker (2011a) report that eugenol was 
micro-capsulated in a gelatine sodium alginate complex coacervate system 
yielding microbeads of davg = 425 µm.  
Paques et al. (2013) shows that emulsification/external gelation approach is 
capable of yielding alginate beads in the range of 0.2 - 5 µm with an average 
of davg = 1 µm. Similarly, in a study by Ciofani et al. (2008), the average size 
of polymeric (alginate and chitosan) particles was davg = 1.2 μm using an 
analogous approach. Silva et al. (2006) show that it is possible to produce 
insulin loaded alginate microspheres with davg = 60 μm using the 
emulsification/internal gelation method. However, the investigation of Song et 
al. (2013) show that the size of microbeads produced by 
emulsification/external and emulsification/internal gelation were davg = 325 ± 
202 µm and davg = 151 ±77 µm respectively. 
Del Gaudio et al. (2005) affirm that most of the alginate beads were below 
750 μm in his study by using electromagnetic laminar jet breakup process. In 
another study involving the same process, Rodríguez-Rivero et al. (2011) 
describe the formation of alginate micro-particles, ranging from 300 to 700 
µm with a mean size of davg = 490 µm.  
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Work by Ribeiro et al. (2004) demonstrate fabrication of uniform-sized 
microspheres of approximately davg = 1000 μm using pure alginate in the 
coaxial air flow induced dripping process. Semyonov et al. (2010) observe 
that particle sizes are distributed between 400 and 1800 μm in a study that 
combines the coaxial air flow induced dripping process and spray freeze 
drying technique for collecting beads.  
Iwanaga et al. (2013a) describe successful production of alginate beads 
(davg= 13 µm) loaded FITC-labelled nanoparticles by using inkjet printing 
technology. In recent years, there has been increased activity in the field of 
printing technologies where various printing techniques of use for 
development of drug delivery systems have been explored (Kolakovic et al., 
2013). Lian et al. (2012) report that a three-dimensional microfluidic droplet 
generator which is rather unconventional technique, is able to produce mono-
disperse alginate microbeads with davg = 14.55 ±1.13 µm.  
The resulting alginate microbeads have excellent biocompatibility within host 
tissues and are able to biodegrade in a controlled manner. This attributes 
make them interesting for use as oral delivery systems (Adelmann et al., 
2008; Joosten et al., 1997; Maurice et al., 2004; Polk et al., 1994). A variety 
of products can be combined with alginate matrices to avoid damage from 
the low pH and proteolytic enzymes encountered in the digestive system. 
Incorporation of products can be conducted under mild conditions, allowing 
sensitive proteins to remain intact within the matrix. Alginate is an anionic 
polymer, with carboxyl end groups. This allows it to attach more readily to 
mucosal surfaces (George and Abraham, 2006). Moreover, alginate 
microbeads are stable at low pH while they dissolve at high pH. As a result, 
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faster release occurs at a higher pH, after microbeads have passed through 
the stomach (Yu et al., 2008). These properties have important implications 
for the oral delivery of macromolecular drug, particularly protein antigens.  
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1.5 Comparative dissolution testing 
In the previous section, crosslinking properties of alginate and the available 
encapsulation methods were reviewed. In this section, the focus is aimed at 
dissolution testing. Dissolution testing is useful for comparing dissolution 
profiles of different alginate formulations assessed in this thesis. To be 
released at the right place in fish is essential for an antigen to be able to 
trigger off an adequate immune response. The issues related to the release 
of bioactive compounds from alginate matrices are addressed in Chapter 4.    
1.5.1 Application of dissolution tests 
In 1897, Noyes and Whitney published the work “The rate of solution of solid 
substances in their own solutions”, in which, for the first time, the process of 
dissolution of solids was described (Noyes and Whitney, 1897). Nowadays, 
in vitro dissolution test is an essential analytical tool necessary for 
understanding delivery systems. For clarity reasons, further in the text, the 
terms “pharmaceutical product” and “solid oral dosage form (SODF)” 
correspond to “oral delivery system plus an active pharmaceutical ingredient 
(API)”. Oral delivery system is herein identified with alginate while API can 
refer to IPNV antigen, blue dextran or HRP.   
In vitro dissolution testing is a main analytical test for determining the in vitro 
release profile of an API. The test information can be used for both optimising 
API release from SODFs and evaluating batch-to-batch uniformity of SODFs 
as a part of quality control (QC) procedure. Dissolution tests can also be 
used to identify the effect of important manufacturing variables on dissolution 
rate of SODFs. Additionally, in vitro dissolution testing is one of the tools 
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recommended by the FDA guidance for determining the level of in vitro-in 
vivo correlation (IVIVC) (Kytariolos et al., 2010), and verifying the level of 
scale-up and post-approval changes (SUPAC) (Van Buskirk et al., 2014). In 
this thesis, dissolution tests were used to develop a fast-dissolving and 
temperature-independent alginate matrix within the temperature range of 
seawater in which A. salmon habituate. 
In the Biopharmaceutics Classification System (BCS) guidelines for 
classifying APIs on the basis of their solubility, permeability and dissolution, 
in vitro dissolution test is a main method for determining dissolution class 
boundaries (Anand et al., 2011). In line with the BCS, APIs are classified in 
four classes with respect to their solubility and permeability (Table 1.1). 
Regarding dissolution boundaries, an immediate release (IR) product is 
considered rapidly dissolving when ≥85% of API dissolves within 30 minutes 
in dissolution medium (≤900 ml) using USP apparatus 1 or 2.  
Table 1.1: Classification of the active pharmaceutical ingredients (APIs) on 
the basis of their solubility and permeability. 
Class Permeabilityi Solubilityii 
1 High High 
2 High Low 
3 Low High 
4 Low Low 
iHighly permeable: the extent of absorption in humans is determined to be ≥90% of 
an administered dose, based on mass-balance or in comparison to an intravenous 
reference dose. 
iiHighly soluble: the highest dose strength of is soluble in ≤250 ml water over a pH 
range of 1 to 7.5.  
 
The widespread application of dissolution tests has resulted in several 
dissolution apparatus which are standardized and specified by the United 
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States Pharmacopoeia (USP). The following apparatus are described in the 
USP General Chapters: 1) the USP Apparatus 1 (basket), 2) USP Apparatus 
2 (paddle) (Gray et al., 2009), USP Apparatus 3 (reciprocating cylinders) 
(Joshi et al., 2008), USP Apparatus 4 (flow-through-cell) (D’Arcy et al., 2010), 
USP Apparatus 5 (paddle-over-disk) (Prodduturi et al., 2009), USP 
Apparatus 6 (cylinder) and USP Apparatus 7 (reciprocating holders) (Zhou et 
al., 2007). Which dissolution test will be applied depends on the intended 
route of administration and characteristics of API and dosage form. For 
evaluation of SODFs, the most relevant dissolution test apparatus and 
methods are USP 1-4. On the other hand, USP 5-7 are recommended for in 
vitro release testing of topical and transdermal drug products (Chang et al., 
2013). The USP 1-4 and USP 5-7 including corresponding test 
methodologies are described in  the USP General Chapters  <711> and 725 
respectively (USP, 2012a, 2012b). 
1.5.2 Development of dissolution method 
Development of a successful dissolution test procedure involves choosing 
factors like dissolution medium, volume, agitation rate, temperature, sampling 
time points, sampling volume and method of analysis suitable for the 
pharmaceutical product of interest (USP, 2012c). This overview will 
concentrate on the USP 1 and 2 because these two systems constitute the 
majority of dissolution testing in the pharmaceutical industry (Figure 1.7), 
(Gray et al., 2009). 
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1.5.2.1 Volume 
The common volumes of dissolution media are between 500 – 1000 ml with 
900 ml as the most frequent volume. With proper justification, the volume 
could also be below 500 ml and above 1000 ml.  
 
 
Figure 1.7: Example of a dissolution tester (ERWEKA DT 626 series, 
www.erweka.com), UPS apparatus 1 and 2. 
 
1.5.2.2 Dissolution medium 
An ideal dissolution medium gradually dissolves SODF resulting in complete 
release (100%) of API within one hour. These qualities are preferable due to 
an increased possibility of observing variations in a formulation or process 
parameters. Therefore, screening with buffer solutions in the range of pH 1.2 
– 6.8 is performed before everything else. In a case of low solubility within 
the selected pH range, addition of surfactants is suggested.  
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Typical dissolution media are 0.1- 0.001M HCl buffer pH 1.2, 0.05M Acetate 
buffer pH 4.1 – 5.5, and 0.05M phosphate buffer pH 5.8 – 8.0. In addition, 
there are simulated gastric and intestinal fluids available in both fed and 
fasted variant.  
1.5.2.3 Agitation rate and temperature 
Agitation speed is normally between 25 – 150 rpm. The typical speed of 
rotating baskets is from 50 – 100 rpm in the USP 1 method. On the other 
hand, the routinely used speed of rotating paddles is 50 or 75 rpm in the USP 
2 method. Other speeds could be applied with justification but rates below 25 
rpm and above 150 rpm are usually unacceptable in both methods. 
Generally, dissolution tests are performed at 37 ± 0.5°C. 
1.5.2.4 Sampling points 
Selection of sampling procedure depends on release technology used in 
designing the SODF. For immediate-release SODFs (IR – SODFs), the test 
time is normally 30 – 60 min with sufficient number of sampling time points to 
properly characterize the ascending and plateau phases of the dissolution 
curve. However, for the APIs –class 1 (according to BSC: highly soluble and 
permeable drug,) which are formulated with fast-dissolving products and 
showing 85% release within 15 min, one-point test is sufficient. For slower-
dissolving APIs, an infinity point may be obtained by increasing the speed of 
rotating device to 150 rpm for another 30 – 60 min at the end of the run after 
which an additional sample is taken. The infinity point, which is not 
mandatory for the pharmacopeial purpose, can provide useful information 
about formulation in the initial phases of the drug development. 
52 
 
For extended-release SODFs (ER – SODFs), a three-point test is sufficient to 
characterise the in vitro API release profile for the pharmacopeial purpose. 
The first sample is usually taken after 1 – 2 hours, while the third sample is 
taken when release of the API is completed. The second sampling point is 
chosen somewhere between these two points. More on method development 
for modified-release dosage forms could be found in the USP General 
Chapter <1088> (USP, 2012d). 
1.5.2.5 Sampling volume and analysis 
At set time points, aliquots of filtered medium (eppendorf tubes: 3 - 5 ml or 
HPLC vials: 1.5 ml) are removed and analyzed for API content by HPLC or 
UV-Vis. During development, HPLC is most commonly used. It has the 
advantage of being able to separate the API from potential interferences from 
the formulation matrix or dissolution medium and can detect API degradation. 
Furthermore, large variations in sample concentration can often be 
accommodated by adjusting injection volume. 
1.5.2.6 Observation of dissolution behaviour 
Visual observation of all vessels and documentation of dissolution behaviour 
is very important part of the testing. Some of the observations that could be 
made are: distribution of particles throughout the vessels, adhering of 
particles to the vessel, floating of particles, coning, mounding, swelling, air 
bubbles etc. 
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1.5.3  Dissolution profiles 
Cumulative dissolution profiles represent the total amount of drug dissolved 
from the formulation over time. When cumulative dissolution is measured in a 
constant-volume system, no correction for the amount lost in sampling needs 
to be made. If sample is removed from the system, the amount consumed in 
analysis must be replaced or accounted for in the calculation (USP, 2012c).  
There are many approaches used for comparing dissolution profiles of 
SODFs. They can be divided into two main groups: 1) model independent 
methods and 2) model dependent methods. Model independent methods, 
which are also recommended by Food and Drug Administration (FDA), use f1 
and f2 factors. The difference factor (f1) directly compares the difference 
between percent drug dissolved per unit time for a test and a reference 
product. Two dissolution profiles are similar when f1 value is between 0 and 
15. The similarity factor (f2) is also a simple measure for the comparison of 
two dissolution profiles. When two profiles are identical, f2 = 100. An average 
difference of 10% at all measured time points results in a f2 value of 50 
(Moore and Flanner, 1996). FDA has set a public standard of f2 value 
between 50 and 100 to indicate similarity between two dissolution profiles 
(Shah et al., 1998). In other words, f2 ≥ 50 should be   a reliable estimate to 
assure product consistency and performance. There are several model 
dependent methods that can be used to compare dissolution profiles. Some 
of them are: First-order model, Hixson-Crowell, Weibull, Higuchi and Logistic 
model (Yuksel et al., 2000). 
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1.6 Fish feed production process 
When dissolution profiles are good and the alginate-encapsulated antigen is 
ready to be administered to fish, the final formulation eventually needs to be 
incorporated into feed pellets. Ultimately, a feed pellet is the main delivery 
vehicle for orally administering bioactive compounds to fish. For this reason, 
the fish feed production process with different inclusion options is reviewed 
here. Thus, this section serves as a prelude to Chapter 6 where stability of 
antigen in fish feed production process is addressed.    
In short, fish feed production process consists of four steps or sub-
processes: 1) formulation of meal mix by grinding and mixing the required 
ingredients, 2) generation of extrudate by extruding the meal mix, 3) 
preparation of base pellet by drying the extrudate, and 4) production of the 
finished product by infusing an appropriate oil mix into the base pellets. Of all 
the above mentioned steps, extrusion is the most important sub-process of 
the production process.  
The verb ”to extrude” derives from Latin words ex (out) and trudere (to 
thrust), and means to force something through a small opening. Extrusion 
cooking can be described as a process whereby moistened starch and 
proteinous material are cooked and transformed into viscous, plastic-like 
dough which is forced through a die opening of desired cross-section (Singh 
et al., 2007). This processing technique has long been used for the 
preparation of human foods and animal feed products (Harper, 1989). 
Process of extrusion has been known for over 200 years. The early extruders 
were ram-type extruders for processing metals such as lead, copper and 
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brass. The first extruder of such type was patented by Joseph Bramah in 
England in 1797 (Pugh and Watkins, 1961). Since then, it had been more 
than 80 years before Gray (1879) patenting the first screw extruder which 
served for wire coating. Furthermore, the end of the 1800s is also the time 
period when the first extruders were adopted for food production. This early 
use of the screw extrudes was intended for producing sausages (Karwe, 
2003). Later on, in the 1930’s extruders were developed to manufacture 
pasta products (Akdogan, 1999). Shortly afterwards, in the 1940’s, extruders 
were used to produce expanded corn products. In the 1950’s this equipment 
was tailored to manufacture dry expanded pet food pellets.  
However, there are other technologies that can convert feed mash into a 
compact, cylindrical form, called a pellet. For instance, such a one 
technology is pelleting by pellet press that was introduced in the 1920’s 
(Schoeff, 1994). A pellet press, when used alone, is adequate for producing 
poultry, swine and shrimp feed. On the other hand, since the late 1980’s, 
pellet press has been coupled with an expander in order to produce suitable 
feed for ruminants. An expander could be briefly described as a pre-pelleting 
conditioner where the feed material is subjected to high temperatures for a 
short period of time (Pipa and Frank, 1989).The first fish feed pellets were 
introduced to farmed trout at the Red River Hatchery near Taos (USA) in the 
1950’s (Sigler and Sigler, 1986). These early fish feed pellets were produced 
by using a pellet press. First in the late 1980’s fish feed producers started 
replacing simple pelleting by extrusion. Since recently, twin-screw extruders 
are being introduced into fish feed factories. It should be mentioned that the 
twin-screw extruders were developed for commercial use first in the 1950’s, 
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although the ground-breaking work came 20 years earlier. Other forms of 
extrusion, which have found application in human and pet food industry but 
not yet in the fish feed industry, are co-extrusion and co-injection. Co-
injection employs a primary system, which is an extruder, to create the outer 
texture of a product. Inner texture is injected into the centre of a product by 
using a secondary system, which is normally a filling pump. Products 
containing multiple layers of texturally different materials are also attainable 
with this technique. Co-extrusion involves the use of two extruders connected 
together to simultaneously extrude two products which fuse into one final 
product.  
The extruders, which were originally designed for producing pasta and cereal 
pellets, are now considered a high temperature-short time bioreactors which 
transform raw materials into semi-finished and finished products (Alam et al., 
2015). Increased use of the extrusion technology in human food and animal 
feed production has advanced the technology into a versatile and very 
productive processing technique. As a result, there is plenty of inexpensive, 
mass-produced food available  in the market today (Dunn, 2011). 
Extrusion cooking is preferable to other feed-processing methods in terms of 
high throughput and continuous process retaining nutritional quality (Makki, 
2002). In addition, the extrusion process achieves high degree of 
gelatinisation of starch, denatures undesirable enzymes, inactivates some 
antinutritional factors (trypsin inhibitors, haemagglutinins, tannins and 
phytates), retains natural colours and flavours of foods, sterilises and 
expends the finished product (Fellows, 2000; Mukhopadhyay et al., 2007; 
Romarheim et al., 2005).  
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In this study, fish feed production process based on a single screw extruder 
was applied. Such a production process consists of a grinder, mixer, supply 
bin, conditioner, extruder barrel, dryer and a vacuum coater. The mixer is a 
place where all the ground raw ingredients are mixed into homogenous 
mixture, so called dry mix. The conditioner has a body with an inlet, an outlet, 
and rotating mixing elements within the body. The inlet of the conditioner is 
connected to a screw conveyer for transport of a dry mix from the supply bin 
to the conditioner. Dry mix is preconditioned to a moisture content of 28-38% 
at temperature from 70°C to 110°C (Tumuluru, 2014). The conditioner is the 
place where most of the starch is gelatinised (Zimonja and Svihus, 2009). 
Furthermore, the outlet of pre-conditioner is operatively coupled with the inlet 
of an extruder barrel for passage of preconditioned material from the 
conditioner into the extruder. 
The extruder barrel has a body with an inlet, and one or two elongated, 
axially rotatable, helically flighted extruder screws within the barrel. The 
barrel is fitted with restricted orifice die at the downstream end (Kartika et al., 
2006). In typical processing, the feed ingredients are fed through the extruder 
barrel where they are subjected to increasing levels of heat, pressure and 
shear (Oke et al., 2012). As the material moves through the extruder the 
pressure within the barrel increases due to a restriction at the outlet of the 
barrel. The restriction is caused by one or more shaped openings called a 
die. Discharge pressure is typically around 20 bar (Kraugerud et al., 2011). 
The feed dough is subjected to high shear rates as it is conveyed through the 
extruder by the action of a screw. Heat is added to the feed dough as it 
passes through the screw by one or more of three mechanisms: 1) viscous 
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dissipation of mechanical energy 2) heat transfer from electrical heaters 
surrounding the barrel and 3) direct injection of steam (Mukhopadhyay et al., 
2007). 
Temperatures in an extruder can reach >150°C but the residence time at this 
elevated temperatures is very short (10 – 15 s) (Köksel et al., 2004). When 
material reaches the end of the barrel it is squeezed out through a die 
openings, where it experiences a sudden drop in pressure, resulting in the 
characteristic puffed product also called the extrudate (Harper, 1978). The 
extrudate may be cut or otherwise subdivided into pellets at the extruder die.  
A typical extrusion system is illustrated in the Figure 1.8. The resulting pellets 
are subjected to post-extrusion treatments such as drying and application of 
fat/oil. Oil is applied to fish feed in a vacuum coater which is an enclosed 
chamber with rotating shafts. While oil and dry feed (base pellet) is mixed 
together, the air is evacuated from the chamber and so from the feed pellet 
pores. After reaching sufficient pressure (<100 mbar), the air is released 
back into the chamber. On its way back, the air is pushing oil into the 
evacuated pellet pores. In this way, possible particles suspended in oil will be 
incorporated into fish feed provided that they are of appropriate size. 
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Figure 1.8: Example of an extrusion system consisting of a supply bin (1), 
screw conveyer (2), pre-conditioner (3), extruder barrel (4), outlet for 
continuation of pellets to a dryer (5) and a knife mechanism (6). This is an 
OPTIMA extruder illustrated by Wenger Manufacturing, Inc. 
 
Extrusion is a complex multivariate process that requires careful control if 
product quality is to be maintained (Samuelsen et al., 2014). This process is 
defined by several input, system and output parameters (Figure 1.9). Input 
parameters, which can modify the extrusion process, are screw speed, flow 
rate, moisture content and hardware setup such as die diameter, screw 
configuration, shear lock position etc. System parameters, which depend on 
input parameters, are known while process is running. These parameters 
include specific mechanical energy (SME), retention time, pressure and 
temperature. Output parameters are defining quality of the fish feed pellet. 
Quality of the fish feed pellet could be defined by physical properties 
(durability, hardness, water stability, fat seepage etc.), chemical properties 
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(nutritional content, content of negative components such as anti-nutrients, 
toxic compounds etc.), biological properties (specific growth rate of the fish, 
feed conversion ratio, health status of the fish etc.) and sensory properties 
(odour, appearance, texture and taste of the fish). The above mentioned 
parameters are used in the modelling, system design and system exploitation 
with a purpose of producing high quality fish feed (Ganjyal et al., 2003).      
 
 
Figure 1.9: An overview of the extrusion process parameters 
 
In the fish farming industry, the feed pellet is the major vehicle for delivery of 
bioactive compounds including microencapsulated antigens. Microbeads can 
be added to the extruded feed in two ways. One way is the pre-extrusion 
addition together with dry mix and water (high temperature). The other way is 
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post-extrusion addition together with oil in a vacuum coater (low temperature) 
(Ljungqvist et al., 2013). The latter can effectively be done only if the size of 
microbeads is small enough to fit into the pores of a feed pellet. Therefore, it 
can be concluded that success of coating depends both on size of 
microbeads and size of the feed pellet’s pore. Though the alginate beads 
with diameters of 170 μm (Bugarski et al., 1994) and 50–200 μm (Sugiura et 
al., 2005) were reported successfully prepared, preparation of smaller beads 
of less than 200 μm with a narrow size distribution has been impractical to 
date. 
It is difficult to determine pore size of an extruded pellet due to the variability 
in the size and shape of the pores. The pores have properties depending on 
size, shape and manner of the constituent particles packing (Draganovic et 
al., 2013). Too large alginate beads will not be able to enter into the pellet 
pores and thus remain on the surface of pellet. This in turn may lead to 
considerable loss of alginate beads causing reduced efficacy of the active 
compound.  
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1.7 Thesis objectives 
The main objective of this study was to develop an oral delivery system 
based on alginate with the following characteristics: 1) easy to incorporate 
into feed pellets via a vacuum infusion coating process, 2) effectively protects 
antigens throughout fish feed production process 3) protects protein antigens 
from thermal, acidic and proteolytic degradation in gastrointestinal tract of A. 
salmon, 4) delivers antigens in the intact form to the distal intestine of salmon 
and 5) releases antigens in vivo, independent of the seasonal temperature 
changes in the natural habitat of salmon.  
In addition, this study aims to assess antigen absorption and immune 
response as a result of feeding salmon with encapsulated antigens. 
1.8 Summary of contribution 
This study will increase knowledge on processing of protein antigens and 
advance alginate encapsulation systems with emphasis on fish health and 
environmentally friendly solutions. Outcome of this study may lead to a 
commercial diet for farmed salmon with functional protein antigen protected 
in alginate matrix. Over the longer term the effective control of aquatic 
diseases would significantly reduce risks and economically benefit the 
salmon farming industry. Effective control of pathogens will increase the 
environmental sustainability of the industry as well. This will reduce mortality, 
improve welfare of cultured animals as well as reduce transmission to wild 
stocks. 
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Chapter Two: Materials and Methods 
In this thesis, a great number of chemicals, stock solutions, tools and 
analytical instruments were used. To get a good overview, four main tables 
have been created each of which contains information on a specific group of 
materials. To make it easier to find information on these materials, all used 
items were tabulated under their unique numbers. Accordingly, the materials 
used in the experiments are referred to with item number and table number 
further in the thesis.   
In the methods section, only common methods are described. Methods which 
are specific to only one study are described in their respective chapters. 
Parameters that vary between experiments are expressed only with symbol 
and unit in this chapter. Values of the parameters are given in the methods 
sections of the chapters which are referring to these common methods.      
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2.1 Materials 
All chemicals, raw material and different products which were used in this 
thesis are listed in the Table 2.1. In the Table 2.2, information on the applied 
tools is condensed while the used instruments are summarised in the Table 
2.3. Type/model, grade, manufacturer and supplier data are declared. In 
addition, stock solutions are listed in the Table 2.4. The items have been 
assigned a specific numbers in the first column. These numbers are used as 
reference numbers further in the thesis. 
Table 2.1: Chemicals and raw materials 
Item 
no 
Name Type/grade Manufacturer Supplier 
C001 Sodium alginate Na-alginate, 
Protanal LF 
20/40, food 
grade 
FMC 
BioPolymer 
AS, Norway 
FMC 
BioPolymer 
AS, Norway 
C002 Calcium chloride 
dihydrate 
CaCl2∙2H2O, ≥99 
AnalaR 
NORMAPUR® 
VWR 
International 
LLC, USA 
VWR Ltd., UK 
C003 IPNV antigeni 
suspension 
IPNV Ag susp., 
109 TCID50 ml
-1 
NSVSii, 
Norway 
NSVS, Norway 
C004 Ethylenediamine 
dihydrochloride 
EDA∙2HCl, 
C2H4(NH2)2 · 
2HCl, ≥98% 
Aldrich 
Chemical Co. 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C004 Sodium bicarbonate NaHCO3, ≥99 
ACS analytical 
reagent 
Alfa Aesar 
Inc., USA 
VWR Ltd., UK 
C005 Phosphate buffered 
saline 
1X Dulbecco’s 
PBS without Ca2+ 
and Mg2+, 
κ=1.6×104 µS cm-
1 
Sigma 
International 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
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Item 
no 
Name Type/grade Manufacturer Supplier 
C006 RNA stabilisation 
solution 
RNAlater® Sigma 
International 
Inc., USA 
Sigma-Aldrich 
AS, Norway 
C007 Base pellet BP, EWOS Opal 
200  
EWOS 
Innovation AS, 
Norway 
EWOS 
Innovation AS, 
Norway 
C008 Commercial feed EWOS Opal 200 EWOS AS, 
Norway 
EWOS AS, 
Norway 
C009 Commercial feed EWOS Opal 500 EWOS AS, 
Norway 
EWOS AS, 
Norway 
C010 Horseradish 
Peroxidase 
HRP, P/N 31491 Thermo Fisher 
Scientific Inc.,  
USA 
Perbio Science 
Ltd., UK 
C011 Sodium hydroxide NaOH flakes, 
≥98%,  
Alfa Aesar 
Inc., USA 
VWR Ltd., UK 
C012 Potassium hydrogen 
phthalate 
KPH, C8H5KO4, 
≥99%  
Alfa Aesar 
Inc., USA 
VWR Ltd., UK 
C013 Hydrochloric acid 
fuming 
HCl, 37%, 
AnalaR 
NORMAPUR® 
VWR 
International 
LLC, USA 
VWR Ltd., UK 
C014 Glycine Gly, C2H5NO2, 
≥99%, 
ReagentPlus® 
Sigma 
International 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C015 Disodium phosphate 
dihydrate 
Na2HPO4 · 2H2O, 
≥99%, analytical 
reagent  
Aldrich 
Chemical Co. 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C016 Monosodium 
phosphate dihydrate 
NaH2PO4 · 2H2O, 
≥98%, analytical 
reagent  
Aldrich 
Chemical Co. 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C017 Blue dextran BD, P/N D5751 
MWavg=2,000,000 
Sigma 
International 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C018 3,3′,5,5′-
Tetramethylbenzidine 
TMB, Ready-to-
use, P/N T8665, 
Sigma 
International 
Sigma-Aldrich 
Ltd., UK 
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Item 
no 
Name Type/grade Manufacturer Supplier 
liquid substrate 
system 
Premium quality 
 
Inc., USA 
C019 Fish oil EWOS ID: 20180 Egersund 
Sildoljefabrikk 
AS, Norway 
Egersund 
Sildoljefabrikk 
AS, Norway 
C020 Sodium chloride NaCl, halite 
≥99%, ACS 
analytical 
reagent 
Sigma 
International 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C021 Barium chloride 
dihydrate 
BaCl2∙2H2O 
≥99%, ACS 
analytical 
reagent 
Sigma 
International 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C022 DI water Deionised water, 
H2O, analytical 
reagent  
Fisher 
Chemical Ltd., 
UK 
Fisher 
Scientific Ltd, 
UK 
C023 DI water  Deionised water, 
AnalaR 
Normapur, 
κ  ≤0.05 µS cm-1 
VWR 
International 
LLC, USA 
VWR Ltd., UK 
C024 Cardiogreen I2633,  
dye content, 
~90% 
Sigma 
International 
Inc., USA 
Sigma-Aldrich 
Ltd., UK 
C025 Anaesthetic Finquel vet. 
tricain mesilate 
Scanvacc AS, 
Norway 
Scanvacc AS, 
Norway 
C026 Meal-mix EWOS OPAL 50 EWOS 
Innovation AS 
EWOS 
Innovation AS 
C026 Multivalent vaccine ALPHA JECT® 
micro 6 
Pharmaq AS Pharmaq AS 
iIPNV antigen – Infectious pancreatic necrosis viral antigen was produced by 
growing  virus (a recombinant Sp strain of IPNV, rNVI-15PTA) as previously 
reported by (Chen et al., 2013). 
iiNSVS – Norwegian School of Veterinary Science, Oslo, Norway 
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Table 2.2: Tools 
Item no Name Type Manufacturer Supplier 
T001 Plastic syringe 
 
1 ml BD™  Dickinson and 
Company Ltd, 
UK 
VWR 
International AS, 
Norway 
T002 Plastic syringe 60 ml BD™ Dickinson and 
Company Ltd, 
UK 
VWR 
International AS, 
Norway 
T003 Syringe pump PHD4400 Harvard 
Apparatus Ltd, 
UK 
Harvard 
Apparatus Ltd, 
UK 
T004 High voltage DC 
unit 
FP-30 Glassman 
Europe Ltd, UK 
Glassman 
Europe Ltd, UK 
T005 High-
performance 
disperser 
T-25 IKA® Werke 
GmbH & Co., 
Germany 
n.a. 
T006 96-well plate Assay plates, 
round-bottom 
Nunc AS, 
Denmark 
Sigma-Aldrich 
Ltd., UK 
T007 Freeze dry 
system 
FreeZone 6 Labconco, USA Nerliens 
Meszansky AS, 
Norway 
T008 Pressure 
regulator 
IR1000 SMC 
Corporation, 
Japan 
n.a. 
T009 Sterile syringe 
filter 
0.2 µm, 
Polyethersulfone 
(PES) 
membrane, PN 
514-0073 
VWR 
International 
LLC, USA 
VWR Ltd., UK 
T010 Coffee filter Ali number 4 Joh. Johannson 
Kaffe AS, 
Norway 
Local 
supermarket, 
Norway 
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Item no Name Type Manufacturer Supplier 
T011 Qualitative filter 
paper 
Whatman™, 
grade 1, d = 125 
mm, Particle 
retention ≥11 
µm 
Whatman part of 
GE Healthcare, 
USA 
VWR 
International AS, 
Norway 
T012 Qualitative filter 
paper 
Whatman™, 
grade 6, d = 125 
mm, Particle 
retention ≥3 µm 
Whatman part of 
GE Healthcare, 
USA 
VWR 
International AS, 
Norway 
T013 Needle ID = 700 µm  Nisco 
Engineering AG, 
Switzerland 
Nisco 
Engineering AG, 
Switzerland 
T014 Needle ID = 2000 µm Nisco 
Engineering AG, 
Switzerland 
Nisco 
Engineering AG, 
Switzerland 
T015 Vacuum coater VC-6, 
No 1870 
Halvor Forberg 
AS, Norway 
Halvor Forberg 
AS, Norway 
T016 Dissolution 
tester 
Caleva 8ST Caleva 
International Ltd., 
UK 
Caleva 
International 
Ltd., UK 
T017 Extruder X85 Wenger Inc., 
USA 
Wenger Inc., 
USA 
T018 Spray/jetting 
head 
n.a Nisco 
Engineering AG, 
Switzerland 
Nisco 
Engineering AG, 
Switzerland 
T019 Needle ID = 1200 µm Nisco 
Engineering AG, 
Switzerland 
Nisco 
Engineering AG, 
Switzerland 
T020 Multivalent 
vaccine 
ALPHA JECT® 
micro 6 
Pharmaq AS Pharmaq AS 
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Table 2.3: Analytical instruments 
Item no Name Model Manufacturer Supplier 
I001 Stereo 
microscope 
Leica MZ10 F Leica 
Microsystems 
GmbH, Germany 
Leica 
Microsystems, 
Germany 
I002 Microplate 
reader 
GENios, 
XFLUOR4 
Version: V 4.40    
Tecan Group Ltd, 
Switzerland 
n.a. 
I003 Microplate 
reader 
VERSAmax Molecular 
Devices LLC, 
USA 
n.a. 
I004 Porosimeter PoreMaster 60 Quantachrome 
Corporation, USA 
 
I005 SEM Field emission 
scanning 
electron 
microscope, 
JSM-7401F 
Joel Ltd., Japan Joel Ltd., UK 
I006 High-resolution 
micro-CT 
scanner 
SkyScan 1172 Bruker – MicroCT 
Ltd., Belgium 
RJL Micro and 
Analytic GmbH, 
Germany 
I007 Laser diffraction 
system 
HELOS BR 
CUVETTE, 
CUV-50ML/US, 
optical module 
R5 
Sympatec GmbH, 
Germany 
Sympatec Ltd., 
UK 
I008 Imaging-based 
particle analysis 
system 
FlowCAM® PV-
100 
Fluid Imaging 
Technologies 
Inc., USA 
Fluid Imaging 
Technologies Inc., 
USA 
I009 In vivo imaging 
system 
IVIS Spectrum PerkinElmer Inc., 
USA 
Caliper Life 
Sciences Ltd., UK 
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Table 2.4: Stock solutions 
Item no Name Description 
S001 EncForm 1 Encapsulation formulation 1 was prepared by dissolving 
Na-alginate (2.0% w/w, Item C001, Table 2.1) in an IPNV 
Ag susp. (Item C003, Table 2.1) derived from viral culture 
with titre of 109 TCID50 ml
-1. 
S002 EncForm 2 Encapsulation formulation 2 was prepared by dissolving 
Na-alginate (2.0% w/w, Item C001, Table 2.1) in ten-fold 
dilution of IPNV Ag susp. (Item C003, Table 2.1) to 
produce a formulation containing IPNV Ag 108 TCID50 ml
-1 
S003 XlinkSol 
CaCl2 
Calcium chloride cross-linking solution (XlinkSol CaCl2) 
was prepared by dissolving CaCl2∙2H2O (36.8 g, Item 
C002, Table 2.1) in DI water (1000 ml, Item C022, Table 
2.1) 
S004 XlinkSol 
EDA∙2HCl 
Ethylenediamine dihydrochloride cross-linking solution 
(XlinkSol EDA∙2HCl) was prepared by dissolving 
EDA∙2HCl (33.3 g, Item C004, Table 2.1) in DI water 
(1000 ml, Item C022, Table 2.1) 
S005 Saturated 
NaHCO3 
solution 
Sodium bicarbonate, NaHCO3 (150 g, Item C004, Table 
2.1) was mixed with DI water (1000 ml, Item C022, Table 
2.1) to produce saturated NaHCO3 solution. Any 
undissolved NaHCO3 crystals were filtered off prior to use. 
S006 BD solution Blue dextran (BD) solution (50 mg ml-1) was prepared by 
dissolving blue dextran (10.00 g, Item C017, Table 2.1) in 
DI water (200 ml, Item C022, Table 2.1) 
S007 BD-EncForm Blue dextran encapsulation formulation, BD-EncForm was 
generated by dissolving Na-alginate (2.0% w/v, Item 
C001, Table 2.1) in a BD solution (200 ml, Item S006 in 
this Table) at ambient temperature.  
S008 0.4M NaCl 
solution 
Sodium chloride, NaCl (23.38 g, Item C020, Table 2.1) 
was dissolved in DI water (1000 ml, Item C022, Table 
2.1). 
S009 0.4M HCl 
solution 
Hydrochloric acid, HCl (33.33 ml, Item C013, Table 2.1) 
was mixed with DI water (1000 ml). 
S010 0.4M KPH 
solution 
Potassium hydrogen phthalate, KPH (81.69 g, Item C012, 
Table 2.1) was dissolved in DI water (1000 ml). 
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Item no Name Description 
S011 0.4M MSP 
solution 
Monosodium phosphate (MSP) dehydrate, NaH2PO4∙2H2O 
(62.40 g, Item C016, Table 2.1) was dissolved in DI water 
(1000 ml). 
S012 0.4M DSP 
solution 
Disodium phosphate (DSP) dehydrate, Na2HPO4·2H2O 
(71.20 g, Item C015, Table 2.1) was dissolved in DI water 
(1000 ml) 
S013 0.4M Glycine 
solution 
Glycine (30.03 g, Item C014, Table 2.1) was dissolved in 
DI water (1000 ml). 
S014 0.4M NaOH 
solution 
Sodium hydroxide, NaOH (16.00 g) was dissolved in DI 
water (1000 ml). 
S015 Buffer pH 1.2 Sodium chloride/hydrochloric acid (NaCl/HCl, pH 1.2) 
buffer was prepared by mixing 0.4M NaCl solution (250 
ml, Item S008 in this Table) with 0.4M HCl solution (425 
ml, Item S009 in this Table). Before making up the volume 
to 1000 ml with DI water, the pH of the buffer solution was 
adjusted to pH 1.2. 
S016 Buffer pH 3.0 Potassium hydrogen phthalate/hydrochloric acid 
(KPH/HCl, pH 3.0) buffer was prepared by combining 
0.4M KPH (500 ml, Item S010 in this Table) with 0.4M HCl 
(223 ml, Item S009 in this Table). The resulting buffer 
solution was adjusted to pH 3.0 before replenishing with 
DI water to give a total volume of 1000 ml. 
S017 Buffer pH 6.8 Phosphate buffer (pH 6.8) was created by mixing 0.4M 
MSP solution (255 ml, Item S011 in this Table) with 0.4M 
DSP solution (245 ml, Item S012 in this Table). The 
resulting buffer was adjusted to pH 6.8 before levelling the 
volume to 1000 ml with DI water. 
S018 Buffer pH 8.0 Phosphate buffer (pH 8.0) was created by combining 0.4M 
MSP (26.5 ml, Item S011 in this Table) with 0.4M DSP 
(473.5 ml, Item S012 in this Table). The resulting buffer 
solution was adjusted to pH 8.0 and then diluted with DI 
water to a final volume of 1000 ml. 
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Item no Name Description 
S019 Buffer pH 8.6 Glycine/sodium hydroxide (Gly/NaOH, pH 8.6) buffer was 
produced by mixing 0.4M glycine solution (250 ml, Item 
S013 in this Table) with 0.4M NaOH (20 ml, Item S014 in 
this Table) to produce Gly/NaOH buffer. After fine-tuning 
the pH to 8.6, the generated buffer solution was diluted to 
a volume of 1000 ml with DI water (Item C022, Table 2.1). 
S020 HRP solution 
(5000 ppm) 
Horseradish peroxidase (HRP) solution (5 mg ml-1) was 
prepared by dissolving HRP powder (10 mg; Item C10, 
Table 2.1) in DI water (2.0 ml, Item C022, Table 2.1) at 
4°C. Aliquots of this HRP solution (20 µl) were stored at -
20°C for application in constructing standard curves in the 
enzyme assay.  
S021 HRP solution 
(400 ppm) 
Horseradish peroxidase (HRP) solution (400 µg ml-1) was 
prepared by dissolving HRP powder (200 mg; Item C10, 
Table 2.1) in DI water (500 ml, Item C022, Table 2.1) at 
4°C. 
S022 HRP-
EncForm 
Horseradish peroxidase (HRP) encapsulation formulation, 
HRP-EncForm was generated by dissolving sodium 
alginate (2.0% w/w, Item C001, Table 2.1) in the 5000 
ppm HRP solution (500 ml, Item S021 in this Table) at 
4°C. 
S023 0.25M BaCl2 
solution 
Barium chloride dehydrate, BaCl2∙2H2O (61.1 g, Item 
C021, Table 2.1) was dissolved in DI water (1000 ml, Item 
C022, Table 2.1) 
S024 Na-alginate 
solution 
(1.5% w/v) 
Sodium alginate (1.50 g, Item C001, Table 2.1) was 
dissolved in DI water (100 ml, Item C023, Table 2.1). 
S025 Na-alginate 
solution 
(2.25% w/v) 
Sodium alginate (2.25 g, Item C001, Table 2.1) was 
dissolved in DI water (100 ml, Item C023, Table 2.1). 
S026 Na-alginate 
solution 
(3.0% w/v) 
Sodium alginate (3.00 g, Item C001, Table 2.1) was 
dissolved in DI water (100 ml, Item C023, Table 2.1). 
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Item no Name Description 
S027 Na-alginate 
solution 
(2.0% w/v) 
Sodium alginate (2.00 g, Item C001, Table 2.1) was 
dissolved in DI water (100 ml, Item C023, Table 2.1). 
S028 Na-alginate 
solution 
(1.8% w/v) 
Sodium alginate (1.80 g, Item C001, Table 2.1) was 
dissolved in PBS (100 ml, Item C005, Table 2.1). 
S029 CG solution 
(1000 ppm) 
Cardiogreen (CG) solution (1 mg ml-1) was prepared by 
dissolving CG (15 mg; Item C024, Table 2.1) in DI water 
(15 ml, Item C022, Table 2.1). 
S030 CG-EncForm Cardiogreen (CG) encapsulation formulation, CG-
EncForm was prepared by dissolving sodium alginate 
(2.0% w/w, Item C001, Table 2.1) in the 1000 ppm CG 
solution (15 ml, Item S029 in this Table). 
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2.2 Methods 
In this section all common methods are described. Moreover, all important 
parameters and process variables are listed with their symbols and units. The 
parameters are assigned values in the methods sections of the chapters 
referring to the methods described here. 
2.2.1 Encapsulation methods 
2.2.1.1 Electrospraying 
Spherical beads were formed by electrostatic extrusion of an encapsulation 
formulation (Item S001, S002 or S007; Table 2.4) through a positively 
charged needle (ID [µm]; Item T013, T014 or T019, Table 2.2) using a 
syringe pump (Item T003, Table 2.2) and a plastic syringe (Item T002, Table 
2.2). The pump was working in the volume mode running at a flow rate of Q 
[cm3 h-1] until the target volume (Vtv [ml]) was delivered. The resulting jet of 
droplets was directed from a distance of x [mm] towards a vessel with cross-
linking solution (Vxls [ml]) which was grounded. The potential difference was 
maintained at constant voltage (U [kV]) by a high voltage DC unit (Item T004, 
Table 2.2). Alginate droplets were collected and cured in a cross-linking 
solution (Item S003 or S004, Table 2.4) under stirring. Solution was removed 
10 min after generating the last bead. Thereafter, the recovered alginate 
beads were washed three times with DI water (5 ml, Item C022, Table 2.1). 
Encapsulation process variables (ID, Q, Vtv, U, x, Vxls) are summarised in the 
Table 2.5. The encapsulation method (electrospraying) is illustrated in the 
Figure 1.5. 
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Table 2.5: Electrospraying - process variables with their respective symbols 
and units. 
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x Vxls 
µm cm3 h-1 ml kV mm ml 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
2.2.1.2 Aerodynamically assisted jetting/ aerodynamically assisted energised 
jetting 
A jet of alginate droplets was generated by dispersing an encapsulation 
formulation (Item S022, S024, S025, S026, S027 or S028; Table 2.4) using a 
jetting/spray head (Figure 1.5; Item T018, Table 2.2). The created jet was 
directed from a predetermined distance (x [mm]) towards a vessel with cross-
linking solution (Vxls [ml]; Item S003, S004, S023; Table 2.4). Hovering 
aerosols and very fine micro-droplets was attracted to the cross-linking 
solution by using a high voltage DC generator (Item T004, Table 2.2). The 
positive voltage output was connected to the jetting head (Item T018, Table 
2.2) while the cross-linking solution was grounded. The applied voltage (U 
[kV]) was modified in accordance with the experimental design. Flow rate (Q 
[cm3 h-1]) was controlled by high precision syringe pump (Item T003, Table 
2.2) working in the volume mode (Vtv [ml]). The air pressure (P [bar]) was 
regulated by a pressure regulator (Item T008, Table 2.2) which was equipped 
with a digital pressure controller. Process variables x, Vxls, U, Q, Vtv and P 
are summarised in Table 2.6. The encapsulation method (aerodynamically 
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assisted energised jetting) is illustrated in the Figure 1.6. Method without any 
voltage applied is called aerodynamically assisted jetting. 
Table 2.6: Air pressure-assisted energised jetting - process variables with 
their respective symbols and units.  
Distancei Volumeii Voltage Flow rate Target 
volume 
Pressure 
x Vxls U Q Vtv P 
mm ml kV cm3 h-1 ml bar 
iDistance between the jetting head and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
2.2.2 Dissolution test 
Dissolution tester (Item T016, Table 2.2) equipped with dissolution vessels (V 
= 1000 ml) and rotating stainless steel baskets (40 mesh) was employed to 
assess release from alginate beads. This setup was in compliance with the 
standard requirements for Apparatus 1 set by United States Pharmacopoeia 
(USP) and described in General Chapter <711> (USP, 2012a). Dissolution 
medium (V [ml]; DM: Item S015, S016, S017, S018 or S019, Table 2.4) was 
added into each of the vessels (nvessel) and then allowed to temperate 
overnight at the experimental temperature (t [°C]). The dissolution test started 
within two hours after producing alginate beads. The alginate beads (AB) 
were placed into rotating baskets (f [rpm]) and then submerged into 
dissolution medium.  
Sample volume (Vsample [ml], nSP) was taken from each vessel at five minutes 
intervals through an extent of 50 minutes (tSP [min]). An equivalent volume of 
dissolution medium was then added back to keep the liquid level in the 
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vessels constant. All samples were filtered through a syringe filter (Item 
T009, Table 2.2) before applying aliquots of 100 µl onto a 96-well polystyrene 
plate (Item T006, Table 2.2). An endpoint assay was then performed using a 
microplate reader (Item I003, Table 2.3) at 610 nm and 24°C. Amount of blue 
dextran (BD) released was determined by applying standard curve approach. 
The standard curves were generated by plotting BD concentrations of nine 
two-fold serial dilutions of BD solution (1.0 mg ml-1) versus absorbance in the 
range of 1.0 to 3.9 × 10-3 mg ml-1. The BD solution (1.0 mg ml-1) was derived 
from BD-EncForm (Item S007, Table 2.4) using the phosphate buffer (Item 
C005, Table 2.1) as a diluent. All of the above-mentioned dissolution 
parameters are listed in the Table 2.7. 
Table 2.7: Dissolution parameters with their respective symbols and units. 
Parameters Symbol Unit 
Alginate beads loaded with blue dextran AB n.a 
Apparatus USP 1 n.a 
Basket rotation f rpm 
Type of dissolution media DM n.a 
Volume of dissolution media V ml 
Temperature of dissolution media t °C 
Number of sampling points  nSP n.a. 
Length of sampling time intervals 
calculated from the test start 
tSP min 
Number of vessels used in the test nvessel n.a 
Sample volume Vsample ml 
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2.2.3 Fish feed production 
Fish feed production was conducted at Technology Centre (Ewos Innovation 
AS) in Dirdal (Norway). 
Extruder runs were performed on the extruder (Item T017, Table 2.2) with 
single-screw volumetric feeder. The extruder barrel was not heated by using 
external devices. Experimental conditions and parameters for extruder runs 
including drying are listed in the Table 2.8. Feed rate, total liquid addition and 
temperature in the dryer were held constant. Temperature is monitored 
throughout the entire process. There are one measurement point in the 
supply bin and pre-conditioner, seven measurement points in extruder and 
three measurement points in the dryer. Pressure is only monitored in seven 
zones of the extruder. Furthermore, the process log contains information on 
flow rates of dry mix, water and steam. Mass flow through the extruder is 
recorded as well. System parameters such as specific mechanical energy, 
extruder screw speed, discharge rate and current are also specified. 
This experimental facility for fish feed production is very well monitored which 
enables high degree of control in the experiments. 
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Table 2.8: The adjustable parameters of the applied extrusion process 
including drying. 
Preconditioner 
Factor Parameters Unit 
Meal 
Feed rate (meal blend) kg/h 
Temperature meal oC 
Water 
Water flow rate kg/h 
Water flow rate (dry mixture) % 
Water temperature oC 
Steam 
Steam flow rate  kg/h 
Steam flow rate (dry mixture) % 
Total 
Total liquid addition kg/h 
Total liquid addition  % 
Extruder 
E
n
g
in
e
 Extruder screw speed rpm 
Extruder motor load kW 
Current A 
Specific mechanical energy (SME) kW/tons/h 
T
e
m
p
e
ra
tu
re
 
Zone 1 (precond. outlet temp.) oC 
Zone 2 oC 
Zone 3 oC 
Zone 4 oC 
Zone 5 oC 
Zone 6 oC 
Zone 7 oC 
Spacer  oC 
P
re
s
s
u
re
 (
g
a
u
g
e
) 
Zone 1 (precond. outlet temp.) oC 
Zone 2 oC 
Zone 3 oC 
Zone 4 oC 
Zone 5 
o
C 
Zone 6 bar 
Zone 7 bar 
spacer bar 
M
a
s
s
 
fl
o
w
 Total die area mm
2 
Total cylinder area mm2 
Extruder discharge rate kg/h 
Dryer 
T
e
m
p
 Zone 1 
oC 
Zone 2 oC 
Zone 3 oC 
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2.2.4 Vacuum infusion coating 
The final feed samples were produced by combining an oil mixture with the 
right amount of base pellet (BP; Item C007, Table 2.1) in a vacuum coater 
(Item T015, Table 2.2). Firstly, the air was evacuated from the mixing 
chamber and so from the feed pellet pores. Secondly, after reaching 
pressure of 88 mbar, the air was released back into the chamber. On its way 
back, the air was pushing oil into the empty pellet pores. In this way, the 
suitably-sized particles suspended in the oil mixture, were incorporated into 
feed pellets. 
The major activities related to the coating process were described with three 
primary process variables: time, pressure and temperature. These activities 
and their variables are listed in the order of execution in the Table 2.9. 
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Table 2.9: The controllable variable related to the applied vacuum infusion 
coating process. The major activities are described by primary process 
variables (time, pressure and temperature) in the vacuum infusion coating 
process. These variables were kept constant for each activity in all trials. 
Order Activity name 
Time 
[sec] 
Pressure 
[mbar] 
Temperature  
[°C] 
Start End Start End Start End 
1 
Adding BP to the 
mixing chamberi 0 10 ambient ambient ambient ambient 
2 
Adding oil mixture to 
BPii 11 20 ambient ambient ambient ambient 
3 Closing the chamber 21 35 ambient ambient ambient ambient 
4 
Turning on the mixing 
gear 36 40 ambient ambient ambient ambient 
5 
Evacuating the air 
from the chamber 41 100 ambient 88 ambient ambient 
6 
Holding the reduced 
pressure 101 105 88 88 ambient ambient 
7 
Letting the air back 
into the chamber 106 285 88 ambient ambient ambient 
8 
Turning off the mixing 
gear 286 290 ambient ambient ambient ambient 
9 Opening the chamber 291 305 ambient ambient ambient ambient 
10 
Emptying the 
chamber 306 360 ambient ambient ambient ambient 
iChamber – part of the coater where mixing of BP with oil takes place under reduced 
pressure  
iiOil mixture had temperature of 37°C prior to addition which took place at ambient 
temperature (18°C) 
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2.2.5 Fish trial designs  
2.2.5.1 Voluntary feeding 
A. salmon (mfish [g]) was randomly distributed in circular tanks containing cold 
seawater (t [°C]) with constant oxygen level (O2 [%]). The tanks were of the 
same size (dtanks [m], Vtanks [m
3]) but could vary in numbers (ntanks) between 
trials. Fish (nfish) were randomly divided into groups (ngroups) with three tanks 
being assigned to each group. Prior to the start of each treatment fish were 
acclimatised for a certain number of weeks (taccl [weeks]). The treatment 
usually lasted for one to two weeks (ttreat [weeks]) after which followed a 
sampling (nsf/t, tSP [weeks]). In the immune response trial, the treatments 
would be followed by an immune induction period, and sampling (nsf/t, tSP 
[weeks]) would take place at the end of each such period. There were two 
treatments so called oral boost (OB) periods (tOB [weeks]), and thus two 
induction intervals [tinduc [weeks]). In accordance with the ordinary veterinary 
procedure, all sampled fish were anesthetised with tricain mesilate (100 mg l-
1; Item C025, Table 2.1). Furthermore, the individual weight of the fish was 
recorded for each sampled fish. In the end, it was noted that the health of the 
fish was relatively good during the trials.  
All of the above-mentioned parameters are condensed in the Table 2.10. The 
applied values of parameters are specified in the method sections of the 
chapters referring to this fish trial design. 
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2.2.5.2 Oral intubation 
A. salmon (mfish [g]) were randomly selected from an acclimatisation tanks 
(pool of several hundred fish) for treatments (ntreat) carried out by oral 
intubation. The orally intubated fish (nfish) which received the same treatment 
were placed in the same tank right after the intubation.  As a consequence, 
the number of treatments corresponded to the number of tanks (ntanks) and 
the number of groups (ngroups). The tanks, which were of the same size (dtanks 
[m], Vtanks [m
3]), contained cold seawater (t [°C]). Level of oxygen (O2 [%]) in 
the seawater was maintained constant during the trail. Fish (nsf/t) were 
repeatedly sampled from each tank at certain time points (nSP) scheduled few 
hours apart (tSP [hours]). Each fish were anesthetised with tricain mesilate 
(100 mg l-1; Item C025, Table 2.1) prior to both intubation and sampling. In 
the end, individual weight of the fish was recorded for each sampled fish. 
The aforementioned parameters are listed in the Table 2.10. The applied 
values of parameters are declared in the method sections of the chapters 
referring to the fish trial by oral intubation 
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Table 2.10: Variable parameters of the fish trials based on voluntary feeding 
and oral intubation 
Parameter Symbol Unit 
Average weight of fish m g 
Oxygen saturation in water O2 % 
Water temperature t °C 
Diameter of a tank d m 
Volume of a tank V m3 
Number of tanks ntanks n.a. 
Number of fish per tank nfish n.a. 
Number of groups ngroups n.a. 
Number of treatments ntreat n.a. 
Number of sampled fish per tank nsf/t n.a. 
Number of sampling points nSP n.a 
Length of the acclimatisation period taccl weeks 
Length of the treatment period ttreat weeks 
Length of the oral boost period tOB weeks 
Length of the immune induction period tinduc weeks 
Length of the time intervals from the end of 
treatment to sampling 
tSP hours/weeks 
 
2.2.6 Statistical analysis 
2.2.6.1 Statistical analysis of high voltage and encapsulation efficiency data 
All statistical modeling of both high voltage and encapsulation efficiency data 
was conducted with the R language (version 3.0.2, released 25/09/2013) and 
its corresponding packages. The data structure of both experiments was 
multilevel with random variation related to replicated samples within the 
experiment that were split to multiple ELISA samples on the 96-well plate in 
the time of analysis. A multilevel model was fitted with the “lmer” function 
from the “lme4” package. Nested models with increasing complexity (null, 
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linear and nonlinear model based on cubic spline function) were compared to 
determine the most likely model in a likelihood ratio test (LRT). Significance 
level was set to P < 0.01. 
2.2.6.2 Statistical analysis of antigen uptake and immunogenicity data 
Statistical modeling of fish trial data was conducted with the R language 
(version 2.15.0, released 30/03/2012) and its corresponding packages. Data 
analysis was performed using regression and multilevel, hierarchical models 
with the “arm” package. This model was selected because multiple samples 
from each group had multiple ELISA values. The ELISA values were 
transformed to logarithms before statistical analysis to account for the 
constrained distribution. For estimation and prediction, linear mixed effect 
model was applied. For fitting of the model, the “lmer” function from the 
“lme4” package was used. Expected responses with 95% credible intervals 
for the respective treatments were generated by posterior simulations of fixed 
effects from the linear mixed effect model (n = 1500 random draws).  
2.2.6.3 Statistical analysis of data obtained from dissolution and release 
studies 
Dissolution profiles of BD shown as curves of the mean percentage of 
cumulative BD release with error bars (95% confidence intervals) over time 
were generated using Data analysis and Scatter plot functions in Microsoft 
Excel 2010. Mean HRP concentrations with error bars (95% confidence 
intervals) found in different compartments of gastrointestinal tract were 
calculated and represented in a graph using IBM SPSS Statistics for 
Windows, version 22.0. 
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2.2.6.4 Statistical analysis of data obtained from the study of antigen stability 
in fish feed production process 
Experimental design was a 22 factorial with process (mild or standard/hot) 
and encapsulation (yes or no) as the factors. In addition, there were another 
two treatments described as “standard process with no antigen (Negative 
control)" and “no process with antigen (Positive control)". These two 
additional treatments were not part of the 22 factorial design and the following 
corresponding statistical analysis but are included in all raw data plots. 
Sampling was performed at five different stages in the production process: 
mixing (dry mix, dm), conditioning (wet mix, wm), extrusion (extrudate, ext), 
drying (base pellet, bp) and coating (final feed, ff). Five samples per 
treatment were taken for each step and analysed in duplicate with ELISA. An 
additional nuisance variable to consider in the statistical modeling was the 
position of the sample on the ELISA plate. The statistical model applied was 
a multilevel (mixed-effects) first degree model for the 22 factorial. A random 
effect of ELISA run was added to account for the variability between 
duplicates. All statistical modelling was conducted with the R language 
(version 2.15.1, released 22/06/2012) and its corresponding packages. 
Loading required “xtable” and “arm” packages and setup of “lmerSim” 
function. 
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Chapter Three:  Uptake and Immunogenicity of IPNV 
antigens 
 
Infectious pancreatic necrosis (IPN) is an acute, clinical disease with large 
impact on salmon production. IPN virus causes mortality in young freshwater 
salmonids with an increasing number of outbreaks during the first months 
after transferring to seawater. For this reason, the main focus of this chapter 
is a systemic priming/oral boost strategy in immunising A. salmon. 
Accordingly, the specific immune response was assessed in the fish which 
were treated with oral IPN vaccines 12 months after intraperitoneal 
vaccination. However, before conducting the immune response trial, the 
ability of A. salmon to absorb both alginate-encapsulated and free IPNV 
antigen was checked in a separate trial. Moreover, the quality of the oral 
IPNV antigen preparations was evaluated by two factors: 1) the 
encapsulation efficiency of alginate matrices, and 2) the effect of high voltage 
(an encapsulation process parameter) on antigen viability. 
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3.1 Introduction 
Farmed salmonid fish are constantly challenged by various pathogens, 
especially during the sea water production phase (Collet, 2014). The 
common practice in the aquaculture industry has been to give an 
intraperitoneal (i.p.) injection to pre-smolt with a multivalent vaccine (e.g. 
ALPHA JECT® micro 4, 5-1 or 6 from Pharmaq). Following a short period of 
immunisation, full-grown smolt  is  transferred into seawater cages (Lillehaug, 
1997). After this point, it is no longer practical to i.p. vaccinate fish.  
In some experts' opinion, the bacterial i.p. vaccines appear to be more 
effective than the viral i.p. vaccines in the field. In their view, some of the viral 
vaccines may not exert sufficient long-lasting protective effects (Gudding and 
Van Muiswinkel, 2013; Robertsen, 2011). Delivery of an oral boost vaccine 
could re-immunise previously vaccinated fish and thus prolong the effect of 
an i.p. vaccine after  some months in seawater (Lauterslager et al., 2003; 
Zhang et al., 2014).  
There are currently several commercially available injection IPN vaccines, no 
immersion and only one oral subunit vaccine. Notably, this oral vaccine 
(AquaVac® IPN Oral, MSD Animal Health) has been given marketing 
authorisation only in Chile (Dhar et al., 2014). However, there are very few 
studies reporting successful development of an oral vaccine against the IPN. 
Allnutt et al. (2007) observe the immune response specific for IPNV which is 
induced by an orally administered yeast-based recombinant DNA vaccine in 
rainbow trout (Oncorhynchus mykiss). The study also demonstrates the 
ability of immunised fish to reduce the IPN viral load in a challenge trial. 
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Rodriguez Saint-Jean et al. (2010) report that alginate microspheres loaded 
with a pDNA encoding for VP2 of the IPN virus, immunise rainbow trout 
obtaining 80% relative survival (RPS) in a challenge trial. Similarly, 
Ballesteros et al. (2012) suggest that alginate beads loaded with a pDNA 
encoding for VP2 immunize rainbow trout against IPN in a way resembling 
IPN virus. Work by Min et al. (2012) describes the mucosal and systemic 
immune responses specific for IPN virus. This immune response is induced 
by an orally administered Lactobacilli-based recombinant DNA vaccine in 
rainbow trout. In the same study, the orally immunised fish with this 
recombinant DNA vaccine reduced the IPN viral load in a challenge trial. 
However, there are several concerns associated with DNA vaccines which 
raise issues in terms of licensing and public acceptance of the technology 
(Evensen and Leong 2013, Hølvold et al. 2014). Some of the issues are the 
hypothetical integration of pDNA into fish genome (Nichols et al., 1995; Smith 
and Klinman, 2001) and the possible release of pDNA into the environment 
(Tonheim et al., 2008). Here, the potential consumption of fish meat 
contaminated with pDNA and the potential uptake of pDNA by intestinal 
bacteria are of particular concern (Hohlweg and Doerfler, 2001; Lorenzen 
and LaPatra, 2005). Despite these concerns there is a plasmid DNA-based 
vaccine that is gained marketing authorization from the Canadian Food 
Inspection Agency (CFIA) in 2005. This i.p. vaccine (Apex®-IHN, Novartis 
Animal Health) is used to prevent infectious hematopoietic necrosis (IHN) in 
salmon farmed in the Pacific Northwest. 
There are also reports showing a successful assessment of oral vaccines 
against bacterial pathogens like P. salmonis (Tobar et al., 2011), E. ictaluri 
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(Thinh et al., 2009) and L. garvieae (Romalde et al., 2004). High RPSs (50-
90%) were achieved when these vaccines were applied as a means of 
boosting the immune response in previously vaccinated fish. However, there 
are studies involving oral vaccines which are not equally successful. For 
instance, Santos et al., (2005) reported that delivering an oral boost vaccine 
after a primary vaccination by injection did not enhance protection of turbot 
(Scophthalmus maximus) against A. salmonicida. 
Many oral vaccines turned out to be ineffective as a result of failing to 1) 
deliver sufficient dosage of antigen, 2) protect antigen from degradation in 
the digestive tract and 3) assist antigen in crossing the intestinal epithelium 
layer (Plant and Lapatra, 2011; Sommerset et al., 2005).  
The present study addresses a systemic priming/oral boost strategy. This 
strategy involves i.p. priming of A. salmon with a combination vaccine (incl. 
IPNV antigens) followed by oral boosting with alginate-encapsulated IPNV 
antigens. These antigens are killed IPN viruses produced by growing  virus (a 
recombinant Sp strain of IPNV, rNVI-15PTA) as previously reported by (Chen 
et al., 2013). The primary aim of this study was to examine whether the orally 
administered alginate-encapsulated IPNV antigens, could boost the specific 
immunity against IPN in the i.p. vaccinated A. salmon. A secondary aim of 
this study was to compare ethylenediammonium alginate- to calcium 
alginate-encapsulated IPNV antigen with respect to the specific immune 
response. To determine the quality of the oral antigen preparations, two 
additional factors were assessed: 1) the encapsulation efficiency of alginate 
matrices, and 2) the effect of high voltage (an encapsulation process 
parameter) on antigen viability.  
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3.2 Adverse effects and efficiency of the encapsulation 
Electrospraying is a method that makes use of high voltage to create a jet of 
droplets for curing in crosslinking solution. Therefore, it is important to learn 
whether that high voltage is harmful for antigens. Moreover, it is also 
essential to know how much of the antigen added to an encapsulation 
formulation is actually encapsulated in alginate beads. This is determined by 
the encapsulation efficiency of alginate along with the encapsulation method. 
3.2.1 Methods 
3.2.1.1 Effect of high voltage on IPNV antigen viability 
To assess the effect of high voltage on IPNV antigen viability, the 
encapsulation formulation (Item S001, Table 2.4) was electrosprayed into 
PBS (Item C005, Table 2.1) at different voltage levels. The electrospraying 
was conducted according to the general method described in the Section 
2.2.1.1 (Chapter 2). The applied process variables are summarised in the 
Table 4.1. The exception was the use of PBS instead of a crosslinking 
solution. Consequently, no alginate beads were formed. In fact, crosslinking 
was an unnecessary action in this study. It would only introduce a need for 
an additional step to dissolve the created alginate beads.   
Five samples were generated at each voltage level (0, 5, 10, 15, 20 and 25 
kV) while the other parameters were kept constant. The samples (0 kV) 
produced without voltage, served as a reference samples (Figure 3.1). 
Concentration of IPNV Ag was determined in an ELISA assay at Norwegian 
School of Veterinary Science (Oslo, Norway). ELISA was performed in 
quadruplicate with minor modifications as previously described by 
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Munang’andu et al. (2012). On the other hand, statistical analysis was carried 
out according to the method described in the Section 2.2.6.1 (Chapter 2). 
 
 
Figure 3.1: Experimental design of the high voltage test. Scheme for 
generating samples in the experiment assessing the effect of high voltage on 
IPNV Ag viability. Encapsulation formulation (EncForm 1: V = 1.0 ml, 2% 
sodium alginate, IPNV antigen 109 TCID50 ml
-1) was extruded into PBS 
solution (9.0 ml) at constant flow rate (100.00 ml h-1) with the assistance of 
voltage. Five samples were generated at each voltage level (0 kV, 5, 10, 15, 
20 and 25 kV). The samples generated without voltage applied (0 kV) served 
as reference samples. Afterwards, each sample was replicated four times in 
an ELISA assay resulting in the total number of 120 samples on the 96-well 
plate.   
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Table 3.1: Process variables with their respective values for testing of the 
effect of high voltage on the antigen viability. 
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x VPBS 
µm cm3 h-1 ml kV mm ml 
2000 100 1.0 variableiii 100 9.0 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of PBS (VPBS) 
iiiSix levels of voltage were used: 0, 5, 10, 15, 20 and 25 kV 
3.2.1.2 Encapsulation efficiency 
Encapsulation efficiency of the IPNV antigen in alginate matrices was 
determined by using two different encapsulation formulations (Item S001 and 
S002, Table 2.4). Those two formulations were in turn combined with two 
types of crosslinking solution (Item S003 and S004). Samples of alginate 
beads (nsample = 30) were produced according to the general method 
described in the Section 2.2.1.1 (Chapter 2). Notably, the non-use of voltage 
(U) was a deviation from the general method. For a better overview, the 
controlled variables of the encapsulation process are condensed in the Table 
3.2. Moreover, the applied encapsulation formulations along with their 
corresponding crosslinking solutions are listed in the Table 3.3. In should 
also be noted that the needle (Item T014, Table 2.2) and the sodium 
bicarbonate solution (Item S005, Table 2.4) were utilised during the process 
of encapsulation. Ultimately, it was generated five of each of the following 
alginate samples: 108-Ca-alg, 109-Ca-alg, 108-EDA-alg and 109-EDA-alg. For 
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clarity reasons, the process of obtaining samples is schematically shown in 
the Figure 3.2. After preparation, the alginate beads were dissolved in the 
saturated sodium bicarbonate solution (9.0 ml). Dissolution was completed 
within an hour under stirring. To equalise all sample volumes, the level of the 
resulting solutions was adjusted to 10.0 ml before taking samples of 1.0 ml. 
Unlike the other samples, the reference samples (Ca-Ref and EDA-Ref) were 
produced by direct extrusion of encapsulation formulations (1.0 ml) into the 
saturated bicarbonate solution (9.0 ml). In the end, each sample was diluted 
with PBS (Item C005, Table 2.1) to an antigen level of 107 TCID50 ml
-1. 
Level of IPNV antigen in the samples was determined in an enzyme-linked 
immunosorbent assay (ELISA) at Norwegian School of Veterinary Science 
(Oslo, Norway). ELISA was performed in triplicate with minor modifications 
as previously described by Munang’andu et al. (2012).  
Encapsulation efficiency was calculated on the basis of the data obtained 
from the ELISA test (Equation 3.1). Encapsulation efficiency was defined as 
the percent ratio of the total amount of encapsulated antigen (EncapAg) to 
the total amount of antigen in a reference sample (RefAg). 
Finally, statistical analysis was performed according to the method described 
in the Section 2.2.6.1. 
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Table 3.2: Encapsulation efficiency test - process variables with their 
respective values. 
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x Vxls 
µm cm3 h-1 ml kV mm ml 
2000 60 1.0 0 50 9.0 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of crosslinking solution (Vxls) 
 
Equation 3.1: Calculation of encapsulation efficiency (%EE) 
100
Re

fAg
EncapAg
EE  
EE – Encapsulation efficiency 
EncapAg – Optical density (OD) of encapsulated antigen (ELISA value) 
RefAg – OD of a reference sample (ELISA value 
 
Table 3.3: Alginate beads generated in the encapsulation efficiency test. 
Generated alginate beads in relation to the type of alginate matrix (Ca-/EDA-
alginate) and encapsulation formulation (EncForm 1 or 2) along with cross-
linking solution (XlinkSol) applied in the encapsulation process. 
 Ca-alginate beads EDA-alginate beads 
 Ca-Ref 108-Ca 109-Ca EDA-Ref 108-EDA 109-EDA 
EncFormi 1 2 1 1 2 1 
XlinkSolii  NaHCO3iii CaCl2 CaCl2 NaHCO3 EDA∙2HCl EDA∙2HCl 
iEncapsulation formulations –  (EncForm) 1: IPNV Ag 109 TCID50 ml
-1 (Item S001, 
Table 2.4), EncForm 2: IPNV Ag 108 TCID50 ml
-1 (Item S002, Table 2.4) 
iiCross-linking solution (XlinkSol): calcium chloride (CaCl2; Item S003, Table 2.4) 
and ethylenediamine dihydrochloride (EDA∙2HCl; Item S004, Table 2.4) 
iiiSaturated sodium bicarbonate (NaHCO3; tem S005, Table 2.4) does not cross-link 
but dissolves sodium alginate. 
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Figure 3.2: Experimental design of the encapsulation efficiency test. Scheme 
for generating samples in the experiment assessing encapsulation efficiency 
of two different IPNV antigen concentrations (108 and 109 TCID50 ml
-1) in two 
types of alginate matrix (calcium alginate [Ca-alg] and ethylenediammonium 
alginate [EDA-alg]). Encapsulation formulation (EncForm 1) was 
electrostatically extruded to produce the reference samples (Ca-Ref and 
EDA-Ref, n = 5 samples each). Similarly, EncForm 1 was used to generate 
the Ca-alg (n = 5 samples) and EDA-alg beads (n = 5 samples) with high 
IPNV antigen concentration. Encapsulation formulation (EncForm 2) was 
utilised to produce Ca-alg (n = 5 samples) and EDA-alg beads (n = 5 
samples) with low IPNV antigen concentration. Both of Ca-alg samples (high 
and low antigen level) were cross-linked with calcium chloride (CaCl2) while 
both of EDA-alg were cross-linked with ethylenediamine dihydrochloride 
(EDA∙2HCl). The reference samples were not cross-linked. Alternatively, they 
were directly extruded into sodium bicarbonate (NaHCO3). Sodium 
bicarbonate was also applied in dissolving cross-linked alginate beads as 
well as in diluting the resulting alginate solutions to an antigen level (107 
TCID50 ml
-1) suitable for ELISA assay. Ultimately, each sample was 
replicated three times in an ELISA assay resulting in the total number of 90 
samples on the 96-well plate.   
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3.2.2 Results 
3.2.2.1 Effect of high voltage on IPNV Ag viability 
According to the likelihood ratio test (LRT), the linear model does not produce 
significantly greater log-likelihood than the null model at 1% significance level 
(p>0.3282). Furthermore, the nonlinear model does not fit significantly better 
than the linear model at the same significance level (p>0.8722). It means that 
even nonlinear model cannot generate greater log-likelihood than null model 
at 1% level (Figure 3.4). In other words, there is no statistically significant 
difference between the reference samples (0 kV) and the electrostatically 
extruded samples (5-25 kV), (Figure 3.3).  
 
Table 3.4: Likelihood ratio test statistic of the high voltage experiment. 
Likelihood ratio test statistic for the nested models (null, linear and nonlinear 
model). Neither linear (p>0.3282) nor nonlinear model (p>0.8722, versus 
linear model) fit significantly better than null model at the 5% significance 
level.  
Model type logLiki Devianceii Chisqiii Dfiv p(>chisq)v 
Null 200.15 -400.30 n.a. n.a. n.a. 
Linear 200.63 -401.26 0.9558 1 0.3282 
Nonlinear 200.98 -401.96 0.7043 3 0.8722 
ilogLik – log-likelihood ratio statistic 
iiDeviance – negative twice the log-likelihood   
iiiChisq – Chi (Χ2) square value 
ivDf – Degrees of freedom – difference between number of free parameters in a 
“complex model” and a “simpler model”. 
vp(>chisq) – Probability of occurrence for an X2 value depending on degrees of 
freedom (p-value). 
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Figure 3.3: Observed OD values in relation to the voltage (kV) in the high 
voltage experiment. The ELISA samples (n = 20 per voltage level) are 
represented by a circlet. The samples taken at each voltage level (n = 5) are 
denoted by five different colours. The difference between the number of 
samples, which are taken and analysed, results from the fact that each 
sample taken was replicated four times on the 96-well plate. The likelihood 
ratio test (LRT) suggests there is no effect of voltage on the viability of IPNV 
antigen. 
    
3.2.2.2 Encapsulation efficiency  
The average encapsulation efficiency of 109-Ca-alg and 109-EDA-alg was 
78% and 97% respectively. However, difference between the sample means 
of Ca-Ref and 108-Ca-alg cannot be considered as statistically significant at 
the 5% level (Figure 3.4). Equally, the ratio of 108-EDA-alg to EDA-Ref is not 
statistically significant at the same level. This suggests that IPNV antigen 
suspended at 108 TCID50 ml
-1 could be entrapped in an alginate matrix with 
negligible loss. 
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Figure 3.4: Results of the encapsulation efficiency test. Encapsulation 
efficiency (EE) of a) Calcium alginate at 108 (n.s. loss) and 109 (EE = 78%) 
TCID50 ml
-1 and b) Ethylenediammonium alginate at 108 (n.s. loss) and 109 
(EE = 97%) TCID50 ml
-1 IPNV antigen. Error bars represent 95% confidence 
intervals. n.s. stands for “not significant” 
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3.3 Uptake of IPNV antigen in A. salmon 
Uptake of IPNV antigen to blood plasma of A. salmon was assessed in this 
study. There were for treatments: 1) alginate-encapsulated antigen, 2) un-
encapsulated antigen, 3) empty alginate beads and 4) PBS. The preparations 
were oral intubated into fish and the IgM level was determined in an ELISA 
assay. 
3.3.1 Methods 
3.3.1.1 Preparation of alginate beads loaded with antigen 
Alginate beads loaded with IPNV antigen were prepared according to the 
general encapsulation method described in the Section 2.2.1.1.  Controlled 
variables of the encapsulation process (electrospraying) are summarised in 
the Figure 4.5. In the process of encapsulation, the following items were 
used: encapsulation formulation (Item S001, Table 2.4), alginate solution 
(Item S028, Table 2.4), a needle (Item, T013, Table 2.2) and cross-linking 
solution (Item S003, Table 2.4). In order to reach the target dose (109 TCID50 
of IPNV antigen per fish), encapsulation efficiency (78%) of IPNV antigen 
(109 TCID50 ml
-1) in calcium alginate was taken into consideration. As a 
result, 30 batches of encapsulation formulation (1.28 ml per batch) were 
processed into alginate beads for “Encapsulated Antigen (EA)” group of fish. 
Similarly, 30 batches of alginate solution (1.28 ml per batch) were turned into 
beads for “Encapsulated Control (EC)”. After preparation, alginate beads 
were dried under reduced pressure for 48 hours. Finally, approximately 100 
mg of dry alginate powder per batch was recovered. 
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Table 3.5: Process parameters of the electrospraying method utilised in 
encapsulating IPNV antigen for the uptake study. These parameters apply to 
the production of one single batch (1.28 ml). 
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x Vxls 
µm cm3 h-1 ml kV mm ml 
700 60 1.28 7.0 50 20 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
3.3.1.2 Oral intubation of A. salmon 
The fish trial was performed according to the general method described in 
the section 2.2.5.2 (Chapter 2) at TempOx lab (EWOS Innovation AS, Dirdal, 
Norway). Parameters applied in this trial are listed in the Table 3.6. 
Moreover, fish was starved one day in advance of the treatment. The 
following groups were formed: “Unecapsulated Control (UC)”, “Un-
encapsulated Antigen (UA)”, “Encapsulated Control (EC)” and “Encapsulated 
Antigen (EA)” (Figure 3.6). The UC group was intubated with PBS (Item 
C005, Table 2.1), the UA was intubated with un-encapsulated IPNV antigen 
while the EC and EA were given empty alginate beads and alginate-
encapsulated IPNV antigen respectively (Figure 3.5). Both UA and EA 
received the same IPNV antigen dose (109 TCID50 per fish). 
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Table 3.6: Parameters applied in the uptake study carried out by oral 
intubation with alginate beads loaded with IPNV antigen. 
Parameter Symbol Quantity 
Average weight of fish m 172 g 
Oxygen saturation in water O2 90% 
Water temperature t 12°C 
Diameter of a tank d 2.0 m 
Volume of a tank V 3.1 m3 
Number of tanks ntanks 4 
Number of fish per tank nfish 30 
Number of groups ngroups 4 
Length of the acclimatisation period taccl 1 week 
Number of treatments ntreat 4 
Number of control fish ncontrol 60 
Number of control groups nctrl-gr 2 
Number of sampled fish per tank per sampling 
point 
nsf/t 10 
Number of sampling points nSP 3 
Length of sampling time intervals calculated from 
the end of treatment 
tSP 
24, 72 and 
168 h 
Total number of sampled fish nsampled 120 
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Figure 3.5: Oral intubation of A. salmon. A) Plastic syringe (size: 1 ml)  is 
inserted in the moth of a fish, B) Syringe with severed tip for intubating fish 
with empty alginate beads (Encapsulated control, EC group) and alginate 
beads loaded with IPNV antigen (Encapsulated antigen, EA group). C) 
Syringe with rubber tip for intubating fish with phosphate-buffered saline (Un-
encapsulated control, UC group) and IPNV antigen suspension (Un-
encapsulated antigen, UA group). 
     
3.3.1.3 Sampling 
Ten fish was sampled from each tank at 24, 72 and 168 hours post 
intubation. Prior to sampling, the fish were anaesthetised with tricain mesilate 
(100 mg l-1; C025, Table 2.1). Weight of individual fish was recorded for 
every sampled fish. Blood was collected from the caudal artery with a 
heparinised blood collection tube (V = 4 ml) fitted with 0.8×38 mm disposable 
needles (Figure 3.6). The blood samples (approx. 4 ml fish-1) were 
centrifuged at 4000 rpm for 10 min immediately after sampling. The plasma 
was then removed and kept frozen at -80oC prior to ELISA test.  
Level of IPNV antigen in the samples was determined in an ELISA assay at 
Norwegian School of Veterinary Science (Oslo, Norway). The assay was 
performed with minor modifications as previously described by Munang’andu 
et al. (2012). The plasma samples were diluted 40-fold with PBS before 
plating 100 µl per well.  
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Figure 3.6: Tank and sampling plan of the IPNV antigen uptake study. The 
tank and sampling plan is illustrated in four vertical segments in this figure. 
Tank arrangement is shown in the first segment. It contains information on 
name of the treatments (UC – phosphate-buffered saline solution, UA – un-
encapsulated IPNV antigen, EC – empty alginate beads and EA – alginate-
encapsulated IPNV antigen), number of intubated fish (n = 30), fish size 
(m(avg) = 172 g), tank volume (3.1 m
3) and temperature (12°C). In the second 
segment, sampling points (24, 72 and 168 hours) are listed. Number of fish 
sampled per tank (10 fish/tank) at specified sampling points (40 fish/sampling 
point) is shown in the third segment. The last segment indicates the number 
of blood plasma samples (BS) taken per fish (1 BS/fish) at any sampling 
point resulting in the total of 120 samples.    
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3.3.2 Results 
At 24 hours post intubation (p.i.), fish intubated with the un-encapsulated 
antigens (UA group) showed higher blood plasma concentrations of IPNV 
antigen than fish administered encapsulated antigens (EA group) (Figure 
3.7). The EA group on the other hand showed a higher uptake than the UA 
group at 72 hours p.i. However, response of the encapsulated control group 
(EC) was surprisingly high. There was no statistical difference in uptake 
between all groups at 168 hours p.i..  
 
 
Figure 3.7: Uptake of IPNV antigen in blood plasma of A. salmon. Optical 
density (OD) responses for different oral treatments with IPNV antigen are 
shown. The responses were measured by an ELISA assay. Error bars shows 
95% credible intervals. Four groups/treatments were: UC – un-encapsulated 
control (PBS solution), UA – unencapsulated antigen (IPNV antigen 
suspension), EC – encapsulated control (empty alginate beads) and EA – 
encapsulated antigen (alginate-encapsulated IPNV antigen). Blood plasma 
samples were taken at 24, 72 and 168 hours post intubation. 
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3.4 Immunogenicity of alginate-encapsulated antigen 
Immune response of A. salmon to IPNV antigen was assessed in this study. 
Fish was treated with four different preparations. These preparations were: 
two oral vaccine formulations with alginate-encapsulated antigen, one 
formulation containing un-encapsulated antigen and one control preparation 
consisting of pure PBS. IgM antibody levels in blood plasma were measured 
by ELISA, The level of expression of IgM, IgT, CD4, GATA3, FOXP3, TGF-β 
and IL-10 genes in head kidney, spline and liver were determined by qPCR 
as well. 
3.4.1 Methods 
3.4.1.1 Fabrication and characterisation of alginate beads with IPNV antigen  
Alginate beads loaded with IPNV antigen were produced according to the 
general method described in the section 2.2.1.1 (Chapter 2). Process 
parameters and their respective values are summarised in the Table 4.8. For 
the purpose of encapsulation, the encapsulation formulation (Item S001, 
Table 2.4) and the needle (Item T014, Table 2.2) were used as well. 
Furthermore, the beads were cross-linked in two different ways using 
crosslinking solutions (Item S003 and S004, Table 2.4). As a result, two 
different alginate products labelled Encap 1 and Encap 2 were produced. The 
Encap 1 product was cross-linked with calcium (Item S003, Table 2.4). 
Seven batches a 60 ml were processed and then combined into one single 
batch totalling 420.0 g of wet calcium alginate beads. Regarding the 
production of Encap 2, five and a half batches were cross-linked with 
ethylenediammonium dication (Item S004, Table 2.4). Thereafter, the 
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resulting ethylenediammonium alginate beads were merged into one batch of 
330.0 g.   
The generated wet alginate beads were filtered off and then dried under 
reduced pressure (0.06 mbar; Item T007, Table 2.2) for 48 hours. The dry 
residue was crushed with mortar and pestle before being sieved through a 
150 µm sieve. The particle size distribution and shape were determined by 
stereo microscope (Item I001, Table 2.3).  
 
Table 3.7: Encapsulation process variables with their respective values 
applied in the study of encapsulation efficiency. 
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x Vxls 
µm cm3 h-1 ml kV mm ml 
2000 100 60 7.0 30 150 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of crosslinking solution (Vxls) 
3.4.1.2 Preparation of oral boost feeds 
Oral boost feeds (OBFs) were prepared by applying an oil mixture (OM) to 
base pellet (BP; Item C007, Table 2.1) in the vacuum infusion coating 
process. OMs were formulated by mixing IPNV Ag suspension (109 TCID50 g
-
1), phosphate buffered saline (PBS; Item C005, Table 2.1), Encap1 
(2.70×1010 TCID50 g
-1) or Encap2 (2.02×1010 TCID50 g
-1) with fish oil (Item 
C019, Table 2.1). Mixing was performed by using high-performance 
disperser (Item T005, Table 2.2) at ambient temperature. The OBF-1, -2 and 
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-3 were composed with the aim of generating feeds containing an antigen 
level of 4.01×107 TCID50 g
-1. This level was selected due to an expected daily 
feed intake of 3.56 g fish-1 during the first oral boost (1.OB) period. For the 
same reason, the targeted antigen level in the OBF-4, -5 and -6 was 
2.99×107 TCID50 g
-1. It is because of the anticipated daily feed intake of 4.77 
g fish-1 in the second oral boost (2.OB) period. Feeding at these rates 
provides a weekly antigen dose of 1×109 TCID50 g
-1 in both OB periods.    
 
Table 3.8: Composition of the oral boost feeds (OBFs) and control feeds 
(CFs) in the immune response study. Base pellet (BP) was coated with an oil 
mixture consisting of fish oil and at most two other components to make 3900 
g of CFs or OBFs. These other components are selected from the following 
group of additives: antigen suspension (Ag susp.), phosphate-buffered saline 
(PBS) and one of the encapsulation products (Encap 1 or 2).   
Feed 
name 
Oil mixture 
BPiv          
[g] 
Total    
[g] 
Fish oil 
[g] 
Ag 
suspi [g] 
PBS              
[g] 
Encap1ii 
[g] 
Encap2iii 
[g] 
CF-1 783.51 0.00 156.50 0.00 0.00 2959.99 3900.00 
OBF-1 783.51 156.50 0.00 0.00 0.00 2959.99 3900.00 
OBF-2 789.31 0.00 150.70 5.80 0.00 2954.19 3900.00 
OBF-3 791.24 0.00 148.77 0.00 7.73 2952.26 3900.00 
CF-2 783.51 0.00 156.50 0.00 0.00 2959.99 3900.00 
OBF-4 783.51 116.80 39.70 0.00 0.00 2959.99 3900.00 
OBF-5 788.00 0.00 152.17 4,33 0.00 2955.66 3900.00 
OBF-6 789.28 0.00 150.73 0.00 5.77 2954.22 3900.00 
iAg susp – antigen suspension derived from IPN viral culture with titre of 109 TCID50 
ml-1 
iiEncap 1 – product generated by encapsulating Ag suspension into Ca-alginate 
matrix 
iiiEncap 2 – product made by encapsulating Ag suspension into EDA-alginate matrix 
ivBP – base pallet is a semi-finished fish feed product which is dry extrudate lacking 
oil mix 
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Control feeds (CF-1 and -2) were produced by mixing PBS with fish oil in 
advance of applying to BP in the vacuum infusion coating process. These 
two formulations were identical and IPNV Ag free. A detailed specification of 
the mixing ratios is shown in the Table 3.8.  
3.4.1.3 Fish trial design 
A. salmon (n = 540, mavg=200g) was distributed randomly among 12 circular 
seawater tanks (d = 1 m, V = 500 l, t = 8°C) at EWOS Innovation AS (Dirdal, 
Norway) 10 weeks prior to the start of the 1.OB period. The tanks were 
randomly divided into four groups (Unecap, Encap 1, Encap 2 and Control), 
with three tanks being assigned to each group. All fish used in this trial were 
vaccinated with the multivalent vaccine (Item C026, Table 2.1) one year prior 
to the trial. For this reason circulating antibodies were expected to be present 
in the fish and the oral vaccinations were considered as immunity boosting 
treatments. Boosting was performed twice for a period of one week each 
time. After 10 weeks long acclimatisation stage, a weeklong 1.OB period took 
place. The 1.OB was succeeded by a seven week long induction period. 
After the end of that period, the first sampling was performed. The 2.OB 
commenced immediately upon completion of the first sampling. After the 
2.OB interval, there was a four week long period of immune induction 
followed by the final sampling (Figure 3.9). The health status of the fish was 
very good during the 23 weeks long span of the trial.  
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3.4.1.4 Feeding plan and feed intake assessment 
All groups were fed with EWOS commercial diets in excess in the periods 
outside the oral boost intervals. During the acclimatisation and the first 
immune induction period fish was provided with EWOS Opal 200 diet. In the 
time of the second induction period, feeding was conducted with EWOS Opal 
500 due to the change in fish size. Throughout the oral boost intervals, fish 
received oral boost feeds (OBFs). Unencap group was fed with OBF-1 in the 
1.OB period and then with the OBF-4 in the 2.OB period. Encap 1 group was 
fed with OBF-2 and OBF-5 in the 1.OB and 2.OB interval respectively. Encap 
2 group was given OBF-3 in the 1.OB period and then OBF-6 in the 2.OB 
period. The Control group was provided with feed free of IPNV antigen in 
both of the OB periods. Each group contained 120 (3×40) fish in the time of 
the 1.OB period. In the 2.OB period, the groups were reduced to 75 (3×25) 
fish each. In order to predict feed intake as accurately as possible, feed 
consumption was measured over a course of seven days, one week ahead of 
the OB intervals. Therefore, the daily portions for all groups were set to 166 g 
and 147 g per tank during the 1.OB and 2.OB respectively (Figure 3.8). 
Unconsumed feed was collected during both boost periods to calculate feed 
intake. Uneaten pellets were spilled out of the tanks within 10 min post 
feeding and filtered off from the outlet water using an automatic collection 
system. Residual pellets were removed from the filters and put into a drying 
cabinet for 24 h at 70 °C. Amount of feed consumed was calculated as the 
difference between the dry weight of the feed served and the dry weight of 
unconsumed feed, expressed as the mass of feed per week per fish. 
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Figure 3.8: Tank arrangement and the corresponding feeding regime in the 
immune response study. Tank arrangement and corresponding feeding 
regime in the predefined trial intervals are outlined in four horizontal 
segments in this illustration. In the first segment of the figure, subsequent 
order of the intervals (from left to right) and number of fish in the tanks are 
denoted. Duration of the intervals is shown in the Figure 3.9. In the second 
segment, tank plan showing tank numbers (T1….T12) and diet codes are 
depicted. The following diet codes are used: EO200 – Ewos Opal 200 
(commercial diet), EO500 – Ewos Opal 500 (commercial diet), OBFs – Oral 
boost feeds (OBF-1….OBF-6) and CF – Control feeds (CF-1 and CF-2) as 
detailed in the Table 2.2. Daily feed servings (DS) along with IPNV antigen 
content per gram feed in each interval are shown in the third segment. “DS = 
acc. to rqt” means that fish were fed according to requirement for the age, 
size and expressed appetite. In the last segment of the figure, the tanks 
assigned to the four treatments/groups (Control, Unencap, Encap1 and 
Encap2) are listed. 
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3.4.1.5 Sampling  
Ten fish was sampled from each tank at each sampling point (Figure 3.9). 
Prior to sampling, the fish were anaesthetised with tricain mesilate (100 mg l-
1; C025, Table 2.1). The weight of individual fish was recorded for every 
sampled fish. Blood was collected from the caudal artery with a heparinised 
blood collection tube (V = 4 ml) fitted with 0.8×38 mm disposable needles. 
The blood samples (approx. 4 ml fish-1) were centrifuged at 4000 rpm for 10 
min immediately after sampling. The plasma was then collected and kept 
frozen at -80oC until measuring antibody levels by ELISA. In addition, head 
kidney, spleen and hindgut were sampled and stabilised in RNAlater® (Item 
C006, Table 2.1). These samples were kept frozen at -20°C until measuring 
the expression of selected genes by qPCR. 
 
Figure 3.9: Immune response study shown in the subsequent order of 
events: 1) acclimation (ten weeks), 2) First oral boost (one week), 4) First 
immune induction (seven weeks), 5) First sampling, 6) Second oral boost 
(one week), 7) Second immune induction (four weeks), and 8) Second 
sampling. Altogether, the total length of the trial sums up to 23 weeks. 
 
 
113 
 
3.4.1.6 Sample analysis 
Apart from measuring the antibody (IgM) levels in blood plasma by ELISA, 
the expression of IgM, IgT, CD4, GATA3, FOXP3, TGF-β and IL-10 genes 
were determined by qPCR. The selection of these genes is in line with the 
theory provided in the Section 1.3. 
ELISA was performed with minor modifications as previously described by 
Munang’andu et al. (2012) at Norwegian School of Veterinary Science (Oslo, 
Norway). As distinct, these plasma samples were diluted 40-fold with PBS 
before plating 100 µl per well. Similarly, qPCR was carried out according to 
Chen at al. (2014) at the same institution. However, only samples from one 
encapsulated group (Encap 1) were examined by qPCR. 
In the end, statistical analysis was conducted according to the method 
described in the Section 2.2.6.2. 
3.4.2 Results 
3.4.2.1 Characterisation of alginate beads loaded with IPNV antigen  
Structure of wet alginate beads was spherical changing to irregularly shaped 
particles consequent to lyophilisation and subsequent grinding (Figure 3.10). 
The mean size of wet alginate beads was roughly 700-750 µm. After 
lyophilisation the average size decreased to 250-300 µm. The size was 
further scaled down to below 150 µm by sifting (150 µm screen) and grinding 
with mortar and pestle (Table 3.9). Theoretical concentration of IPNV Ag in 
the lyophilised alginate products Encap 1 and Encap 2 was 2.70×1010 and 
2.02×1010 TCID50 g
-1 respectively. 
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Figure 3.10: Stereo microscope zoom (SMZ) images of alginate beads. SMZ 
(Item I001, Table 2.3) images of a) Wet Ca-alginate beads loaded with IPNV 
Ag (Encap 1), b) Wet EDA-alginate beads loaded with IPNV Ag (Encap 2) c) 
Lyophilised Ca-alginate beads loaded with IPNV Ag (Encap 1: 2.70×1010 
TCID50 g
-1), d) Lyophilised EDA-alginate beads loaded with IPNV Ag (Encap 
2: 2.02×1010 TCID50 g
-1). 
 
Table 3.9: Size of the alginate beads in the immune response trial.  
 Wet size 
µm ±SD 
Dry size 
µm ±SD 
Post sifting size 
µm 
Encap 1i 736±32 299±45 <150 
Encap 2ii 712±28 268±37 <150 
iEncap 1 – product generated by encapsulating Ag susp into Ca-alginate matrix 
iiEncap 2 – product made by encapsulating Ag susp into EDA-alginate matrix 
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3.4.2.2 Feed intake of oral boost feeds (OBFs) and IPNV Ag dose 
Theoretical concentration of IPNV Ag in the OBF-1,-2, and -3 was 4.01×107 
TCID50 g
-1 decreasing to 2.99×107 TCID50 g
-1 in the OBF-4,-5 and -6. In the 
1.OB period, the fish were served 29.1 g but consumed 23.9 ±1.3 g fish-1 for 
the entire period while in the 2.OB period the weekly feed intake was around 
38.4 ±2.2 g of 41.2 g fish-1 offered. Average fish weight was 397 ±104 g in 
the 1.OB and then it doubled to 804 ±120 g in the 2.OB period. The attained 
average antigen dose in both OB periods was more or less 1×109 TCID50 
fish-1 which correspond the targeted weekly dose. However, due to the 
doubling of fish weight in the 2.OB period, the dose per unit of fish body 
weight was almost twice as low as the 1.OB dose. Control feeds (CFs) were 
IPNV antigen free (Table 3.10). 
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Table 3.10: Antigen dose related to the fish size in unit of mass and the 
weekly feed intake (FI) per fish. The dose is shown as a weekly IPNV antigen 
dose per fish (TCID50 fish
-1) and a weekly IPNV antigen dose per unit of fish 
mass (TCID50 kg
-1). 
Periodi Groupii Feediii 
Fish 
size 
(g) 
±SD 
FI  
(g fish-1 
week-1) 
±SD 
IPNV Ag 
dose (TCID50 
fish-1 week-1) 
±SD 
IPNV Ag dose  
(TCID50 kg
-1 
week-1)  
±SD 
1.OB 
Control CF-1 395  
±92 
24.7  
±0.4 
0.00 0.00 
Unencap OBF-1 375  
±82 
23.9  
±2.4 
9.6×108 
±1×108 
2.6×109 
±6×108 
Encap 1 OBF-2 426 
±121 
23.1  
±0.9 
9.3×108 
±4×107 
2.2×109 
±6×108 
Encap 2 OBF-3 395 
±115 
24.1  
±0.8 
9.7×108 
±3×107 
2.4×109 
±7×108 
2.OB 
Control CF-2 846 
±135 
39.6  
±0.4 
0.00 0.00 
Unencap OBF-4 796 
±126 
37.3  
±3.9 
1.1×109 
±1×108 
1.4×109 
±3×108 
Encap 1 OBF-5 782 
±105 
38.0  
±1.3 
1.1×109 
±4×107 
1.5×109 
±2×108 
Encap 2 OBF-6 792 
±108 
38.6  
±2.4 
1.2×109 
±7×107 
1.5×109 
±2×108 
iPeriods – two weeklong immunisation periods designated the first oral boost (1.OB) 
and the second oral boost (2.OB),  
iiGroups – treated with PBS (Control), un-encapsulated IPNV Ag (Unencap), Ca-
alginate-encapsulated IPNV Ag (Encap 1) and EDA-alginate-encapsulated IPNV Ag 
(Encap 2) 
iiiFeeds – oral boost feeds 1-6 (OBFs) associated with corresponding alginate 
products and control feeds 1 and 2 (CFs) added PBS. 
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3.4.2.3 Assessment of immune responses by ELISA 
At seven weeks following the 1.OB, there was a significantly higher antibody 
response in fish fed with OBF-1/Encap1 feed than in fish fed with any other 
OBF (Figure 3.11). Fish fed with OBF-2/Encap 2 and OBF-3/Unencap had 
similar response to the un-boosted control. After the 2.OB, the antibody 
response of the Unencap group remained lower than the response of any 
other group. Although the OD values of the groups fed with OBFs (Encap1 
and Encap 2) rose from the 1.OB to 2.OB, there was no significant difference 
between them and control feed. Particularly, OD value of the control group 
increased in the 2.OB. At the same time, possibility of the ELISA assay being 
more sensitive in the second run cannot be entirely excluded either. Notably, 
the fish received only half of the antigen dose per unit of fish mass in the 
2.OB compared to the 1.OB period. 
 
 
Figure 3.11: Antibody response in the immune response trial. Antibody 
response in plasma for different treatments in the 1.OB (a) and the 2.OB (b). 
Error bars show 95% credible interval. Fish treated with PBS (Control), un-
encapsulated IPNV Ag (Unencap), Ca-alginate-encapsulated IPNV Ag 
(Encap 1) and EDA-alginate-encapsulated IPNV Ag (Encap 2). 
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3.4.2.4 Assessment of gene expression by qPCR 
In order to verify whether antibody response was humoral, the expression of 
CD4 and GATA-3 genes was examined. These genes are known to be 
associated with Th2 responses, especially in the head kidney and spleen.  
Seven weeks after the 1.OB and four weeks after the 2.OB, the 
Encapsulated group had significantly higher CD4 expression (p < 0.04) in all 
three tissue samples (head kidney, spleen and hindgut) compared to the Un-
encapsulated group (Figure 3.12). In this group, the CD4 gene was slightly 
suppressed although non-significantly. Similarly, the expression of GATA-3 in 
the Encapsulated group was significantly up-regulated (p < 0.04) at both 
sampling points in all three organs (Figure 3.13). On the other hand, GATA-3 
was not induced in the Un-encapsulated group which is in accordance with 
the results of CD4.  
 
Figure 3.12: CD4 expression: Mean CD4 expression of boosted groups 
relative to un-boosted control.  n = 30; *statistically significant p < 0.05. There 
was significant up-regulation of CD4 in all tissue samples of the 
Encapsulated group in both oral boost periods. 
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Figure 3.13: GATA-3 expression in different groups of A. salmon. Mean 
values of boosted relative to un-boosted controls, qPCR. n = 30; *statistically 
significant p < 0.05. There was significant up-regulation of GATA-3 in all 
tissue samples of the Encapsulated group in both oral boost periods. 
 
In addition to CD4 and GATA-3, the expression of IgT and IgM genes was 
examined with the purpose of assessing the gut mucosal antibody response. 
After the 1.OB, marginal but non-significant inductions of IgT were observed 
in both Encapsulated and Un-encapsulated group relative to the Control 
(Figure 3.14). After four weeks following the 2.OB, the expression 
significantly increased in the encapsulated group, particularly in the hindgut 
(p < 0.01). Interestingly, CD4 and GATA-3 expression in this organ had a 
similar pattern to IgT (Figure 3.12 and 3.13), especially for the encapsulated 
group. Conversely, CD4 and GATA-3 expression in the Un-encapsulated 
group were generally not induced in relation to the Control group. 
Additionally, the expression of IgM in the hindgut was not differentially 
expressed in all groups at all-time points examined (Figure 3.15). 
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Figure 3.14: IgT expression in the different organs of A. salmon. Means of 
boosted groups relative to the un-boosted control, qPCR, n = 30; *statistically 
significant p < 0.05. IgT was significantly up-regulated in head kidney and 
hindgut of the Encapsulated group.  
 
Figure 3.15: IgM expression in different groups of A. salmon. Mean values of 
boosted relative to un-boosted controls, qPCR, n = 30; *statistically 
significant p < 0.05. IgM was significantly expressed in spleen of both 
Encapsulated and Unencapsulated group at both sampling point. However, 
the level of expression was on a declining path from the 1st to 2nd oral boost. 
In addition, level of expression increased in head kidney of the Encapsulated 
group at the 2nd sampling point.  
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The assessment of IgT expression was extended to the head kidney and 
spleen where this gene was only differentially expressed in head kidney of 
the Encapsulated group, (Figure 3.14). More accurately, IgT was only 
significantly up-regulated in head kidney at the 2nd sampling point (p < 0.03). 
The reduction in blood plasma antibodies following administration of antigens 
can be due to their consumption (Munang’Andu et al., 2013). Thus to check 
that the suppression in the present study was not due to consumption, we 
examined the transcript levels of IgM. Figure 3.15 shows significant down 
regulation of IgM transcripts both in the kidneys (p < 0.01) and spleen (0.001) 
of the Un-encapsulated group between the 1st to the 2nd sampling. A similar 
change was observed in the spleen of the Encapsulated group (p<0.01) but 
with no differential regulation in the kidneys. 
In order to understand weak immune response of the Un-encapsulated 
group, expression of FoxP3, TGF-β and IL-10 was assessed. In higher 
vertebrates, FoxP3 is a key transcription factor of regulatory T cells (Tregs) 
while TGF-β is known to supress effector T cells except from Tregs (Li and 
Flavell, 2008). On the other hand, IL-10 is an anti-inflammatory cytokine that 
can induce immune tolerance (Weiner et al., 2011). These genes have also 
been described in fish although their functions related to immune tolerance 
remain to be characterised. Consistent with the suppression of antibodies in 
the Un-encapsulated group, the expression of FoxP3, TGF-β and IL-10 were 
significantly up-regulated (p < 0.003, 0.035 and 0.0048, respectively) in 
kidneys at the 1st sampling point (Figure 3.16, 3.17 and 3.18). In contrast, no 
differential expressions of either of these genes were observed in the spleen 
of any group at the same sampling point. 
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In the hindgut, FoxP3 was only induced in the Un-encapsulated group after 
the 2.OB (Figure 3.16) while both TGF-β (p < 0.02) and IL-10 (p < 0.01) were 
significantly induced in both Encapsulated and Un-encapsulated group. 
In summary, immune response of the Encapsulated group was humoral in 
the 1.OB. This assumption is based on the fact that CD4, GATA-3 and IgM 
were up-regulated in both head kidney and spleen of the fish. However, in 
the 2.OB, the immune response was on decline. This conclusion is backed 
by the evidence of increasing levels of TGF-β and IL-10 in the hindgut. As it 
is known, TGF-β and IL-10 are associated with Th3 response (Carrier et al., 
2007). This type of response suggests that the Encapsulated group were 
eventually in the process of developing oral tolerance against IPNV antigen. 
The immune system of the Un-encapsulated group did not respond to the 
oral vaccine treatment in the 1.OB. The elevated IgM levels most likely 
originated from the treatment with injectable vaccine one year prior to 
boosting with oral vaccine. In the 2.OB, all gens (TGF-β, FoxP3 and IL-10) 
related to the regulatory pathways (Treg and Th3) were induced. It indicates 
that small amount of antigen has passed through the stomach and reached 
the hindgut. Accordingly, the antigen dose was too low and thus the immune 
system probably responded by up-regulating Treg and Th3. Induction of these 
cells most likely led to down-regulation of the immune response with immune 
tolerance as a result. This theory is in line with numerous studies related to 
immune tolerance (Möbs et al., 2008; Sakaguchi et al., 2008; Weiner, 2001; 
Zouali, 2014). 
123 
 
 
Figure 3.16: FoxP3 expression of boosted groups relative to the un-boosted 
control, n = 30; *statistically significant p < 0.05. FoxP3 was up-regulated in 
both head kidney and hindgut of only Un-encapsulated group.  
 
Figure 3.17: TGF-β expression in different organs of A. salmon. Means of 
boosted groups relative to un-boosted control, n = 30; *statistically significant 
p < 0.05. TGF-β was induced in both head kidney and hindgut of the Un-
encapsulated group at both sampling points. However, TGF-β was only up-
regulated in hindgut of the Encapsulated group at the 2nd sampling point.   
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Figure 3.18: IL-10 expression in different organs of A. salmon. Means of 
boosted groups relative to un-boosted control, n = 30; *statistically significant 
p < 0.05. IL-10 was expressed in both head kidney and hindgut of the Un-
encapsulated group at both sampling points. On the other hand, IL-10 was 
only induced in hindgut of the Encapsulated group at the 2nd sampling point.  
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3.5 Discussion 
For an encapsulation process, being non-damaging towards active 
compounds is an important quality. This study shows that electrospraying 
utilizing high voltage up to 25.0 kV could be safely used as an encapsulation 
method for IPNV antigen. This is in accordance with a large number of 
studies that provide strong evidence for variety of cells and other agents 
retaining their viability when electrosprayed. For instance, electrospraying 
does not impair viability of cells such as the human brain astrocytoma cells 
(Eddaoudi et al., 2010), bone marrow derived mesenchymal stem cells 
(Braghirolli et al., 2013; Sahoo et al., 2010), embryonic stem cells 
(Abeyewickreme et al., 2009), neuroblastoma rat cells (Gasperini et al., 
2013), microorganisms as lactobacilli (Jiménez-Pranteda et al., 2012) and 
virions like bacteriophage (Jung et al., 2009). 
For an encapsulant, it is important to be highly efficient at entrapping the 
active compounds. Our results showed that EDA-alginate and Ca-alginate 
were characterised by high encapsulation efficiency of IPNV antigen. 
However, it can also be seen that differences existed between these two 
alginate matrices. Use of EDA∙2HCl as a cross-linker could lead to higher 
encapsulation efficiency than use of CaCl2. This difference is mostly 
expressed when encapsulating IPNV Ag suspensions approaching 
concentration of 109 TCID50 ml
-1. According to previous reports (Ainsley Reid 
et al., 2005; Anjani et al., 2007; Dashevsky, 1998; Suksamran et al., 2009), 
encapsulation efficiency of large macromolecules in Ca-alginate is ranging 
from 50 to 96%. This is in agreement with our encapsulation efficiency results 
for Ca-alginate ranging from 78% to almost 100% or not statistically 
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significant (NSS) loss. On the other hand, the obtained encapsulation 
efficiency for EDA-alginate (97% to nearly 100% or NSS loss) makes this 
alginate matrix very interesting from the oral delivery point of view. However, 
the EDA-alginate as a potential oral delivery system is very little described in 
the literature.  
From our study of antigen uptake it can be seen that the intubated fish carry 
IPNV antigen in blood plasma (Figure 3.7). Interestingly, the group intubated 
with un-encapsulated antigens (UA group) showed higher blood plasma 
levels than fish administered encapsulated antigens (EA group) at 24 hours 
post intubation (p.i.). The EA group on the other hand showed a higher 
antigen concentration than the UA group at 72 hours p.i. However, this result 
may be questionable due to the high response of the control group intubated 
with empty alginate beads (EC group). Nevertheless, it can be proposed that 
the alginate encapsulation is delaying uptake of protein antigens. These 
findings are in accordance with number of studies that have demonstrated 
antigen uptake from the intestine to the blood in the systemic circulation 
(Fuglem et al., 2010; Georgopoulou et al., 1988; Vandenberg, 2007; 
Villumsen et al., 2014).   
Ultimately, there was not statistically significant difference in uptake between 
all groups at 168 hours p.i.. This indicates that the antigen could be 
neutralised and processed after one week post ingestion. One of the 
challenges faced in this study was the fact that the experimental fish had 
previously been i.p. vaccinated against IPN. Therefore, the fish could have 
circulating antibodies that neutralised the absorbed antigens (Boxus et al., 
2014; El-Attar et al., 2013). Additionally, the wide natural variation, which is 
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inherent in fish as a living organism, could have made it difficult to discern 
differences in the current trial (Wang et al., 2014). For instance, it can be 
assumed that the applied trial design was not powerful enough to detect 
statistically significant differences in the model (Moher, 1994). In general, any 
increase in statistical power requires additional resources which are 
commonly in shortage (Fox, 1997). Even so, the current results may be 
encouraging to make a future trial large in order to increase sensitivity. As an 
alternative, the same trial could be performed with involving adjuvants. There 
are number of reported adjuvants with ability to induce antigen uptake across 
the gastrointestinal tract epithelium (Lavelle and O’Hagan, 2006). Some of 
the tested adjuvants are immune-stimulating complexes (ISCOM™) 
(Sjölander, 1998), bacterial toxins such as heat-labile enterotoxin (Douce et 
al., 1999) and cholera toxin (Bowen et al., 1994), bio-adhesives such as 
lectins (Lavelle et al., 2000) and chitosan (van der Lubben et al., 2002).   
Furthermore, the immunogenicity of IPNV antigen (both encapsulated and 
un-encapsulated) was explored in a feeding study. At the moment, the 
knowledge of an i.p. priming and oral boost strategy involving inactivated IPN 
virus is limited. The outcome of the 1.OB suggests that the alginate-
encapsulated IPNV antigen, which is orally administered via feed, could 
boost the immune response of A. salmon. The results also show that type of 
alginate matrix could have a great significance for the outcome of antibody 
response. At the same time, non-encapsulation would most likely result in a 
poor specific immune reaction. 
From the results of second boosting phase (2.OB), it can be assumed that 
the applied antigen dose (109 TCID50 fish
-1) is either insufficient or excessive 
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for A. salmon approaching size of one kilogram. This assumption is based on 
the theory of oral tolerance which was first described almost 70 years ago 
(Owen, 1945). Today, oral tolerance generated through ingestion of antigenic 
substances is very well known phenomena (Jump and Levine, 2004; Siewert 
et al., 2008; Weiner et al., 2011). Pabst and Mowat (2012) suggest that both 
high and low antigen dose may induce oral tolerance. According to their 
report, higher doses of antigen favour anergy/deletion while low doses favour 
the induction of regulatory T cells (Tregs) as a mechanism of tolerance. 
According to Chen et al. 1996, immune tolerance could be induced with 
either one single high dose or multiple low doses of antigen. Given this, it can 
be concluded that the provision of an appropriate boosting dose is essential 
for the success of an oral IPN preparation. 
Following the lead of oral tolerance it can be assumed that the hypo-
responsiveness to the IPNV Ag entrapped in Ca-alginate (Encap 1) was 
induced in the 2.OB rather than in the 1.OB interval. The opposite can be 
said about IPNV Ag entrapped in EDA-alginate (Encap 2). Apparently, the 
Encap 2 induced immune tolerance already in the 1.OB period. Therefore, it 
did not perform significantly different from the control in either of the two 
intervals. The main argument is essentially that EDA-alginate dissolves faster 
than Ca-alginate. As a consequence, the Encap 2 group of fish probably 
received a higher peak dose than Encap 1. Thus, the Encap 2 group might 
have developed the immune tolerance as early as in the 1.OB. Regarding the 
unprotected IPNV Ag (Unencap), it is unclear whether its inability to induce 
immune response is an issue of immune tolerance or antigen degradation in 
the gut. 
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Furthermore, the findings of the present study demonstrate that oral boosting 
of A. salmon with alginate encapsulated IPNV antigens induces both 
systemic and mucosal (gut) humoral responses. The significant up-regulation 
of CD4 (p < 0.02) and GATA-3 (p < 0.04) genes in the head kidneys and 
spleens of the Encapsulated group (Figure 3.12 – 3.15) fit very well with the 
induction of serum antibodies and point towards a predominantly Th2 
response. In higher vertebrates, the intestinal mucosa contains high basal 
levels of IL-4, IL-10 and TGFβ that are induced shortly after oral vaccination 
(Gonnella et al., 1998). This micro-environment is thought to tip responses of 
oral vaccines towards Th2 (Weiner, 2001). Furthermore, the main mechanism 
of action of alginate encapsulated antigens has been proposed to be biased 
towards Th2 responses (Maurice et al., 2004; Mutwiri et al., 2002; Salvador et 
al., 2012; Sarei et al., 2013). These findings are consistent with reports of 
others using different antigens (Thinh et al., 2009; Tobar et al., 2011), and 
suggest that oral boosting with alginate encapsulated antigens holds promise 
as a means of augmenting immune responses against IPN.      
In conclusion it can be said that multi-boosting with high antigen doses is not 
advantageous for the purpose of inducing specific immune response. It is 
neither advantageous to apply unprotected antigens as well as high 
concentrated antigens entrapped in fast-dissolving alginate matrices.  On the 
other hand, an oral vaccine with too low dose could also fail to induce the 
specific immune responses and succeed in inducing immune tolerance. 
According to observations in this study and reviewed literature, short-term but 
adequate doses would be the optimum strategy for oral boost vaccination. 
Since the dose-response of the oral IPNV Ag in A. salmon is very little 
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known, additional research should address this issue. In the event that the 
dose represent limiting factor, testing of uptake-stimulating adjuvants should 
be seriously considered. There are also questions regarding duration of an 
oral IPNV Ag dose action which could be answered in a future study. 
On the whole, this study shed light on the opportunities and issues related to 
i.p. priming/oral boost strategy involving an inactivated IPN virus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
Chapter Four: Release from alginate matrices 
Difference between the endothermic animals like human and ectothermic 
animals like fish are evident with respect to body temperature at which 
digestion reactions occur. In most studies, release of an active 
pharmaceutical ingredient from a cross-linked alginate is assessed in a dual 
dissolution test at one acidic pH 1 – 2 and another nearly neutral pH 6.8 – 
7.4. The test temperature, which is adapted to humans, is normally 
maintained constant at 37°C. Release from most cross-linked alginates is 
both pH- and temperature-responsive. Consequently, seasonal temperature 
changes could pose a risk of uneven release of alginate-encapsulated 
antigens in A. salmon.    
Therefore, the main objective of this study was to develop a fast-dissolving 
and temperature-independent oral delivery system within the temperature 
range of seawater in which A. salmon habituate. In addition, this study 
assesses a new dissolution test strategy with respect to chemical properties 
of alginate and physiological conditions for A. salmon. The new strategy is 
based on one single dissolution test combining pH 3.0 for 15 min with pH 8.0 
for 50 min. The test is performed at two different temperatures (4°C and 
18°C). It is demonstrated that the results generated in the redesigned 
dissolution test are in strong correlation with the results produced in the in 
vivo study. However, an attempt to localise release from calcium alginate 
beads by in vivo imaging was not successful. In conclusion, 
ethylenediammonium alginate proved to be an excellent oral delivery system 
for macromolecular drugs to A. Salmon. 
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4.1 Introduction 
A. salmon is a carnivorous fish with a rather short digestive system (Løkka et 
al., 2013). Insight into digestive physiology of salmonid fish is very important 
for delivering therapeutic proteins via oral route to A. salmon (Shaji and 
Patole, 2008). Digestion is a catabolic process of solubilising and degrading 
nutrients into smaller components that are more easily absorbed into a blood 
stream (Biology-Online.org, 2014). Digestive tract of salmon as a carnivorous 
fish can be subdivided into the foregut (mouth, oesophagus and stomach), 
midgut (pyloric ceca or proximal intestine and mid intestine) and hindgut or 
distal intestine terminating in the rectum (National Research Council, 2011). 
The major digestive components secreted in the stomach are pepsinogen 
and hydrochloric acid (HCl) and secretion of both of them are stimulated by 
feed intake (Volkoff, 2010). Study by Bucking and Wood (2009) shows that 
an average gastric pH of 2.7 increases to 4.9 when Rainbow trout 
(Oncorhynchus mykiss) goes from starved to fed state. The increased pH is 
maintained for eight hours post-feeding. However, most of the proteins are 
degraded by the action of HCl and pepsin in stomach (National Research 
Council, 2011). After processing in stomach, mixture of dissolved nutrients 
and partially digested feed material pass into the pyloric caeca. The pyloric 
caeca is a compartment where the other proteolytic enzymes like trypsin, 
chymotrypsin and aminopeptidase are completing peptide hydrolysis 
(Einarsson et al., 1996; Krogdahl and Bakke-McKellep, 2005). According to 
Krogdahl et al. (1999), most proteins are absorbed into the blood stream as 
free amino acids and short peptides in the pyloric region. When the acidic 
chime reaches the proximal intestine it becomes rapidly neutralised by 
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bicarbonate (HCO3
-) in bile and pancreatic juice (Cooper, 2008). Bucking and 
Wood (2009) observe an average pH of 8.2 throughout the whole intestinal 
section before feed intake. After feeding, pH is decreasing to 7.5 in the 
proximal and mid intestine while it remains almost unchanged in the distal 
section. However, the pH increases again in the period after feeding, 
reaching its highest value after eight hours. At that point, the pH can be 
above 8.5 all along the intestinal tract with increasing trend toward the distal 
part. 
However, despite the harsh proteolytic environment in the foregut and 
midgut, some proteins make it through to the distal intestine where they can 
be absorbed. Distal intestine is considered to be the most important place of 
absorption of large peptides including antigens used in oral vaccines 
(Hernandez-Blazquez and Silva, 1998; Valle et al., 2008). Additionally, the 
second segment of mid intestine and the distal intestine are the places with 
the highest levels of immune transcripts of immune-related genes in A. 
salmon (Løkka et al., 2014a). For instance, Petrie and Ellis (2006) provide 
evidence for uptake of particles (d <3 µm) by the hindgut of A. salmon 
following anal intubation of inert polystyrene microspheres. Løkka et al. 
(2014b) demonstrate uptake and possible transport of anally intubated yeast 
particles (5 – 10 µm) over the epithelium by macrophage-like cells in A. 
salmon.  
Thamotharan et al. (1996) suggest that intestinal transport of peptides in 
herbivorous and carnivorous fishes is proton gradient dependent and 
resembles the peptide transport proposed for mammals. On the other hand, 
the passage time of feed material through the entire digestive system can be 
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very short. According to Storebakken (1985), intestinal transit time depends 
on meal size, feed composition and structure, and it could be anything from 5 
to 35 hours after feed intake. Therefore, the main focus of this study is to 
assess an oral delivery system that protects at a low pH of the stomach and 
releases an active pharmaceutical ingredient (API) at an alkaline pH of the 
distal intestine. For the reasons that oral delivery of macromolecular drug is 
of special interest in the current study, blue dextran (BD) was selected as an 
appropriate model API. Additionally, bio-adhesive properties, fast release and 
temperature independency are preferable characteristics of an oral delivery 
system. These properties are useful in counteracting conditions occurred due 
to a possible short intestinal transit time and seasonal temperature effects. 
Taking these prerequisites into account, cross-linked alginates excel in an 
oral delivery systems exhibiting aforementioned properties (Augst et al., 
2006; Maurice et al., 2004; Rombout et al., 2011; Tian et al., 2008). 
Moreover, considering the physical properties of cross-linked alginates, salts 
of calcium and ethylenediammonium alginate were investigated in this study. 
Ethylenediammonium alginate (EDA-alginate) is of particular interest due to 
better solubility than calcium alginate (Ca-alginate) (Cooper et al., 1962). 
However, design of an alginate matrix characterised with well-timed release 
is a typical challenge in delivering bioactive compounds to the distal intestine 
of A. salmon.  
Most studies test dissolution of alginate matrices under conditions which are 
relevant for the human digestive system (pH = 1.1-2.0 and pH = 6.8-7.4 at 
37°C)(Bashir et al., 2014; Ferreira Almeida and Almeida, 2004; Kaushik K. et 
al., 2011; Lee and Min, 1996). As previously mentioned it can be seen that 
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pH > 2.7 is most common in the stomach of salmonid fish. At the same time 
pH > 7.5 is prevalent in the intestinal sections, although pH > 8.5 is not an 
unusual condition either. Furthermore, winter temperature could be below 
4°C while summer temperature could be at its most extreme above 18°C in 
Norwegian seawaters (Aldrin et al., 2013; Hevrøy et al., 2012). Despite these 
facts, there is no scientific study published evaluating in vitro dissolution of 
oral delivery systems based on alginates at test conditions relevant for A. 
Salmon. Therefore, this study is engaged in adapting the current dissolution 
test to the digestive conditions that are representative for salmonid fish as 
ectothermic animals. 
The primary objective of this study was to develop an oral delivery system 
based on alginate with the following characteristics: 1) deliver antigens to the 
distal intestine of A. salmon in the intact form, and 2) releases the antigen in 
vivo independently of the seasonal temperature oscillations in the natural 
habitat of A. salmon.   
The secondary objectives of this study were: 1) to develop a dissolution test 
that is representative for salmonid fish as ectothermic animals with alkaline 
pH in the intestine, and 2) to produce a test that is able to determine the 
release site of alginate-encapsulated antigens in vivo. 
In order to meet the objectives of present study, several in vitro dissolution 
tests were assessed with the aim of comparing EDA-alginate to Ca-alginate. 
The tests were performed with BD as a model compound at relevant 
temperature and pH for A. salmon. Furthermore, an attempt was made to 
localise the site of Ca-alginate dissolution in A. salmon using an in vivo 
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imaging technique. The in vivo trial was based on the oral intubation of Ca-
alginate-encapsulated cardiogreen as a model compound. In the end, 
another effort was made to localise the site of both Ca-alginate and EDA-
alginate dissolution in A. salmon using an enzyme assay approach. The in 
vivo trial was based on feeding the fish with Ca-/EDA-alginate-encapsulated 
horseradish peroxidase (HRP) infused into feed.  
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4.2 In vitro study of blue dextran release from alginate 
matrices 
In this section, release of BD from Ca-alginate and EDA-alginate beads was 
assessed in a standard dissolution test (pH 1.2 and 6.8 at 37°C). Thereafter, 
release from the same alginates was tested in alkaline dissolution media (pH 
8.0 and 8.6) at 18°C. This was done in order to find an appropriate substitute 
for dissolution medium having pH 6.8. This medium is representative for 
conditions in duodenum of humans. However, conditions in the salmon 
intestine are alkaline (pH 8 – 8.6). Finally, based on the results from the 
previous tests, a new dissolution test strategy (pH 3.0/8.6 at 4°C/18°C) was 
assessed.    
4.2.1 Methods 
4.2.1.1 Preparation of alginate beads loaded with blue dextran 
Alginate beads loaded with blue dextran (BD) were prepared according to the 
common encapsulation method described in the Section 2.2.1.1 (Chapter 2). 
The non-use of voltage (U) was the only variation to the general method. 
Process parameters and their respective values are listed in the Table 4.1. In 
the process of encapsulation, the following items were used: plastic syringe 
(Item T002, Table 2.2), needle (Item T014, Table 2.2), encapsulation 
formulation (Item S007, Table 2.4) and crosslinking solution (Item S003 and 
S004, Table 2.4). 
By utilising this setup, 40 batches of BD-Ca-alg and 40 batches of BD-EDA-
alg beads were produced. For the purpose of determining encapsulation 
efficiency, ten batches of each type of beads were used while the remaining 
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batches were used in dissolution tests (Table 5.1). The particle size 
distribution and shape were determined by stereo microscope (Item I001, 
Table 2.3). Electrospraying - process variables with their respective values 
Table 4.1: Electrospraying process variables applied in encapsulating blue 
dextran by for dissolution testing.  
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x Vxls 
µm cm3 h-1 ml kV mm ml 
2000 50 1.5 0 100 10 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls)  
4.2.1.2 Encapsulation efficiency of blue dextran 
BD-Ca-alg beads (10 batches) and BD-EDA-alg beads (10 batches) which 
preparation is previously described in the Section 4.2.1.1, were separately 
added to the saturated NaHCO3 solution (380 ml per batch; pH 8.0; Item 
S005, Table 2.4). As a result, all beads were completely dissolved after two 
hours under stirring in glass beakers (Figure 4.1). An aliquot (10 ml) from 
each beaker was filtered through a syringe filter (Item T009, Table 2.2). The 
filtrates were then applied in the volume of 100 µl per well onto a 96-well 
polystyrene plate (Item T006, Table 2.2). An endpoint assay was carried out 
on a microplate reader (Item I003, Table 2.3). Absorbance of BD was 
measured at 610 nm and 24°C. Concentration of BD in the samples was 
determined by using standard curve in the range of 1.0 to 3.9 × 10-3 mg ml-1. 
Standard curves were generated by plotting BD concentrations of nine two-
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fold serial dilutions of BD solution (1.0 mg ml-1) versus absorbance. The BD 
solution (1.0 mg ml-1) was prepared by diluting BD-EncForm (Item S007, 
Table 2.4) with saturated NaHCO3 solution (Item S005, Table 2.4). 
 
Figure 4.1: Execution of encapsulation efficiency test: BD-EncForm - 
encapsulation formulation containing sodium alginate [Na-alg] = 20 mg ml-1 
and blue dextran [BD] = 50 mg ml-1. BD-Ca-alg – calcium alginate beads 
loaded with blue dextran. BD-EDA-alg – ethylenediammonium alginate beads 
loaded with blue dextran. EDA▪2HCl – ethylenediamine dihydrochloride 
solution. CaCl2 – calcium chloride solution. Sat. NaHCO3 – saturated sodium 
bicarbonate solution. Ten batches of BD-Ca-alg beads were generated by 
extruding BD-EncForm (1.5 ml per batch) into collection containers 
containing crosslinking solution (CaCl2, 10 ml per container). Another ten 
batches of BD-EDA-alg beads were formed by extruding BD-EncForm (1.5 
ml per batch) into collection containers containing crosslinking solution 
(EDA▪2HCl, 10 ml per container). The resulting alginate beads were removed 
from crosslinking solutions by filtration and then transferred into glass 
beakers containing sat. NaHCO3 (380 ml per beaker). The beads were 
dissolved under stirring. Part of the solution (10 ml) from each beaker was 
filtered and then applied in the volume of 100 µl per well onto 96-well plate.  
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4.2.1.3 Standard dissolution test 
This dissolution test is widely used to assess dissolution properties of oral 
dosage forms. For this reason, it was the first conducted test, although the 
test conditions were not representative for A. salmon. 
Test alginate beads (10 batches of BD-Ca-alg and 10 batches BD-EDA-alg) 
loaded with BD were produced according to the method described in the 
Section 4.2.1.1. The following dissolution tests were performed in 
quintuplicate at 37°C: 1) BD-Ca-alg at pH 1.2, 2) BD-EDA-alg at pH 1.2, 3) 
BD-Ca-alg at pH 6.8 and 4) BD-EDA-alg at pH 6.8 (Table 4.2). Both 
dissolution tests and later sample analysis were carried out according to the 
method described in the section 2.2.2 (Chapter 2). 
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Table 4.2: Dissolution conditions applied in the standard dissolution test 
using UPS Apparatus 1. The dissolution conditions apart from pH were 
identical in all four tests. 
Parameters Test 1 Test 2 Test 3 Test 4 
Alginate beads (AB) BD-Ca-algi BD-EDA-algii BD-Ca-alg BD-EDA-alg 
Apparatus UPS 1 UPS 1 UPS 1 UPS 1 
Basket rotation (f) 100 rpm 100 rpm 100 rpm 100 rpm 
Dissolution media 
(DM) 
NaCl/HCliii 
pH 1.2 
NaCl/HCl 
pH 1.2 
PhBiv 
pH 6.8 
PhB 
pH 6.8 
Volume of media (V) 380 ml 380 ml 380 ml 380 ml 
Temperature (t) 37°C 37°C 37°C 37°C 
Number of sampling 
points (nSP)  
10 10 10 10 
Sampling points 
(tSP) 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
Number of vessels 
(nvessel) 
5 5 5 5 
Sample volumev 
(Vsample) 
1.0 ml 1.0 ml 1.0 ml 1.0 ml 
iBD-Ca-alg – calcium alginate beads loaded with blue dextran  
iiBD-EDA-alg – ethylenediammonium alginate beads loaded with blue dextran 
iiiNaCl/HCl – sodium chloride/hydrochloric acid buffer, pH 1.2 (Item S015, Table 2.4) 
ivPhB – phosphate buffer, pH 6.8 (Item S017, Table 2.4) 
vSampled volume (1 ml per sampling point per vessel) was replaced by an 
equivalent amount of dissolution medium  
 
4.2.1.4 Assessment of alkaline dissolution media 
Four additional dissolution tests were performed in order to select an alkaline 
dissolution medium, which would be representative for the conditions found 
in A. salmon intestine. Test alginate beads (10 batches of BD-Ca-alg and 10 
batches of BD-EDA-alg) loaded with BD were produced according to the 
method described in the Section 4.2.1.1. The same setup as the one 
described in the section 2.2.2 (Chapter 2) was applied in performing these 
new tests.  The tests were carried out with five replications in two different 
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dissolution media: 1) phosphate buffer (pH 8.0; Item S018, Table 2.4) and 2) 
Gly/NaOH buffer (pH 8.6; Item S019, Table 2.4) at 18°C. Accordingly, the 
following tests were conducted: 5) BD-Ca-alg at pH 8.0, 6) BD-EDA-alg at pH 
8.0, 7) BD-Ca-alg at pH 8.6 and 8) BD-EDA-alg at pH 8.6 (Table 4.3). The 
dissolution conditions other than pH were identical in all four tests. 
Concentration of BD in the samples was determined by using standard curve 
approach as previously described in the Section 2.2.2 (Chapter 2). 
Table 4.3: Dissolution conditions applied in the four tests assessing alkaline 
dissolution media best suited for simulating intestinal conditions in A. salmon. 
The dissolution conditions other than pH were identical in all four tests. 
Parameters Test 5 Test 6 Test 7 Test 8 
Alginate beads (AB) BD-Ca-algi BD-EDA-algii BD-Ca-alg BD-EDA-alg 
Apparatus UPS 1 UPS 1 UPS 1 UPS 1 
Basket rotation (f) 100 rpm 100 rpm 100 rpm 100 rpm 
Dissolution media 
(DM) 
PhBiii 
pH 8.0 
PhB 
 pH 8.0 
Gly/NaOHiv 
pH 8.6 
Gly/NaOH 
pH 8.6 
Volume of media (V) 380 ml 380 ml 380 ml 380 ml 
Temperature (t) 18°C 18°C 18°C 18°C 
Number of sampling 
points (nSP)  
10 10 10 10 
Sampling points 
(tSP) 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
Number of vessels 
(nvessel) 
5 5 5 5 
Sample volumev 
(Vsample) 
1.0 ml 1.0 ml 1.0 ml 1.0 ml 
iBD-Ca-alg – calcium alginate beads loaded with blue dextran  
iiBD-EDA-alg – ethylenediammonium alginate beads loaded with blue dextran 
iiiPhB – phosphate buffer, pH 8.0 (Item S018, Table 2.4) 
ivGly/NaOH – glycine/sodium hydroxide buffer, pH 8.6 (Item S019, Table 2.4) 
vSampled volume (1 ml per sampling point per vessel) was replaced by an 
equivalent amount of dissolution medium.  
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4.2.1.5 New dissolution test strategy 
Conditions that alginate beads could be exposed to during their passage 
through gastrointestinal tract of A. salmon were simulated in another four 
dissolution tests. For that reason, alginate beads were first submerged into 
acidic dissolution medium (pH 3.0; Item S016, Table 2.4) to simulate the 
gastric conditions. After 15 minutes, the acidic medium was replaced with an 
alkaline medium (pH 8.0; Item S018, Table 2.4) to simulate the intestinal 
conditions in A. salmon. Test alginate beads (10 batches of BD-Ca-alg and 
10 batches of BD-EDA-alg) loaded with BD were produced according to the 
method described in the Section 4.2.1.1. The tests were conducted using the 
UPS Apparatus 1 as shown in the Figure 4.2. In order to replicate the natural 
conditions in which A. salmon habituate as fully as possible, two different 
temperatures (4°C – winter and 18°C – summer) were applied in these tests. 
Consequently, the following four dissolution tests were carried out in 
quintuplicate: 9) BD-Ca-alg at pH 3.0 – 8.0 and 4°C, 10) BD-EDA-alg at pH 
3.0 – 8.0 and 4°C, 11) BD-Ca-alg at pH 3.0 – 8.0 and 18°C, 12) BD-EDA-alg 
at pH 3.0 – 8.0 and 18°C (Table 4.4). The first sample was taken after 15 min 
in the KPH/HCl buffer (pH 3.0) or just before changing the dissolution 
medium. Further sampling, which started 5 min after replacing dissolution 
medium, were carried out according the general method described in the 
Section 2.2.2 (Chapter 2). Concentration of BD in the samples was 
determined by using standard curve approach along with an endpoint assay. 
The details regarding assay can be found in the Section 2.2.2 (Chapter 2) as 
well. The resulting dissolution profiles were compared by a model 
independent approach using both difference factor (f1, Equation 4.1) and 
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similarity factor (f2, Equation 4.2). Two dissolution profiles are similar when 
the f1 value is between 0 and 15 and f2 value between 50 and 100 (Costa 
and Sousa Lobo, 2001). It is important to note that encapsulation efficiency of 
BD was taken into consideration when designing the dissolutions tests. 
Finally, statistical analysis of the obtained data was performed according to 
the description in the Section 2.2.6.3 (Chapter 2). 
 
Equation 4.1: Difference factor (f1) where, n is the number of observations, 
Rt is the average percentage of drug dissolved from a reference formulation 
at time t and Tt is the average percentage of drug dissolved from a test 
formulation at time t. Difference factor is defined as the percent (%) difference 
between two curves at different time points. It represents the measurement of 
relative error between two curves. 
 
 
𝑓1 = 100 [
∑ |𝑅𝑡 − 𝑇𝑡|
𝑛
𝑡=1
∑ 𝑅𝑡
𝑛
𝑡=1
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Equation 4.2: Similarity factor (f2) where, n is the number of observations, Rt 
is the average percentage of drug dissolved from a reference formulation at 
time t and Tt is the average percentage of drug dissolved from a test 
formulation at time t. Similarity factor is defined as a logarithmic reciprocal 
square root transformation of the sum of the squared error. 
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Figure 4.2: Assessment of a new dissolution test strategy using UPS 
Apparatus 1. BD-Ca-alg – calcium alginate beads loaded with blue dextran. 
BD-EDA-alg – ethylenediammonium alginate beads loaded with blue dextran. 
KPH/HCl – potassium hydrogen phthalate/hydrochloric acid buffer (pH 3.0). 
The tests were performed using two different dissolution media at 4°C and 
18°C. Alginate beads were first submerged into KPH/HCl buffer (pH 3.0) for 
15 min and then the acidic medium was replaced by phosphate buffer (pH 
8.0). The first sample was taken after 15 min or just before changing the 
dissolution medium. Thereafter, one sample was taken with replacement 
from each vessel at five minutes intervals through an extent of 50 minutes 
totaling 10 samples per vessel.  
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Table 4.4: Dissolution conditions applied in the four tests assessing the new 
dissolution test strategy most suited for A. salmon. The dissolution conditions 
other than temperature were identical in all four tests. 
Parameters Test 9 Test 10 Test 11 Test 12 
Alginate beads (AB) BD-Ca-algi BD-EDA-algii BD-Ca-alg BD-EDA-alg 
Apparatus UPS 1 UPS 1 UPS 1 UPS 1 
Basket rotation (f) 100 rpm 100 rpm 100 rpm 100 rpm 
Dissolution media 
(DM) 
1) KPH/HCliii 
pH 3.0 
2) PhBiv 
pH 8.0 
1) KPH/HCl 
pH 3.0 
2) PhB 
pH 8.0 
1) KPH/HCl 
pH 3.0 
2) PhB 
pH 8.0 
1) KPH/HCl 
pH 3.0 
2) PhB 
pH 8.0 
Volume of media (V) 380 ml 380 ml 380 ml 380 ml 
Temperature (t) 4°C 4°C 18°C 18°C 
Number of sampling 
points (nSP)  
10 10 10 10 
Sampling points  
at pH 3.0 (tSP) 
15 min 15 min 15 min 15 min 
Sampling points  
at pH 8.0 (tSP) 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
5,10,15,20, 
25,…50 min 
Number of vessels 
(nvessel) 
5 5 5 5 
Sample volumev 
(Vsample) 
1.0 ml 1.0 ml 1.0 ml 1.0 ml 
 iBD-Ca-alg – calcium alginate beads loaded with blue dextran  
iiBD-EDA-alg – ethylenediammonium alginate beads loaded with blue dextran 
iiiKPH/HCl – potassium hydrogen phthalate/hydrochloric acid buffer, pH 3.0 (Item 
S016, Table 2.4) 
ivPhB – phosphate buffer, pH 8.0 (Item S018, Table 2.4) 
vSampled volume (1 ml per sampling point per vessel) was replaced by an 
equivalent amount of dissolution medium. 
 
 
 
147 
 
4.2.2 Results 
4.2.2.1  Encapsulation efficiency of blue dextran  
After encapsulating BD formulation (BD-EncForm, [BD] = 50 mg ml-1; Item 
S007, Table 2.4), the actual average concentration (±SD) of BD in EDA-
alginate and Ca-alginate beads dropped to 35 ±1.4 mg ml-1 and 45 ±1.8 mg 
ml-1 respectively (Table 4.5). From this, it can be derived that the average 
encapsulation efficiency (±SD) of BD in Ca-alginate and EDA-alginate was 
90% (±4%) and 70% (±4%) respectively. Furthermore, the mean size (dmean 
±SD) of the Ca-alginate beads was 3.0 ±0.04 mm while the mean size (±SD) 
of the EDA-alginate beads reached 3.7 ±0.11 mm. From the Figure 4.3, it can 
be seen that shape of the beads was spherical for both type of the alginate 
beads. 
 
Table 4.5: Encapsulation efficiencies of blue dextran (BD) in 
ethylenediammonium alginate (EDA-alg) and calcium alginate (Ca-alg). 
Variability of the data set is expressed by standard deviation (SD) based on 
ten replications of each formulation sample. 
Formulation 
name 
Theoretical 
BD concentration  
(mg ml-1) 
Actual 
BD concentration 
     (mg ml-1) 
Encapsulation 
efficiency  
(%) 
SD 
  
(%) 
BD-EDA-algi 50 35 70 4 
BD-Ca-algii 50 45 90 4 
iBD-Ca-alg – calcium alginate beads loaded with blue dextran 
iiBD-EDA-alg – ethylenediammonium alginate beads loaded with blue 
dextran 
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Figure 4.3: Stereo microscope zoom (SMZ) images of alginate beads loaded 
with blue dextran. SMZ (Item I001, Table 2.3) images of a) BD-Ca-alg beads, 
dmean (±SD) = 3.0 (±0.04) mm, b) BD-EDA-alg beads, dmean (±SD) = 3.7 
(±0.11) mm. BD-Ca-alg – calcium alginate beads loaded with blue dextran, 
BD-EDA-alg – EDA-alginate beads loaded with blue dextran. 
 
4.2.2.2 Dissolution tests 
Release of BD from both Ca-alginate and EDA-alginate matrices was below 
the quantification limit (LoQ = 3.9 × 10-3 mg ml-1) of the assay within the first 
hour in the standard dissolution tests. Similarly, the release of BD from both 
alginate matrices was below LoQ (3.9 × 10-3 mg ml-1) at both pH 8.0 and pH 
8.6 in the alkaline dissolution test.  
In the dissolution tests adapted to the way in which salmonid fish process 
alginate, sufficient release of BD was observed in all four tests (Figure 4.4). 
So that the release, which was below LoQ (3.9 × 10-3 mg ml-1) in pH 3.0 after 
15 min, turned into a fairly rapid one in pH 8.0 during the following 50 
minutes.  
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Figure 4.4: Dissolution profiles shown as curves of the mean percentage of 
cumulative blue dextran (BD) release from alginate beads over time. 
Dissolution tests performed in potassium hydrogen phthalate /HCl buffer (pH 
3.0) for 15 min followed by phosphate buffer (pH 8.0) for the next 50 min. 
Release was below LoQ (3.9 × 10-3 mg ml-1) in the acidic medium so the 
figure depicts only release in the alkaline dissolution medium. The error bars 
represent standard deviation (SD) based on five samples at each point. BD-
EDA-alg denotes ethylenediammonium alginate beads loaded with BD while 
BD-Ca-alg means calcium alginate beads loaded with BD. 
 
From the Table 4.6, it can be seen that the release rates of BD (ROC and 
AROC) from EDA-alginate beads were between 2.1% and 2.2% per minute. 
This release rate was very close to linear (0.96< R2 >0.97) in the time interval 
(0, 50 min). Interestingly, the dissolution rates of EDA-alginate seemed to be 
unaffected by temperature in the interval (4, 18°C). On the other hand, the 
release rate of BD form Ca-alginate beads (ROC = 1.8% at 18°C and 0.6% at 
4°C) seemed to be temperature dependent. In accordance with the 
dissolution profiles of EDA-alginate, the dissolution rates of Ca-alginate 
beads also followed the linear relationship (0.95< R2 >0.99) in the same time 
interval (0, 50 min).   
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Table 4.6: Rates of blue dextran release (ROCii and AROCiii) from calcium 
and ethylenediammonium alginate were determined at 4°C and 18°C. First- 
and second-order approximations of dissolution curves are shown with 
corresponding coefficients of determination (R2). Data fits very well both 
linear and non-liner function in the time interval 0 to 50 minutes after 
changing dissolution medium. 
Product Orderi Dissolution curves R2  ROCii AROCiii 
BD-EDA-algiv 
at 18°C 
1st  y=2.2101x-3.9877 0.97 2.21 n.a. 
2nd  y=-0.0112x2+2.7696x-8.1836 0.98 n.a. 2.21 
BD-EDA-alg 
at 4°C 
1st  y=2.1061x+2.251 0.96 2.11 n.a 
2nd  y=-0.0264x2+3.4249x-7.6404 0.99 n.a. 2.10 
BD-Ca-algv  
at 18°C 
1st  y=1.8109x+1.7095 0.99 1.81 n.a. 
2nd  y=-0.01x2+2.3088x-2.0247 1.00 n.a. 1.81 
BD-Ca-alg  
at 4°C 
1st  y=0.5760x+4.0063 0.95 0.58 n.a. 
2nd  y=-0.0067x2+0.91121x+1.4852 0.98 n.a. 0.58 
iorders of approximation: first- and second-order approximation applied here 
iiROC – rate of change or release of blue dextran (% per minute) derived from the 1st 
order approximation. 
iiiAROC – average rate of change or release of blue dextran (% per minute) derived 
from the 2nd order approximation. 
ivBD-EDA-alg – ethylenediammonium alginate beads loaded with blue dextran 
vBD-Ca-alg – calcium alginate beads loaded with blue dextran  
 
From the Table 4.8, it can be seen that 85% of BD was released from EDA-
alginate beads within 40 minutes in pH 8.0 regardless of temperature. 
Dissolution rate of Ca-alginate at 18°C was a little lower than that of EDA-
alginate resulting in 85% release within 50 min. However, only 31% of BD 
was released from Ca-alginate beads after 50 min at 4°C. This was 
significantly lower compared to the dissolution rates in the other three tests. 
According to USP General Chapter <1092>, these dissolution results may be 
considered highly variable because of the RSD > 20% at time points below 
10 min and RSD > 10% at the time points above 10 min (USP, 2012c). 
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Dissolution profile of Ca-alginate at 4°C was obviously different and therefore 
it was not mathematically compared with the other profiles.   
The other three dissolution profiles were compared by calculating both 
difference factor (f1) and similarity factor (f2). In order to consider two 
dissolution profiles as similar, the f1 value should be close to 0 and values f2 
should be close to 100. Generally, f1 values lower than 15 and f2 values 
higher than 50 indicate the similarity of the dissolution profiles. From the 
Table 4.7, it can be seen that the dissolution profiles excluding Ca-alginate at 
4°C are quite similar. This may be argued even though the comparison of 
BD-Ca-alg at 18°C with BD-EDA-alg at 4°C resulted in the f1 = 16 and f2 = 
48. These values as shown in the Table 4.7 are barely above (f1 ≤15) and 
below (f2 ≥50) the threshold.  
Table 4.7: Similarity of dissolution profiles was determined by both difference 
factor (f1) and similarity factor (f2). Conventionally, f1 values lower than 15 
and f2 values above 50 show the similarity of the dissolution profiles. 
Compared formulations f1 f2 
BD-Ca-algi at 18°C vs 
BD-EDA-algii at 18°C 14 52 
BD-EDA-alg at 4°C 16 48 
BD-EDA-alg at 18°C vs BD-EDA-alg at 4°C 12 59 
iBD-Ca-alg – calcium alginate beads loaded with blue dextran  
iiBD-EDA-alg – ethylenediammonium alginate beads loaded with blue dextran 
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Table 4.8: The average value (Mean) and standard deviation (SD) of 
cumulative percentage drug dissolved for two different blue dextran (BD) 
formulations at two different temperatures (4°C and 18°C). Variability in the 
data set is expressed by relative standard deviation in terms of percentage 
(%RSD). It is obtained by dividing SD by Mean and then multiplying by 100. 
 BD-Ca-algi at 18°C  BD-EDA-algii at 18°C 
Time 
(min) 
Mean SD %RSD 
Time 
(min) 
Mean SD %RSD 
5 8.73 8.09 93 5 2.42 3.32 138 
10 18.94 13.92 74 10 12.59 8.02 64 
15 29.22 15.01 51 15 26.85 12.59 47 
20 38.78 17.54 45 20 37.34 5.30 14 
25 48.84 16.77 34 25 53.57 4.96 9 
30 58.62 18.31 31 30 74.61 18.95 25 
35 68.83 17.21 25 35 78.32 6.95 9 
40 76.91 21,27 28 40 86.88 5.66 7 
45 81.76 16.57 20 45 94.55 9.78 10 
50 86.17 16.26 19 50 96.79 9.84 10 
BD-Ca-alg at 4°C  BD-EDA-alg at 4°C 
Time 
(min) 
Mean SD %RSD 
Time 
(min) 
Mean SD %RSD 
5 5.28 7.15 135 5 4.30 4.87 113 
10 13.00 9.34 72 10 19.29 6.07 31 
15 14.15 5.03 36 15 34.09 6.40 19 
20 17.93 3.42 19 20 48.09 7.48 16 
25 19.25 6.46 34 25 62.69 5.52 9 
30 21.39 5.27 25 30 77.81 5.79 7 
35 23.44 5.31 23 35 83.03 9.88 12 
40 27.89 3.28 12 40 88.84 13.82 16 
45 29.45 6.46 22 45 89.77 14.75 16 
50 30.68 6.47 21 50 96.04 18.09 19 
iBD-Ca-alg – calcium alginate beads loaded with blue dextran  
iiBD-EDA-alg – ethylenediammonium alginate beads loaded with blue dextran 
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4.3 Dissolution of alginate beads visualised by the in vivo 
imaging technique 
The aim of this study was to follow the in vivo displacement of one single 
alginate bead as a function of time. Eventually, the site of Ca-alginate 
dissolution in A. salmon would be localized by using an in vivo imaging 
technique. For this reason, fish was orally intubated with one Ca-alginate 
bead loaded with cardiogreen. Cardiogreen is a fluorescent marker which is 
used in medicine as an indicator compound.  
4.3.1 Methods 
4.3.1.1 Preparation of alginate beads loaded with cardiogreen 
Alginate beads loaded with cardiogreen (CG) were prepared according to the 
common encapsulation method which is described in the Section 2.2.1.1 
(Chapter 2). Disconnected voltage (U) was the only variation to the general 
method. Process parameters and their respective values are summarised in 
the Table 4.9. The following items were specific to this encapsulation 
process: needle (Item T014, Table 2.2), encapsulation formulation (Item 
S030, Table 2.4) and crosslinking solution (Item S003, Table 2.4). 
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Table 4.9: Electrospraying - process variables with their respective values in 
the in vivo imaging trial. 
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x Vxls 
µm cm3 h-1 ml kV mm ml 
2000 50 10 0 100 50 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
4.3.1.2  Fish trial – oral intubation 
The fish trial was performed according to the general method described in 
the section 2.2.5.2 (Chapter 2) at TempOx lab (EWOS Innovation AS, Dirdal, 
Norway). Parameters applied in this trial are listed in the Table 4.10. 
Moreover, fish was starved one day in advance of the treatment. Control fish 
(ncontrol = 2) were sampled directly from the acclimatisation tank just before 
the intubation. Each fish (nfish = 30) was orally intubated with one alginate 
bead loaded with cardiogreen (davg = 3.2 mm). Whole fish samples (nsampled = 
18) were stored at -20oC prior to the in vivo imaging. The in vivo imaging 
analysis of the fish was conducted by IVIS Spectrum (Item I009, Table 2.3) at 
Caliper Life Sciences Ltd. (Runcorn, UK). Trans-illumination (from the 
bottom) was used to illuminate the fluorescence source (alginate beads 
loaded with cardiogreen) in the fish. Excitation was induced at wavelength of 
745 nm while the intensity of the emitted fluorescence was measured at 840 
nm. The field of view was adjusted to 13.1 ˣ 13.1 cm. Images (2048 ˣ 2048 
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pixels) with pixel size of 13.5 µm were taken with read noise < 5 electrons for 
bin of 8 pixels at lens speed f/2 
Table 4.10: Electrospraying – process parameters applied in the in vivo 
imaging trial carried out by oral intubation with alginate beads loaded with 
cardiogreen. 
Parameter Symbol Quantity 
Average weight of fish m 157 g 
Oxygen saturation in water O2 90% 
Water temperature t 10°C 
Diameter of a tank d 2.0 m 
Volume of a tank V 3.1 m3 
Number of tanks ntanks 1 
Number of fish per tank nfish 30 
Number of groups ngroups 1 
Length of the acclimatisation period taccl 1 week 
Number of treatments ntreat 1 
Number of control fish ncontrol 2 
Number of sampled fish per tank per sampling 
point 
nsf/t 2 
Number of sampling points nSP 8 
Length of sampling time intervals calculated from 
the end of treatment 
tSP 
0, 2, 4, 6, 8, 
10, 24, 72 h 
Total number of sampled fish nsampled 18 
 
4.3.2 Results 
The Figure 4.5 shows that the alginate bead did not change position 
considerably from the time of intubation (0 hours) to 72 hours post intubation 
(p.i.). It seems that cardiogreen was becoming systemic at 72 hours p.i. but 
the highest concentration was still at the same focal point. This suggests that 
cardiogreen was rather leaking from an unimpaired alginate bead than it was 
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spreading from leftovers of a degraded bead. This observation is also 
consistent with previous knowledge of alginate presence in acidic 
environment as it found in stomach. It is well known that alginate is poorly 
soluble at low pH. The reason for the alginate bead not migrating might be 
the fact that fish did not take in feed after intubation. Intake of some feed 
after intubation would obviously help to push the bead further down the 
gastrointestinal tract. Like this, it appears that the bead got stuck in the 
stomach as shown in the Figure 4.6. Therefore, the true place of dissolution 
could not be determined in this trial. 
 
Figure 4.5: Visualisation of alginate beads loaded with cardiogreen by an in 
vivo imaging system (I009, Table 2.3). The beads did not move and due to 
fish not eating after intubation. For this reason, the real place of dissolution 
could not be determined in this trial.  
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Figure 4.6: Imaginary alginate bead loaded with cardiogreen is shown stuck 
in the stomach of A. salmon. 
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4.4  In vivo study of HRP release from alginate matrices 
This study was conducted with the aim of localising the site of both Ca-
alginate and EDA-alginate dissolution in A. salmon using an enzyme assay 
approach. In accordance with the aim, the fish was voluntary fed with Ca-
/EDA-alginate-encapsulated horseradish peroxidase (HRP) infused into feed 
pellets.    
4.4.1 Methods 
4.4.1.1 Preparation of alginate microbeads loaded with HRP 
Calcium alginate (HRP-Ca-alg) and ethylenediammonium alginate (HRP-
EDA-alg) microbeads loaded with HRP were produced according to the 
general method described in the Section 2.2.1.2 (Chapter 2). Encapsulation 
was conducted without voltage (U) so the method was an aerodynamically 
assisted jetting. Process parameters and their respective values are 
summarised in the Table 4.11. The encapsulation formulation (Item S022, 
Table 2.4) and cross-linking solutions (Item S003 and S004; Table 2.4) were 
specific to this process. The HRP-Ca-alg microbeads were formed by 
processing four batches à 60 ml of encapsulation formulation in combination 
with crosslinking solution (Item S003, Table 2.4). The HRP-EDA-alg 
microbeads were generated in the same way but using different crosslinking 
solution (Item S004, Table 2.4). Later, four and four batches of alginate 
microbeads were combined into one single batch. The resulting batches were 
filtered off by suction filtration applying a filter paper (Item T012, Table 2.2). 
Thus, the obtained mass of HRP-Ca-alg and HRP-EDA-alg microbeads was 
81.54 g and 78.29 g respectively. In the end, a laser diffraction system (Item 
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I007, Table 2.3) was used to measure the size of the generated alginate 
beads at wavelength λ = 632.8 nm. All steps of the encapsulation process 
were performed at 4°C. The products (HRP-Ca-alg and HRP-EDA-alg) were 
store at -20°C until they were used in the feed preparation.  
Table 4.11: Air pressure-assisted energised jetting - process variables with 
their respective values 
Distancei Volumeii Voltage Flow rate Target 
volume 
Pressure 
x Vxls U Q Vtv P 
mm ml kV cm3 h-1 ml bar 
100 500 0 100 60 3 
iDistance between the jetting head and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
 
4.4.1.2 Preparation of the experimental feeds  
As the first step, alginate microbeads (dmedian = 25 – 26 µm) loaded with HRP 
were suspended in in fish oil (Item C019, Table 2.1). The resulting fish oil 
suspension was then combined with base pellet (Item C007, Table 2.1) in a 
vacuum infusion coating process. The coating was performed according to 
the method described in the Section 2.2.4. Three batches of feed (5.0 kg 
each) were produced according to the mixing ratios shown in the Table 4.12. 
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Table 4.12: Composition of the experimental feeds HRP-Ca-feed, HRP-EDA-
feed and Ctrl-feed.   
Feed name 
Oil mixture 
BPiii [g] Total [g] Fish oil 
[g] 
HRP-Ca-algi 
[g] 
HRP-EDA-algii 
[g] 
Ctrl-feed 1210.0 0.00 0.00 3790.00 5000.00 
HRP-Ca-feed 1210.0 81.54 0.00 3708.46 5000.00 
HRP-EDA-
feed 
1210.0 0.00 78.29 3711.71 5000.00 
iHRP-Ca-alg – product generated by encapsulating HRP solution into Ca-alginate 
matrix 
iiHRP-EDA-alg – product made by encapsulating HRP solution into EDA-alginate 
matrix 
iiiBP – base pallet is a semi-finished fish feed product, dry extrudate lacking oil mix 
(Item C007, Table 2.1) 
 
  
4.4.1.3 Fish trial 
The fish trial was performed according to the general method described in 
the section 2.2.5.2 (Chapter 2) at Lab G (EWOS Innovation AS, Dirdal, 
Norway). In addition, feed intake was measured. All Parameters relevant to 
this trial are listed in the Table 4.13. 
The three groups of fish were named as Ca-alginate, EDA-alginate and 
Control group. Ca-alginate and EDA-alginate group were treated with HRP-
Ca-feed and HRP-EDA-feed respectively. The Control group was fed with 
Ctrl-feed. The health status of the fish was good during the 11 weeks long 
span of the trial.  
The following samples were collected 1) Stomach, 2) Pyloric Caeca, 3) Mid 
intestine and 4) Distal intestine (Figure 4.7). Each of the sampled 
gastrointestinal compartments was opened by longitudinal incision and 
placed into a container with DI water (10.0 ml, t = 4°C). After vigorous 
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shaking, the solid content was separated from the liquid phase by gravity 
filtration. The resulting filtrate (2 ml) from each container was transferred to 
an eppendorf tube and stored at -20oC until assayed.  
Table 4.13: Parameters applied in the fish trial carried out by feeding fish 
with feed containing alginate microbeads loaded with HRP 
Parameter Symbol Quantity 
Average weight of fish m 394 g 
Oxygen saturation in water O2 95% 
Water temperature t 5°C 
Diameter of a tank d 1.0 m 
Volume of a tank V 0.5 m3 
Number of tanks ntanks 9 
Total number of fish nfish 495 
Number of groups ngroups 3 
Length of the acclimatisation period taccl 9 weeks 
Length of the treatment period ttreat 2 weeks 
Number of sampled fish per tank per sampling 
point 
nsf/t 15 
Number of sampling points nSP 1 
Length of the time intervals from the end of 
treatment to sampling 
tSP 0 
Total number of sampled fish nsampled 135 
 
 
Figure 4.7: Gastrointestinal tract of A. salmon. Sampled compartments: 
stomach, pyloric caeca, mid and distal intestine are marked off with division 
lines. 
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4.4.1.4 Sample analysis 
The samples were thawed and spun down at 4000 rpm for four minutes prior 
to use. Stomach and pyloric caeca samples were applied undiluted while mid 
and distal intestine samples were diluted 1:200 with DI water (4°C; Item 
C022, Table 2.1) before assaying. For diluted mid and distal intestine 
samples (1:200) below quantification limit (0.391 ng ml-1), lower dilutions like 
1:10 and 1:100 or no dilution were used to increase sensitivity. Kinetic assay 
was carried out by pipetting aliquots of samples (50 µl) onto 96-well 
polystyrene plates (Item T006, Table 2.2). Reaction was initiated by adding 
50 µl per well of liquid substrate (Item C018, Table 2.1) at 37°C. Absorbance 
measurements were conducted by using a microplate reader (Item I003, 
Table 2.3) at 655 nm. Kinetic rates were recorded every 20 seconds for a 
total of 10 minutes at 37°C. HRP concentration of the samples was 
determined by using standard curve as a quantification tool in the range of 
0.391 to 200 ng ml-1. The standard curve was generated by plotting HRP 
concentrations of 10 two-fold serial dilutions of HRP solution (200 ng ml-1; 
Item S020, Table 2.4) against their kinetic rates (slope of the absorbance 
versus time curves). 
Finally, statistical analysis of the obtained data was performed according to 
the description in the Section 2.2.6.3 (Chapter 2). 
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4.4.2 Results    
In the current trial, a fish consumed 12-13 g feed on average during the 
weeklong treatment with feed containing alginate encapsulated HRP. As a 
result, the treated fish (mavg = 490 – 500 g) received between 230 and 240 
µg of HRP in the period (Table 4.14). 
Table 4.14: HRP dose related to the fish size in unit of mass and the weekly 
feed intake (FI) per fish. The dose is shown as a weekly HRP dose per fish 
(µg fish
-1 week-1) and a weekly HRP dose per unit of fish mass (µg fish
-1 
week-1) 
Groupi Feed 
Fish size 
(g) 
±SD 
FI  
(g fish-1 
week-1)  
±SD 
HRP doseii  
(µg fish
-1 
week-1)  
±SD 
HRP dose  
(µg kg-1 
week-1)  
±SD 
Control Ctrl-feed 492 ±121 12.7 ±1.7 0.00 0.00 
Ca-alginate HRP-Ca- 
feed 
495 ±95 12.5 ±1.4 239 ±26 483 ±46 
EDA-
alginate 
HRP-
EDA-feed 
499 ±108 12.1 ±0.9 232 ±17 465 ±50 
iGroups were treated with following feeds: feed without HRP (Ctrl-feed), feed with 
calcium alginate encapsulated HRP (HRP-Ca-feed) and feed with 
ethylenediammonium alginate encapsulated HRP (HRP-EDA-feed) 
iiHRP dose is theoretical and assumes very little loss due to processing. 
 
Group of fish (Ca-alginate) fed with HRP-Ca-feed showed significantly higher 
concentration of HRP in the distal intestine compared to the other 
gastrointestinal (GI) compartments (Figure 4.8). On the other hand, fish 
served HRP-EDA-feed had significantly higher concentration of HRP in the 
mid intestine than in the other GI sections. Additionally, this group had also 
notably high HRP concentration in the distal intestine.  In contrast to the HRP 
treated groups, peroxidase activity was quite low in the control group.    
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Figure 4.8: HRP concentration in four GI compartments (stomach, pyloric 
caeca, mid and distal intestine) of three groups of A. salmon (Ca-alginate, 
EDA-alginate and Control). The error bars represent 95% confidence 
intervals. Ca-alginate group were treated with calcium alginate encapsulated 
HRP (HRP-Ca-alg). EDA-alginate group was treated with 
ethylenediammonium alginate encapsulated HRP (HRP-EDA-alg). Control 
group did not receive any HRP. 
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4.5 Discussion 
From the present in vitro study it could be seen that both Ca-alginate and 
EDA-alginate matrix are poorly soluble in buffers with pH 1.2 at 37°C, pH 6.8 
at 37°C, pH 8.0 at 18°C and pH 8.6 at 18°C within a time frame of 60 
minutes. Drug, which is encapsulated in alginate matrices, is released by two 
mechanisms: 1) diffusion of the drug through the pores of the polymer 
network and 2) degradation of the polymer network (Wee et al., 2012). Unlike 
the low molecular weight drugs, BD (M.W. = 2,000,000) is so large that it 
cannot diffuse through the pores of an alginate matrix without their further 
expansion (Kim and Lee, 1992).  
According to Kikuchi et al. (1999), the lag stage of initial release was longer 
with an increasing molecular weight of dextran (M.W. = 9,400 –145,000). It 
was observed very low release rate of FITC-dextran (M.W. = 145,000) at pH 
7.4 during the first hour. As a result, most of the BD release from alginate 
matrices presumably happens due to degradation of polymer network. 
Accordingly, very little of this degradation is expected to occur at pH < 7.6 in 
case of EDA-alginate (pKa 1 = 7.56 and pKa 2 = 10.71). This is due to the 
fact that most of the ethylenediamine (uncharged form) will exist as 
ethylenediammonium (positively charged, 2+) at pH < 7.6.  
However, in Mumper et al 1993, Ca-alginate previously exposed to low pH, 
degraded faster in pH 7.4 solution than Ca-algnate exposed solely to solution 
of pH 7.4.Therefore, an effective way to weaken the cross-linked structure of 
an alginate matrix would be to use an acidic dissolution medium (pH < 3.5) 
before applying an alkaline medium (pH > 7.6). At pH below 3.5 (alginic acid, 
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pKa = 1.5 – 3.5), hydrogen ions (H+) replace cations (+) in alginate networks 
yielding an unlinked structure of alginic acid. Although alginic acid is poorly 
water soluble it may ease subsequent conversion to sodium alginate, which 
is aqueous soluble form of alginate at higher pH. As it can be anticipated, 
foregoing treatment with acidic medium (pH < 3.5) may give much faster 
release rate then direct treatment with alkaline medium (pH > 7.6). Taking 
this into account, it can also be concluded that direct treatment with pH < 7.6 
will be ineffective in dissolving EDA-alginate. In other words, applying 
standard conditions (pH = 1.2 and 6.8 at 37°C) in two separate dissolution 
tests will most likely result in very slow dissolution rates producing 
inconclusive results.  
This reasoning is in agreement with the results in the current study where pH 
= 3.0 was combined with pH = 8.0 to generate successful results shown in 
the Figure 4.4. Putting alginate beads in an acidic buffer (pH = 3.0) for a 
short period of time would convert some EDA-alginate to alginic acid. 
Consequently, alginic acid and any remaining EDA-alginate are readily 
dissolved when acidic buffer is replaced with alkaline one (pH = 8.0). In the 
same manner, disintegration rate of Ca-alginate matrix is accelerating with 
increasing pH of the dissolution medium. At the same time, attraction of 
charged sodium (Na+) towards carboxylic groups of alginate is increasing 
when pH is greater than 8 (Oberyukhtina et al., 2001). On the other hand, 
calcium phosphate may already start precipitating from a system containing 
Ca2
+ and phosphate buffer at pH > 6.7 (Feenstra and De Bruyn, 1979).  
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For the above reasons and for the reason that pH of the stomach is 2.7 - 4.9 
and pH of the intestine is 7.5 - 8.5, the dissolution test strategy pH 3.0/8.0 
was selected. According to Shi et al. (2011), dissolution of cross-linked 
alginate is pH- and temperature-responsive. However, from the Figure 4.4, it 
may be concluded that dissolution of EDA-alginate is pH-responsive but not 
temperature-responsive in the range of 4 – 18°C.  
Contrary to EDA-alginate, dissolution of Ca-alginate is in compliance with the 
previous study. Release rate of BD from Ca-alginate matrix is significantly 
lower than release rate from EDA-alginate matrix at 4°C. This observation is 
in agreement with the results from the in vivo trial which was carried out at 
5°C. From the Figure 4.8, it can be seen that HRP release in vivo is 
significantly faster from EDA-alginate than from Ca-alginate beads.  
According to the observations in this study, it is not expected that drug 
release from the EDA-alginate is affected by seasonal temperature changes 
in the habitat of A. salmon. These attributes make delivery system based on 
EDA-alginate very interesting with respect to salmonid fish.  
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Chapter Five:  Size adaptation of alginate beads for 
improved integration with fish feed pellets                                                         
During recent years, the use of functional ingredients in aquaculture industry 
has increased dramatically and a broad range of functional feeds are now 
widely available for use in fish farming. In connection with that, there is 
ongoing research which deals with developing oral delivery systems for 
delivering of sensitive bioactive compounds to fish. A variety of products 
(nutrients, medicines and vaccines) can be incorporated into alginate 
matrices to avoid damage from the low pH and proteolytic enzymes 
encountered in the digestive tract of fish. However, there has been very little 
research reported on the effectiveness of those oral delivery systems in 
terms of their performance within feed pellets, in a vacuum infusion coating 
process. Furthermore, the reported sizes of alginate delivery systems, which 
are generated by an extrusion method, require further reduction to be 
suitable for effective association within feed pellets. As a result, the main 
objective of this study is to develop a technology capable of providing an 
economical and high throughput method for producing fine alginate beads 
containing a wide range of small molecules capable of lodging themselves in 
fish feed pellets during their production. The results of these investigative 
studies significantly improve understanding of the issues regarding 
incorporation of delivery systems into fish feed in the current manufacturing 
process and have unearthed a novel approach for functionalizing fish feed 
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5.1 Introduction 
Fish feed has evolved into a fairly advanced product that will most likely go 
towards increasingly sophisticated for each year to come (Pandey, 2013). 
Because of the fish farmer’s growing demand for ever increasing weight gain 
and food safety authorities pursuit for healthy farmed fish (Thorud et al., 
2007), feed industry has responded with enhancing focus on functional 
feeds. To put things into perspective, EWOS AS (Norway), which is a fish 
feed company, has experienced a dramatic increase in sale of functional 
feeds. Share of functional feeds rose from 16% in 2008 to 47% in 2011 
(Cermaq, 2012). Functional feeds are diets that improve both health and 
growth of the animals, by providing additional bioactive compounds apart 
from the basic nutritional requirements for growth alone (Martinez-Rubio et 
al., 2012; Olmos et al., 2011; Tacchi et al., 2011).  
Some of the bio-actives (e.g. proteinous compounds) are thermos-sensitive 
and prone to acidic and proteolytic degradation in the gastro intestinal tract. 
One way to come around this problem is to entrap/encapsulate these 
compounds into some sort of protective delivery system ahead of 
incorporating them into feed pellet (Bernkop-Schnurch, 2009; Bruno et al., 
2013; Rosenmayr-Templeton, 2013). Although getting the delivery system 
into feed pellet remains a formidable challenge, options are few, if any. 
Delivery systems could be incorporated into the extruded feeds by so called 
oil infusion coating process (Goeritz et al., 2014; Ljungqvist et al., 2012). 
Success of coating depends both on size of delivery system and pore size of 
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the feed pellet. On the other hand, Eldridge et al. (1990) demonstrate that 
particles smaller than 10 μm can cross the epithelial barrier.  
From the gut lumen, micro-/submicro-particles are taken by micro-fold (M) 
cells across the epithelial layer. Afterwards, these particles are delivered to 
antigen presenting cells such as macrophages (van der Lubben et al., 2002). 
Time-course studies on the fate of the poly(DL-lactide-co-glycolide) 
microspheres within the gut-associated lymphoid tissue shows that the 
majority of the microspheres (diameter, d < 5 µm) are transported through 
the efferent lymphatics within macrophages, while the majority of those with 5 
< d < 10 µm remains fixed in the Peyer's patches. In another study Petrie & 
Ellis (2006) provides evidence for uptake of particles d < 3μm by the distal 
intestine of A. salmon following anal intubation of inert polystyrene 
microspheres. Given this, it can be concluded that generation of very fine 
microbeads d < 10 µm is essential for both efficient post-extrusional 
incorporation into feed pellet and successful uptake by distal intestine. 
This study was commissioned to assess an alginate based delivery system. 
Alginates are polysaccharides isolated from brown algae such as 
Ascophyllum sp., Durvillaea sp., Ecklonia sp., Laminaria sp., Lessonia sp., 
Sargassum sp. and Macrocystis pyrifera found in coastal waters around the 
globe (McHugh et al., 2003). Marine alginates are composed of two forms of 
uronic acid: mannuronic (M) and guluronic (G). Two blocks of adjacent 
polymer chains can be cross-linked with multivalent cations (e.g., Ca2+ or 
Ba2+) through interactions with the carboxylic groups in the uronic acid, which 
leads to the formation of a gel network (Augst et al., 2006) The resulting 
cross-linked alginate beads have excellent biocompatibility within host 
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tissues and are able to biodegrade in a controlled manner. These attributes 
make alginate an ideal compound for use as oral delivery system (Adelmann 
et al., 2008; Joosten et al., 1997; Maurice et al., 2004; Polk et al., 1994). 
Alginate beads are stable at low pH and dissolves at high pH. As a result, a 
faster release from alginate beads occurs in the intestine (alkaline 
conditions), after the beads have passed through the proteolytic and acidic 
environment of the stomach (Yu et al., 2008).  
The crosslinking properties of alginate form the basis for various 
encapsulation techniques including both extrusion and emulsion processes 
(Vemmer and Patel, 2013). Extrusion processes could be further subdivided 
into electric and non-electric driven methods. Typical electric driven 
approaches are electromagnetic laminar jet breakup (Martinez et al., 2004), 
inkjet printing technology (Xu et al., 2008) and electrostatic driven 
encapsulation process which is also called electrospraying  (Gomez and 
Tang, 1994). General non-electric driven approaches are coaxial air flow 
induced dripping (Koch et al., 2003) and aerodynamically assisted jetting 
(Jayasinghe and Suter, 2006). Most common emulsion techniques frequently 
used are coacervation (de Kruif et al., 2004; Veis, 2011), internal and 
external gelation (Quong et al., 1998).  
Among the aforementioned techniques, aerodynamically assisted jetting 
(AAJ) distinguishes itself with characteristics such as being fairly 
inexpensive, easy up-scalable, gentle and high-throughput encapsulation 
process. These features make this process very well-suited for industrial 
application where effective large batch processes are favourable 
(Arumuganathar and Jayasinghe, 2008; Jayasinghe, 2011).  
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In general, there has been very little research reported on the behaviour of 
alginate particles and oral delivery systems in a vacuum infusion coating 
process. This process is the standard industrial method for adding formulated 
sensitive substances to fish feed. In our view, the reported sizes of alginate 
delivery systems (Table 5.8), which are generated by an extrusion method, 
are too large to be suitable for effective association with feed pellet. To check 
this assertion, a vacuum infusion coating test was performed in the first 
phase of this study. As a part of this test, we analysed pore size of feed 
pellets and examine morphology of the pellet pores. This is to determine the 
particle size suitable for sufficient incorporation into large feed pellets (d ≥ 10 
mm) in the vacuum coater. To evaluate the outcome of the test, we looked 
for barium alginate (Ba-alginate) particles inside a pellet using an X-ray 
computed tomography technique.  
In the second phase, the present study aims to produce the smallest calcium 
alginate (Ca-alginate) particles attainable with the APAEJ conjointly 
supported by electrostatic force. To achieve this goal, the APAEJ was 
optimised in a controlled experiment. This is to increase chance of getting 
alginate beads both inside smaller feed pellets (d < 10 mm) and inside the 
intestinal epithelial layer. Finally, morphology of calcium alginate particles 
was examined by the imaging-based particle analysis system. 
In the large perspective, this study contributes much to the effort of creating a 
successful oral delivery system for delivering of sensitive bioactive 
compounds to fish which in turn contributes to improved health and welfare of 
cultured animals. 
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5.2 Assessment of association of alginate microbeads with 
fish feed pellets 
High level of incorporation of alginate microbeads into feed pellets is the key 
factor for successful delivery of encapsulated therapeutics to fish. Therefore, 
as the first step in this study, pore sizes of feed pellets were measured by 
mercury intrusion porosimetry. This is performed with the aim of determining 
a suitable particle size for sufficient incorporation into feed pellets by the 
vacuum infusion coating method. Thereafter, vacuum infusion coating test 
was carried out with barium alginate microbeads adequately sized for 
incorporation into feed pellet with diameter around 10 mm. The results of 
coating test were examined by micro-CT (computed tomography) scanning. 
In the end, morphology of alginate microbeads was analysed by a fluid 
imaging-based particle analysis system.  
5.2.1 Methods 
5.2.1.1 Characterisation of feed pellet pores by mercury intrusion 
porosimetry and scanning electron microscopy 
The pore size distributions of three base pellets: BP1 (d=10 mm, m = 0.4908 
g, V = 0.6708 cm3), BP2 (d = 10 mm, m = 0.4111 g, V = 0.6494 cm3) and 
BP3 (d =10 mm, m = 0.4895 g, V =0.5948 cm3) were determined by mercury 
intrusion porosimetry. The analysis was carried out by a porosimeter (Item 
I004 Table 2.3) at low and high pressure ranging from 0.2 to 50 psi and from 
20 to 60,000 psi respectively. Specimens were placed in the long cell with 
internal diameter of 4 mm. Mercury (Hg) volume was recorded at each 
pressure point and normalised by the sample weight. The output data was 
generated in the scan mode (Autospeed). Both extrusion and intrusion Hg 
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contact angles were set to 130°. In addition, surface tension of Hg was 
adjusted to 470 erg cm-2. Determination range of low-pressure and high-
pressure porosimetry was 4.3 –1000 μm and 0.0035 – 7 μm respectively. 
Pellet pores were also examined by SEM (Item I005, Table 2.3) with the aim 
of getting insight into the shape and size of the entry pores. 
5.2.1.2 Preparation of barium alginate microbeads 
Barium alginate (Ba-alginate) microbeads were produced according to the 
general method described in the Section 2.2.1.2 (Chapter 2). Encapsulation 
was conducted with the aid of voltage so the method was an aerodynamically 
assisted energised jetting. Process parameters and their respective values 
are summarised in the Table 5.1. The following items were specific to this 
process: encapsulation formulation (Item S027, Table 2.4), jetting head (Item 
T018, Table 2.2) and cross-linking solution (Item S023, Table 2.4). 
The generated Ba-alginate beads were washed three times DI water (10 ml; 
Item C022, Table 2.1) and then filtered off by suction filtration ahead of 
vacuum infusion coating step. An amount of 7.24 g Ba-alginate microbeads 
was recovered.  
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Table 5.1: Aerodynamically assisted energised jetting – process parameters 
applied in producing Ba-alginate microbeads for the vacuum coating 
experiment. 
Distancei Volumeii Voltage Flow rate Target 
volume 
Pressure 
x Vxls U Q Vtv P 
mm ml kV cm3 h-1 ml bar 
85 100 10 50 20 1.75 
iDistance between the jetting head and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
5.2.1.3 Incorporation of Ba-alginate microbeads into feed pellets by the 
vacuum infusion coating method 
Firstly, fish oil (Item C019, Table 2.1) was triple filtered using three different 
filter papers. There were used: coffee filter (Item T010, Table 2.2), qualitative 
filter paper grade 1 (Item T011, Table 2.2) and grade 6 (Item T012, Table 
2.2) in the given order. Thereafter, Ba-alginate microbeads (dmedian = 25 µm, 
7.24 g) were suspended in the triple filtered fish oil (moil = 250g). The 
resulting fish oil suspension was then combined with base pellet (mBP = 
742.76 g; davg = 10 mm; Item C007, Table 2.1) in a vacuum infusion coating 
process. The coating was performed according to the method described in 
the Section 2.2.4. Finally, feed (mfeed = 1000 g) containing Ba-alginate 
microbeads was produced and one random pellet was taken out of the final 
batch for micro-CT (computed tomography) scanning. 
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5.2.1.4 Micro-CT scanning of a feed pellet infused with Ba-alginate beads 
One fish feed pellet infused with Ba-alginate microbeads was scanned by 
high-resolution micro-CT (Item I006, Table 2.3) at RJL Micro and Analytic 
GmbH (Karlsdorf-Neuthard, Germany). The micro-CT scanning was 
performed with the purpose of detecting Ba-alginate particles inside a coated 
pellet. In addition, size distribution of the detected Ba-alginate particles inside 
pellet was measured.  Size distribution of Ba-alginate particles before the 
infusion coating was determined by laser diffraction equipment (Item I007, 
Table 2.3).  
5.2.2 Results and discussion 
5.2.2.1 Characterisation of feed pellet pores  
It is challenging to determine the pore size distribution of an extruded pellet 
and relate it to the size of a delivery system. It is primarily due to the highly 
irregular shape of pores. The pores have properties dependent on the degree 
of expansion along with the size, shape and the way the constituent particles 
are packed together. The largest number of pore sizes is around 100 µm in 
three analysed pellets (Figure 5.1). There is also another smaller peak at 
around 400 µm. In general, the most pore sizes are in the range from 10 µm 
to 500 µm in all three pellets. Draganovic et al. (2013) reported that most 
pore sizes in the fish feed pellet (davg=8.7 mm) were below 330 μm. This 
measurement is a result of micro-CT scanning that produces a visualization 
of pore space and solid material in a cross-sectional plane. This technique 
provides very little information about the surface pores and their size 
distribution. Furthermore, it struggles with recognising pore sizes below 11 
μm. These are highly relevant factors for successful incorporation of delivery 
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systems into feed pellet. Based on this reasoning, measurement of surface 
pore size distribution by the mercury intrusion porosimetery would 
presumably be more suitable analytical method (León y León, 1998; Nimmo, 
2004; P. Rigby et al., 2004). This presumption is further strengthened by 
careful examination of SEM images (Figure 5.2).  
 
 
Figure 5.1: Pore size distribution by mercury intrusion porosimetry. Results 
expressed as difference in mercury volumes intruded between the pressures 
P2 and P1 (dV/dP) as function of pore diameter. Most of the pores are 
around 100 µm ranging from 10 to 500 µm. BP – base pellet.    
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Figure 5.2: SEM images of a typical 10 mm fish feed pellet. A typical 10 mm 
pellet is shown in the image (a). Characteristic SEM micrographs of the 
surface of a fish feed pellet, scale bar represents b) 1 mm, c) 100 µm and d) 
10 µm showing the variation of pore size. The green circle and the closed red 
curve are added to the image (c) in order to depict the largest diameter which 
can fit into the indicated pore. This pore opening is areally four times larger 
than an imaginary circular area representing a spherical alginate bead.   
 
In the Figure 5.2, the dark area, which is located within the closed red curve, 
indicates the void space inside a feed pellet. This void space is identified as a 
pore. The entry hole of that pore is irregularly shaped. Most of the 
porosimeters will mathematically convert this irregularly shaped entrance to a 
circular one. For instance, the mercury porosimeter will assume the 
cylindrical shape of a pore (Quantachrome Instruments, 2009). As a 
consequence of the assumption, the estimated pore diameter may be much 
larger than the widest gap in the original shape. It implies that the spherical 
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objects, which are approximately of the same size as the estimated diameter 
of a pore, will not be able to enter into that specific pore.  In this particular 
case, the encircled dark area is four times larger than the area of the blue 
spot. The blue spot is apparently the largest diameter which can fit into the 
indicated pore. It means that the diameter of a spherical object to go in needs 
to be at least two times smaller than the estimated pore diameter.  
The above discussion is based on one pinpointed pore. It is true that the 
other pores may have entry holes with higher degree of circularity which 
brings the estimated diameter of a pore closer to a diameter of a 
circle/sphere. On the other hand, there are other factors that contribute to 
estimating the size of surface pores to be larger than what they actually are.  
Based on the results of the present study and supported by the previously 
reported research which we referred to above, it may be assumed that the 
size of inner pores (air pockets) is larger than the size of entry holes (surface 
pores). This suggests that the overall pore size distribution is not directly 
transferrable to the size distribution of the surface pores alone. The actual 
surface pore sizes are expected to be smaller than the overall pore size 
distribution measured by an instrument. Therefore, it is important to ensure 
that the actual alginate beads are able to access feed pellets of interest 
through the outer openings of the pellet pores. One of the options to check 
whether alginate beads of a certain size go inside feed pellets is to carry out 
a vacuum coating test. Afterward, amount of alginate beads inside the coated 
pellet can be measured by X-ray computed tomography. 
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5.2.2.2 High resolution micro-CT scanning of fish feed pellet infused with Ba-
alginate particles 
Based on the results discussed in the previous section, it can be assumed 
that a great number of surface pore sizes on a fish feed pellet (d = 10 mm) 
are smaller than 100 μm. It implies that delivery systems with d > 100 µm 
could not enter into the pellet pores in large numbers.  A significant number 
of particles larger than 100 µm would lie on the surface of a pellet exposed to 
external conditions. The micro-CT scan revealed large number of white 
objects inside a feed pellet coated with Ba-alginate particles (Figure 5.3). 
Based on the size distribution it may be concluded that these objects are Ba-
alginate beads. The results show that roughly, 82% of bright objects are 
below 50 µm, while half of them are below 23 µm (Figure 5.4). This 
corresponds very well to the median size of Ba-alginate particles which was 
25 µm right after preparation. In addition, very large proportion (98%) of 
these Ba-alginate particles was smaller than 50 µm. Alginate particles of this 
size could apparently be coated in larger quantities, withstand the 
mechanical force encountered in feeding systems at fish farm and remain 
within the feed pellet whilst exposed to the aqueous environment. Though 
smaller Ba-alginate particles could be incorporated even more effectively, we 
opted for slightly larger particles (dmedian = 25 µm) to ensure better 
detectability at micro-CT scanning. Smaller particles are also useful for 
associating with smaller feed pellets (davg < 10 mm) and uptake by distal 
intestine.  
In brief, to enable high degree of inclusion, a reasonable target size of 
delivery systems could be in the region of one quarter of the estimated pellet 
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pore size. Some additional research could be done to identify the largest 
suitable particle size in relation to a given pore size of feed pellet.   
 
Figure 5.3: Micro-CT scan image of one quarter of a pellet (d=10 mm), which 
is cut along its central axis. The white objects represent barium alginate 
particles. 
 
Figure 5.4: Volume percentage of barium alginate particles expressed as 
function of particle diameter. From the graph it can be seen that 82% of the 
particles are smaller than 50 µm while 50% are below 23 µm. 
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5.3 Optimisation of the encapsulation process 
For optimal incorporation into feed pellets, small-sized alginate beads are 
preferable. In addition to associating very well with feed pellet, sufficiently 
small oral delivery systems are capable of crossing the intestinal epithelial 
layers as well. Therefore, the encapsulation process was optimised for 
producing the smallest possible calcium alginate microbeads in a controlled 
experiment. 
5.3.1 Methods 
5.3.1.1 Experimental design and statistical analysis 
With the aim of optimising the APAEJ encapsulation process for production 
of minimal Ca-alginate beads, several general types of variables were 
considered: uncontrollable, background, constant, primary and response 
variables. As a result, five primary variables were identified: flow rate of 
alginate solution (Q), alginate concentration (C), distance between spray 
head and cross-linking solution (x), air pressure (P) and voltage (U). The 
ranges of the levels of the variables used in the experiment are shown in the 
Table 5.2. 
Internal diameter of the nozzle (350 µm), diameter of exit orifice (350 µm), 
volume of crosslinking solution (80 ml), concentration of cross-linker (0.25M), 
volume of extruded alginate solution per sample (6.0 ml), and conductivity of 
alginate solvent (DI water, κ≤0.05 µS/cm) were kept constant. Background 
variables which included temperature (18oC) and relative humidity (56%) 
were measured but not treated as covariates in the model because they 
remained unchanged during the entire experiment. Ambient concentration of 
183 
 
particulates was singled out as an uncontrollable variable. The median 
particle size (dmedian) was used as a response variable. 
In order to meet the objective of producing alginate beads of the smallest 
size, a three-stage experimental approach following the response surface 
methodology (Box and Draper, 2007) was selected as the most suitable 
design.  
In stage 1, the primary variables were screened to identify the active ones 
with a 25 factorial design with five centre points. In stage 2, the response 
surface around the minimal particle size was mapped with the help of a 
central composite design (CCD) on the active factors identified in stage 1. In 
stage 3, the results were verified by performing some runs around the 
stationary point, i.e. conditions resulting in the minimal particle size. Bayesian 
model discrimination (Box and Meyer 1993) was applied to the data set 
generated in stage 1.  
This screening method identified the most probable model among all possible 
combinations of factors. After identifying the most probable active factors a 
first-order response surface model with these factors was fitted to the data 
from stage 1 with the help of generalised linear models. The importance of 
first-order interactions between the factors was studied with the help of a 
likelihood ratio test between two nested models (with and without the 
interactions). In stage 2, the original first-order design from stage 1 was 
augmented by adding six star points (assuming the experimental space is a 
cube) and four centre points to achieve a complete CCD design. A block 
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effect was added to the model in order to account for any effect of conducting 
the runs in two different steps.  
Modelling was conducted with the help of nested general linear models of 
increasing complexity: first order model with main effects only, first-order 
model with first-order interactions and second order model with squared 
terms. Likelihood ratio tests were used to decide upon the most parsimonious 
but sufficient model. Modelling of stage 2 revealed the stationary point. In 
stage 3, nine runs around stationary point without any special design and one 
run at the stationary point were performed for the sake of verifying the 
results. All statistical modelling was conducted with the R language (R 
Development Core Team, 2012) and its corresponding packages (R version 
2.15.3). 
Table 5.2: Primary variables and their experimental levels applied in 
optimising the encapsulation process (aerodynamically assisted energised 
jetting). 
Variable Symbol Low Centre High Unit 
Flow rate Q 5.00 50.50 105.00 cm3 hr-1 
Alginate C 1.50 2.25 3.00 % 
Distance x 65 85 105 Mm 
Pressure P 0.50 1.75 3.00 bar 
Voltage U 0.0 10.0 20.0 kV 
 
 
5.3.1.2 Conduct of experimental runs – sample preparation 
Samples of alginate microbeads were produced in experimental runs 
conducted according to the general method described in the Section 2.2.1.2 
(Chapter 2). Generally, all solutions along with water used in this experiment 
were filtered by syringe filter (Item T009, Table 2.2) prior to use. As 
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previously described in the Section 5.3.1.1, important process parameters 
such as flow rate (Q), alginate concentration (C), distance (x), pressure (P) 
and voltage (U) were varied according to the experimental design. The 
experimental range of values for the variables C, Q, P, x and U are shown in 
Table 5.2. Volume of the crosslinking solution (Vxls = 80 ml) and target 
volume (Vtv = 6.0 ml) were kept constant throughout the entire experiment. 
All performed runs and the applied levels of variables are listed in the Tables 
4.3, 4.4 and 4.5.  
The following items were specific to this process: alginate solution with 1.5% 
alginate (Item S024, Table 2.4), alginate solution with 2.25% alginate (Item 
S025, Table 2.4), alginate solution with 3.0% alginate (Item S026, Table 2.4) 
and cross-linking solution (Item S003, Table 2.4). 
5.3.1.3 Particle size measurement 
Size of the generated alginate beads was measured by a laser diffraction 
instrument (Item I007, Table 2.3). The instrument was equipped with laser 
diffraction sensor (HELOS BR) and cuvette (CUV-50ML/US). Optical module 
(R5) with laser beam (d = 13 mm) was used to illuminate the sample at 
wavelength λ = 632.8 nm. This configuration was specially designed for the 
analysis of particles which are sized from 0.5 to 875 µm and suspended in 
volumes lower than 50 ml. The system was specified to perform with 
accuracy of δ < 2% and repeatability of δ < 0.04%.  
Sample with suspended alginate beads was added to the cuvette containing 
filtered DI water (40 ml; Item C023, Table 2.1) under stirring (100 rpm) until 
optical concentration (Copt > 11%) was reached. Calculations were performed 
186 
 
in the Fraunhofer enhanced evaluation (FREE) mode which is based on the 
Fraunhofer theory (Bertero et al., 1985). Particle size was recorded as the 
average of three consecutive measurements. The instrument was controlled 
by the software package WINDOX 5 (Version 5.8.0.0). 
5.3.2 Results and Discussion 
In the first phase, 37 runs were carried out as a part of a 25 factorial 
experiment (Table 5.3). The applied Bayesian model discrimination technique 
suggested a model including three factors concentration (C), distance (x) and 
pressure (P) as the most probable model (Probability = 0.998). The most 
likely model was then fitted using the first-order response surface 
methodology. A model with two-way interactions proved to be the best 
option, based upon a likelihood-ratio test.  
The residuals of the interaction model plotted against each of the factors 
indicated a nonlinear response within the experimental region. This suggests 
the stationary point (i.e. the minimum particle size) may be located within the 
experimental region. Therefore, the usual next step in the response surface 
methodology, finding the path of the steepest ascent, was skipped and the 
full response surface model was sought directly. This was achieved by 
expending the design with the star points of the central composite design 
(CCD) involving only three most probable factors (C, x and P). As a result, 
the additional 10 runs linked to the expended central composite design 
(CCD), were performed in the second phase (Table 5.4).  
The results suggested that the particle size was minimised at the stationary 
point C = 1.60%, x = 105 mm and P = 3.00 bar (Figure 5.5). In the last 
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phase, nine runs around stationary point and one run at the stationary point 
itself confirmed the theory and demonstrated that the median particle size 
(15.9 µm) was in fact smallest at the stationary point (Table 5.5).  
 
Figure 5.5: Response surface slices of the second-order model showing the 
stationary point (red dot). 
 
 
As previously mentioned, it has been concluded that concentration (C), 
distance (x) and pressure (P) are significant process variables. The inference 
made on the effect of concentration is supported by the observations of other 
researchers. According to Watthanaphanit & Saito (2013) concentration of 
sodium alginate in solution is directly proportional to the viscosity of the 
solution. Furthermore, Paine et al. (2007) states that for liquids having higher 
viscosity, more energy is required to draw liquid out of a nozzle. For this 
reason, the droplets are formed with lower frequency than for liquids of low 
viscosity. According to the Jaworek et al. (2000) the size of the droplets could 
be controlled by the frequency of formation.   
In the present study, it was observed that too short distance could cause the 
crosslinking solution to splash back towards the jetting head. Such conditions 
lead to agglomeration of alginate droplets and even to the blockage of the 
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exit orifice. Another reason, why too short distance is not desirable, is that it 
may cause a short circuit in the system when high voltage is applied. It was 
also noticed that too long distance led to dispersion of very small droplets in 
such a way that they could hardly reach the crosslinking solution. In other 
words, they would become airborne or land elsewhere than onto the surface 
of the crosslinking solution. Given this, it can be concluded that the adequate 
distance is essential for the optimal performance of this encapsulation 
process.  
Since both distance and sodium alginate concentration are normally adjusted 
before the process start, pressure remains the only variable that could be 
used to control size of alginate particles while encapsulating. Changyuan et 
al. (2012) came to the same conclusion in their study where effect of 
pressure on droplet size in an air-assisted spraying process was 
investigated.  
Output from the Bayesian model screening indicated that the voltage and 
flow rate were statistically insignificant variables for the function of adjusting 
process to produce minimal particle size. It is arguable whether or not these 
variables are producing any effect at all. When it comes to the voltage, 
limiting factor may be the measuring range of HELOS BR instrument with R5 
lens. Measuring range of this configuration is quoted to be 0.5/4.5-875 µm. 
According to Sympatec, this system is not extremely accurate below 4.5 µm.  
As already stated, primary goal with introducing voltage to the current 
encapsulation process was to bring down possible hovering alginate droplets 
generated at the exit orifice of the jetting head. The main reason for the 
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ineffectiveness of voltage could be found in the size of these airborne 
droplets which presumably may be smaller than 4.5 µm. Such presumption 
suggests that the voltage could have an effect but it is not measurable with 
the applied lens. With reference to the first and ninth run in the Table 5.5, it 
can be seen that the changes, which were made to the stationary point run in 
terms of voltage and flow rate, did not notably affect median particle size. 
Thus, it may be concluded that the inference made by the Bayesian model 
screening was correct. On the other hand, it would not be unreasonable to 
expect the median particle size to increase with a large upturn of flow rate 
while the other parameters are kept at the same level. This assumption is not 
very strong counterargument since the objective is to minimise, not to 
maximise the particle size. All things considered, the applied statistical 
models figured out the stationary point with good accuracy.  
Droplets diameter may also depend on the liquid (alginate solution) 
properties like density, viscosity, conductivity, gas-liquid surface tension, and 
relative permittivity (Gañán-Calvo et al., 1997). However, we have chosen 
not to vary these factors in this experiment because they are more related to 
encapsulation material properties than to the encapsulation process itself. 
Although concentration of sodium alginate was included in the experimental 
design, primarily, we wanted to optimise only variables which could be 
adjusted while running the process. Another advantage of limiting the 
experimental design to fewer variables is that the complexity and size of the 
experiment stays at manageable levels. Now, as the effects of process 
variables are identified it is easier to optimise the liquid variables in a 
separate design when the encapsulation material is known.  
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In the next section, the main topic is morphology characterisation of Ca-
alginate particles but we use Na-alginate solution with higher conductivity 
than the Na-alginate solution used in this experiment. This is to test whether 
the liquid properties affect the size of the final product. 
Table 5.3: Stage 1 – results from the 25 factorial experiment with five centre 
points (cp01 to cp05). Constitutive letters in the run name express which 
factor was at high level in the run.   
Run 
order 
Run 
name 
Flow 
rate  
Q 
[ml/h] 
Alginate 
 
C 
[%] 
Distance 
 
x 
[mm] 
Pressure 
 
P 
[bar ] 
Voltage 
 
U 
[kV] 
Response 
 
dmedian 
[µm] 
1 QxP 105.0 1.50 105 3.00 0.0 25.8 
2 CPU 5.0 3.00 65 3.00 20.0 27.1 
3 Q 105.0 1.50 65 0.50 0.0 103.3 
4 QCU 105.0 3.00 65 0.50 20.0 46.5 
5 cp03 50.5 2.25 85 1.75 10.0 25.9 
6 P 5.0 1.50 65 3.00 0.0 19.3 
7 QPU 105.0 1.50 65 3.00 20.0 24.9 
8 C 5.0 3.00 65 0.50 0.0 50.3 
9 U 5.0 1.50 65 0.50 20.0 78.8 
10 cp01 50.5 2.25 85 1.75 10.0 26.1 
11 QCP 105.0 3.00 65 3.00 0.0 24.0 
12 cp02 50.5 2.25 85 1.75 10.0 25.8 
13 QCx 105.0 3.00 105 0.50 0.0 51.6 
14 CxP 5.0 3.00 105 3.00 0.0 24.6 
15 QCxPU 105.0 3.00 105 3.00 20.0 23.6 
16 xPU 5.0 1.50 105 3.00 20.0 19.6 
17 CxU 5.0 3.00 105 0.50 20.0 55.3 
18 x 5.0 1.50 105 0.50 0.0 38.5 
19 QxU 105.0 1.50 105 0.50 20.0 41.2 
20 cp04 50.5 2.25 85 1.75 10.0 25.5 
21 cp05 50.5 2.25 85 1.75 10.0 25.9 
22 CU 5.0 3.00 65 0.50 20.0 50.6 
23 Qx 105.0 1.50 10 0.50 0.0 42.2 
24 CxPU 5.0 3.00 105 3.00 20.0 24.0 
25 xP 5.0 1.50 105 3.00 0.0 20.7 
26 QCxU 105.0 3.00 105 0.50 20.0 49.0 
27 Cx 5.0 3.00 105 0.50 0.0 62.4 
28 QxPU 105.0 1.50 105 3.00 20.0 26.2 
29 QCxP 105.0 3.00 105 3.00 0.0 23.5 
30 xU 5.0 1.50 105 0.50 20.0 37.5 
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Run 
order 
Run 
name 
Flow 
rate  
Q 
[ml/h] 
Alginate 
 
C 
[%] 
Distance 
 
x 
[mm] 
Pressure 
 
P 
[bar ] 
Voltage 
 
U 
[kV] 
Response 
 
dmedian 
[µm] 
31 PU 5.0 1.50 65 3.00 20.0 36.7 
32 QU 105.0 1.50 65 0.50 20.0 76.3 
33 0 5.0 1.50 65 0.50 0.0 97.7 
34 QC 105.0 3.00 65 0.50 0.0 48.6 
35 QP 105.0 1.50 65 3.00 0.0 25.7 
36 QCPU 105.0 3.00 65 3.00 20.0 24.0 
37 CP 5.0 3.00 65 3.00 0.0 25.7 
 
Table 5.4: Stage 2 – six star points of the full central composite design 
(CCD) and four additional centre points with three factors: alginate, distance 
and pressure. Flow rate and voltage are kept constant at centre levels. 
Constitutive letters in the run name express which one of the other three 
factors was at high level in the run. 
Run order Run 
name 
Flow rate 
Q 
[cm3 h-1] 
Voltage 
U 
[kV] 
Alginate 
C 
[%] 
Distance 
x 
[mm] 
Pressure 
P 
[bar] 
Response 
dmedian 
[µm] 
1 x 50.5 10 2.25 105 1.75 25.5 
2 -P 50.5 10 2.25 85 0.50 38.3 
3 P 50.5 10 2.25 85 3.00 19.4 
4 C 50.5 10 3.00 85 1.75 26.7 
5 cp 50.5 10 2.25 85 1.75 26.2 
6 -x 50.5 10 2.25 65 1.75 25.5 
7 cp 50.5 10 2.25 85 1.75 26.5 
8 cp 50.5 10 2.25 85 1.75 25.8 
9 -C 50.5 10 1.50 85 1.75 24.3 
10 cp 50.5 10 2.25 85 1.75 25.7 
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Table 5.5: Stage 3 – stationary point run and nine runs around the stationary 
point are shown. Alginate, distance and pressure are varied while flow rate 
and voltage are kept constant except from the last run where voltage and 
flow rate were reduced. 
Run name Flow rate 
Q 
[cm3 h-1] 
Voltage 
U 
[kV] 
Alginate 
C 
[%] 
Distance 
x 
[mm] 
Pressure 
P 
[bar] 
Response 
dmedian 
[µm] 
Stationary 
point (SP) 
50.5 10 1.6 105 3.00 15.9 
1. Around SP 50.5 10 1.6 95 3.00 16.2 
2. Around SP 50.5 10 1.6 105 2.38 19.3 
3. Around SP 50.5 10 1.6 95 2.38 18.9 
4. Around SP 50.5 10 1.9 105 3.00 20.1 
5. Around SP 50.5 10 1.9 95 3.00 17.9 
6. Around SP 50.5 10 1.9 105 2.38 20.7 
7. Around SP  50.5 10 1.9 95 2.38 23.9 
8. Around SP 50.5 10 1.9 75 3.00 18.3 
9. Around SP 28.0 0 1.6 105 3.00 16.0 
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5.4 Morphology characterisation of alginate particles 
From the previous section (Section 5.2), it can be concluded that sphere-like 
shape is the most preferable form of alginate microbeads. However, alginate 
particles produced by air pressure-assisted energised jetting (Section 5.3) 
are so small that their shape can hardly be defined by an ordinary stereo 
microscope. Therefore, morphology of alginate microbeads were 
characterised by a fluid imaging particle analysis system (Item I008, Table 
2.3) in this study.  
5.4.1 Methods 
5.4.1.1 Preparation of alginate microbeads 
Two samples of alginate microbeads were produced according to the general 
method described in the Section 2.2.1.2 (Chapter 2). Encapsulation was 
conducted with the aid of voltage so the method was an aerodynamically 
assisted energised jetting. Process parameters and their respective values 
are summarised in the Table 5.6. The following items were specific to this 
process: alginate solution (Item S028, Table 2.4), jetting head (Item T019, 
Table 2.2) and cross-linking solution (Item S003, Table 2.4). It is important to 
note that the alginate solvent used in this experiment was PBS (Item C005, 
Table 2.1). PBS is different from DI water (Item C023, Table 2.1) which was 
applied in the previous section (Section 5.3) in terms of conductivity (κ). 
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Table 5.6: Aerodynamically assisted energised jetting – process parameters 
applied in producing alginate particles for the study of their morphology. 
Distancei Volumeii Voltage Flow rate Target 
volume 
Pressure 
x Vxls U Q Vtv P 
mm ml kV cm3 h-1 ml bar 
100 80 10 50 6.0 3.00 
iDistance between the jetting head and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
5.4.1.2 Morphology measurements of alginate microbeads 
The morphology and size of alginate microbeads were studied by the 
imaging-based particle analysis system (Item I008, Table 2.3). Two samples 
were analysed at Fluid Imaging Technologies Inc., (Scarborough, ME, USA). 
Images of individual particle (n = 50,000) were captured, allowing visual 
detection and measurement of multiple shape parameters. These shape 
measurements formed the basis for generation of data shown in the Table 
5.7.  
5.4.2 Results and Discussion 
The shape of the alginate particles made of alginate dissolved in PBS was 
characterised with five parameters: length, width, aspect ratio, circularity, 
convexity and diameter (Table 5.7). Aspect ratio (mean = 0.8, median = 0.8-
0.9) suggests that the shape of alginate particles is fairly close to circular. 
This observation is also supported by the circularity parameter (mean = 0.9, 
median = 0.9 – 1.0). A selection of the FlowCAM® images further supports 
the claim of circularity (Figure 5.6). Maximum convexity score (1.0) indicates 
that, in addition to being circular, particles were smoothly shaped as well.  
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The most fascinating is that the mean diameter (davg) of the particles was 
10µm while the median (dmedian) was only 8 µm. Despite the factum that the 
levels of process parameters (Q, C, x, P and U) were almost identical to the 
levels set at the stationary point, the resulting dmedian was half of the size 
previously achieved at the stationary point (Table 5.5). The main reason for 
this large reduction could be a significant difference in conductivity between 
the two alginate solvents. The indicated conductivity of DI water and PBS 
was κ ≤ 0.05 µS cm-1 and κ = 1.6×104 µS cm-1 respectively. This difference 
suggests that the conductivity probably has a synergistic effect with voltage 
on minimising alginate particle size. Therefore, the question arises as to 
whether the conductivity of alginate solvent could enhance the effect of 
voltage. Study by Jaworek & Sobczyk (2008) points in that direction as it 
demonstrates that droplet size can be decreased by increasing liquid 
conductivity in an electrospraying process.  
One of the reasons for replacing water with PBS in this experiment was to 
simulate the usual situation where biological material to be encapsulated is 
suspended in PBS. It was also assumed that this conductivity change would 
not affect other shape parameters then size. In the previous section we 
discussed optimisation of process variables for generating the smallest 
possible alginate beads from sodium alginate dissolved in DI water. This 
section confirms that particle size can be further decreased by optimising 
variables related to liquid properties as well. However, It can be claimed that 
the obtained mean particle size of 10 µm with 50% of particles smaller than 8 
µm is probably the smallest generated alginate particle size with an extrusion 
method.  
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Table 5.7: Morphology measurements by the imaging-based particle analysis 
system (I008, Table 2.3). Measured diameter is equivalent to the spherical 
diameter (ESD), median particle size is denoted by dmedian and SD stands for 
standard deviation.  
Sample Parameter Diameter 
[µm] 
Length 
[µm] 
Width 
[µm] 
Aspect 
ratio 
Convexity Circularity 
1 
Mean 10 11 8 0.8 1.0 0.9 
SD 9 10 7 0.2 0.1 0.1 
dmedian 8 9 7 0.8 1.0 0.9 
2 
Mean 10 11 8 0.8 1.0 0.9 
SD 7 8 6 0.1 0.1 0.1 
dmedian 8 9 7 0.9 1.0 1.0 
 
 
 
Figure 5.6: A small selection of the 50,000 alginate particles photographed 
by the imaging-based particle analysis system (I008, Table 2.3). The 
particles are small (dmedian = 8 µm) and possess high degree of circularity.  
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Although there is some reports on optimization of encapsulation processes 
for drug release characteristics, there is a very few reports on process 
optimization for the smallest particle size in a controlled experiment 
(Caballero et al. 2014). As a result, it is only possible to compare our particle 
size to the sizes which other researchers usually obtain when using this or 
other encapsulation techniques. For instance, in a study by Arumuganathar 
et al. (2007), the average droplets size observed in the jet formed by the 
same aerodynamically assisted jetting device were between 55 and 87 μm 
(Table 5.8). Reported average alginate particle sizes using methods 
mentioned in the Introduction section and shown in the Table 5.8 vary from 7 
nm to 1000 μm. In addition, Lian et al. (2012) demonstrate that a three-
dimensional microfluidic droplet generator which is rather unconventional 
technique, is able to produce monodisperse alginate microbeads with davg= 
15 µm (SD = 1). In recent years, there has also been increased activity in the 
field of printing technologies where various printing techniques of use for 
development of drug delivery systems have been explored (Kolakovic et al., 
2013). 
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Table 5.8: An overview of alginate encapsulation methods and reported 
particle sizes. Particle diameter is represented by lowercase “d”. Mean 
diameter is designated by “d̅”. Particle size varies from 7 nm – 1000 µm. The 
smallest extruded particle size is 13 µm (Inkjet printing). Abbreviations: BCA - 
Bicinchoninic acid, PASMC cells - pulmonary artery smooth muscle cells, 
FITC - Fluorescein isothiocyanate.  
Encapsulation method Active 
compound 
Particle size Reference 
Coacervation 
None d̅=339.8 nm 
(SD=0.2) Sahu & Prusty 
(2010) BCA  d̅=474 nm 
(SD=19) 
Eugenol d̅=425 µm Shinde & 
Nagarsenker (2011) 
Emulsification/external 
gelation 
Congo red d̅=1 µm Paques et al. (2013) 
None d̅=7 nm (SD=2) Nesamony et al. 
(2012) 
Emulsification/internal 
gelation 
Insulin d̅=60 μm Silva et al. (2006) 
Yeast cells d̅=151 µm 
(SD=77) 
Song et al. (2013) 
Electromagnetic 
laminar jet breakup 
None d<750 μm Del Gaudio et al. 
(2005) 
None d̅=490 µm 
Rodríguez-Rivero et 
al. (2011) 
Coaxial air flow 
induced dripping 
None d̅=1000 μm Ribeiro et al. (2004) 
Maltodextrin 
and trehalose 
400<d̅<1800 μm 
Semyonov et al. 
(2010) 
Electrospraying 
Adenovirus d̅=150 µm Park et al. (2012) 
None d̅=170±100 µm Bugarski et al. 
(1994) 
Inkjet printing  
FITC-labelled 
nanoparticles 
d̅=13 µm 
Iwanaga et al. 
(2013) 
Microfluidic droplet 
generator 
None d̅=15 µm (SD=1) Lian et al. (2012) 
Aerodynamically 
assisted jetting 
PASMC cells 55<d̅<87 µm 
Arumuganathar et al. 
(2007) 
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5.5 Conclusion 
Air pressure-assisted energised jetting was optimised to produce alginate 
beads with median size of 16 µm using DI water as sodium alginate solvent. 
This was done with the conclusion that sodium alginate concentration, 
pressure and distance are significant variables while the opposite is true for 
voltage and flow rate.  
Furthermore, it was demonstrated that the median particle size dropped 
down to 8 µm when alginate solvent was changed to PBS, indicating a 
possible effect of conductivity. In comparison with the particle sizes 
previously reported, we believe that, the size in the current study is probably 
the smallest reported size of alginate beads generated by an extrusion 
method. Therefore it can be concluded that, air pressure-assisted energised 
jetting could be used to produce alginate beads of a size which can readily 
be integrated into the fish feed pellet with a size of davg = 10 mm and 
probably smaller. In addition to associating very well with feed pellet, oral 
delivery systems of the size d ≤ 10 µm are reported to be capable of crossing 
the intestinal epithelial layers as well.  
The practical implication of the results of the porosimetry and SEM image 
analysis is the suggestion that the spherical particles should preferably be at 
least four times smaller than the estimated pore size of a feed pellet. This is 
to ensure easy passage of a greater number of beads through the entry 
holes of the surface pores which appear to be rather irregular.  
From the outcome of the micro-CT scan it can be seen that micro-particles 
with dmedian = 25 µm are readily able to access the pellet with predominant 
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pore sizes of 100 µm. Since the significance of voltage for minimising particle 
size remained unclear, future research should either assess the effect of 
voltage coupled with an increasing conductivity of alginate solution, or should 
assess the effect of liquid properties on particle size at the stationary point.   
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Chapter Six:  Stability of antigens in fish feed 
production process 
 
Fish feed is normally produced by extrusion cooking these days. This 
technology is converting feed mash into a compact, cylindrical form, called 
pellet. This process achieves high degree of starch gelatinisation, denatures 
undesirable enzymes, inactivates some anti-nutritional factors, sterilises and 
expends the finished product. In short, the extrusion cooking is a high 
temperature, high pressure short time process. For this reason, it is an open 
question whether the protein antigens are capable of surviving conditions 
which can be encountered in fish feed production. Survival of both alginate-
encapsulated and free IPNV antigen was assessed in a trial arranged 
according to a 22 factorial design of experiment. Additionally, the specific 
amount of heat added in to the process runs was described by enthalpy. The 
findings suggest that IPNV antigen may survive throughout fish feed 
production machinery at temperature ≤108°C. 
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6.1 Introduction 
Currently, most of the fish feed is produced by extrusion cooking. The 
extrusion cooking is often called the high temperature short time (HTST) 
process (de-Oliveira et al., 2012). This kind of processes tends to maximise 
the beneficial of heating feeds while minimising the detrimental effects.  
According to Morken et al. (2012), an increasing extrusion temperature 
significantly improves digestibility of major nutrients and amino acids in A. 
salmon. However, most biological proteins will lose their higher-order 
structure after being exposed to heat treatment. They first coagulate and then 
become denatured (Eronina et al., 2011; Kilara and Sharkasi, 1986). Loss of 
three-dimensional structure usually produces a loss of biological activity 
(Privalle et al., 2011). This is the major concern when it comes to processing 
protein antigen using the current fish feed manufacturing technology. 
Proteins show a very wide range of extrusion behavior that is probably 
related to large differences in their association properties (Arêas, 1992). 
Interestingly, some proteins like Glutamate dehydrogenase present is certain 
type of prokaryotes (e.g. Pyrococcus furiosus) may be stable at 100°C 
(Pavesi, 2014). Regarding IPN virus, Mortensen et al. (1998) observe 
reduction of IPNV virus already at temperature above 20°C. Tu et al. (1975) 
stats that half-life of IPN virus is 5-6 days at 15°C. According to MacKelvie 
and Desautels (1975), IPNV (107 TCID50 ml
-1) was reduced by 99.9% in the 
first 30 min of exposure to 60° at neutral pH and 0.0001% of the virus was 
still viable after five hours. 
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The main objective of this study was to assess stability of IPNV antigen in the 
current fish feed production process. Additionally, effect of factors 
(encapsulation state and process temperature) on antigen survival were 
studied.  
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6.2 Methods 
6.2.1  Experimental design 
Survival of both encapsulated and free IPNV antigen was assessed through 
both “standard/hot” and "mild" process setup. Basically, only two factors were 
varied, A: encapsulation state (yes/no) and B: feed production conditions 
(hot/mild). Because there were only two levels for each factor we assumed 
that the response (ELISA OD = antigen survival) was approximately linear 
over the range of the factor levels selected. Based on that assumption the 22 
factorial design with both positive and negative control was chosen (Figure 
6.1). All runs that are product of the experimental design are summarised in 
the Table 6.1. 
 
Figure 6.1: Combination of feed production runs in the 22 factorial design 
including two control runs (positive and negative). Two factors were varied: 
encapsulation state of IPNV antigen (yes/no) and feed production conditions 
(hot/mild). Hot conditions are standard conditions which would normally be 
applied for that type of feed. Mild conditions are normally not applied in 
everyday production. 
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Table 6.1: Description of the four runs suggested by the 22 factorial design in 
the antigen stability study. As a result of the 22 factorial design, four runs 
should be performed. Four runs with dry mix containing IPNV antigen in 
either encapsulated or free state and one run (negative control) without any 
antigen. Positive control is unprocessed dry mix with free antigen.  
Run Name Encapsulation 
state 
Process conditions 
1 Unencap-Mild No Mild 
2 Encap-Mild Yes Mild 
3 Unencap-Std No Standard/hot 
4 Encap-Std Yes Standard/hot 
Control negative Ctrl-negative n.a. Standard/hot 
Control positive Ctrl+positive n.a. n.a. 
n.a. – not available 
6.2.2 Preparation of alginate beads loaded with IPNV antigen 
Alginate beads loaded with IPNV antigen were prepared according to the 
common encapsulation method. This method (electrospraying) is described 
in the section 2.2.1.1 (Chapter 2). Process parameters and their respective 
values are summarised in the Table 6.2. The following items were specific to 
this encapsulation process: needle (Item T019, Table 2.2), encapsulation 
formulation (Item S001, Table 2.4) and crosslinking solution (Item S003, 
Table 2.4). Encapsulation formulation (2000 ml) was extruded in small 
portions of 50 ml due to the maximum capacity of the available syringe (Item 
T002, Table 2.2). Later, two batches of alginate beads were formed. Each 
batch was formed of encapsulation formulation corresponding to 1000 ml.   
The resulting alginate beads loaded with IPNV Ag were dried under reduced 
pressure for 48 hours before being weighed and antigen concentration 
calculated. Batch 1 was reduced to 44.82 g resulting in an IPNV antigen 
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concentration of 2.19 ˣ 1010 TCID50 g
-1. Batch 2 weighed 45.77 g which gave 
an IPNV antigen concentration of 2.14 ˣ 1010 TCID50 g
-1. The size of the 
beads was then be reduced to below 150 µm by grinding with mortar and 
pestle followed by sifting. The resulting alginate particles were suspended in 
PBS just before mixing with feed material (dry mix). 
Table 6.2: Electrospraying - process parameters applied in the antigen 
stability study.   
Internal 
diameter 
(needle) 
Flow rate Target 
volume 
Voltage Distancei Volumeii 
ID Q Vtv U x Vxls 
µm cm3 h-1 ml kV mm ml 
1200 200 50 7.0 30 50 
iDistance between the needle tip and the surface of crosslinking solution (x) 
iiVolume of the cross-linking solution (Vxls) 
 
6.2.3 Preparation of dry mixes for feed trial 
For the purpose of feed trial, six dry mixes were prepared. The dry mixes are 
named “Unencap-Mild”,  “Unencap-Std”,  “Encap-Mild”,  “Encap-Std”, “Ctrl-
negative” and “Ctrl+positive”. The dry mixes with free antigen (“Unencap-
Mild” and “Unencap-Std”) were prepared by mixing free suspended IPNV 
antigen (900 g; 109 TCID50 g
-1; Item C003, Table 2.1) with meal mix (89.1 kg; 
C026, Table 2.1). Furthermore, “Encap-Mild” and “Encap-Std” were prepared 
by mixing dry mix (89.0 kg) with encapsulated IPNV antigen suspended in 
PBS (Item C005, Table 2.1). Encapsulated IPNV antigen (42.03 g; Batch 2, 
Section 6.2.2) was suspended in PBS (957.97 g) for “Encap-Mild” dry mix. 
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On the other hand, encapsulated IPNV antigen (41.16 g; Batch 1, Section 
6.2.2) was suspended in PBS (958.84 g) for “Encap-Std” dry mix.  
Dry mix which served as a positive control (Ctrl+positive) was prepared by 
mixing meal mix (99.00 g) with IPNV antigen suspension (1.00 g,109 TCID50 
g-1). This small reference sample was used “as is” and thus it was not 
processed. Dry mix of the feed named “Ctrl-negative” was not added any 
IPNV antigen but it was processed under standard conditions. As a result, 
the final IPNV antigen concentration in all five dry mixes with antigen was 107 
TCID50 g
-1. Compositions of dry mixes are summarised in the Table 6.3. 
 
Table 6.3: Compositions of the dry mixes. Their relation to the extruder runs 
is shown in the Table 6.1 
Feed name 
PBS suspension Free 
IPNV Ag 
susp. [g] 
Meal mix 
[kg] 
Dry mix  
[kg] 
PBS  
[g] 
 Encapsulated 
IPNV Ag [g] 
Unencap-Mild 0 
957,97 
0 
 0 900 89.1 90 
Encap-Mild  42.03 0 89 90 
Unencap-Std  0 900 89.1 90 
Encap-Std 958,84  41.16 0 89 90 
Ctrl-negative 0  0 0 100 100 
Ctrl+positive 0  0 1.00 9.9ˣ10-4 1.0ˣ10-3 
 
 
6.2.4  Feed trial   
Feed trial was performed according to the method described in the section 
2.2.3 (Chapter 2) at Technology Centre of EWOS Innovation AS (Dirdal, 
Norway). All produced feeds were 5 mm in size. Standard runs/feeds (Run 3 
and 4) were produced in a production process which was defined as hot. On 
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the other hand, the “mild” runs (Run 1 and 2) were performed under more 
moderate conditions. All the runs were compared to the Control run (Ctrl-
negative, Table 6.1) which was conducted under standard conditions. In 
addition to some other parameters, these runs were characterised by 
temperature and pressure measured in different compartments of the 
process (Table 6.4, 6.5 and 6.6). Temperature and pressure were measured 
at eight different places in the extrusion process. The first measurement point 
was at the outlet of the preconditioner. The following seven measurement 
points were distributed over the seven zones in the extruder barrel. The last 
zone which was called “spacer” is positioned at the end of an extruder barrel 
(Table 6.5).  
In order to describe the process in terms of applied heat per kilogram of the 
feed material, the specific enthalpy of the process (liquid part) was 
calculated. The calculation was performed using the Equation 6.1 and 6.2. 
Specific heat of the water and “dry mix” mixture was unknown. Since the 
same feed recipe was used for all five runs, the change of enthalpy of water 
was applied in calculating the ratio between experimental runs and the 
control run.   
Equation 6.1: Change in enthalpy of a system (Δh) 
∆ℎ =  ∆𝑢 + 𝑣 ∆𝑝 
h – specific enthalpy of a system [kJ kg-1] 
u – specific internal energy of a system [kJ kg-1] 
v – specific volume [l kg-1]. This is a tabulated value. 
p – absolute pressure [MPa] 
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Equation 6.2: Change in internal energy of a system (Δu) 
∆𝑢 = 𝑐 ∆𝑇 
u – specific internal energy of a system [kJ kg-1] 
T – temperature [K] 
c – specific heat of an incompressible substance [kJ kg-1 K-1]. It is equal to 
specific heat capacity (Cp) in this equation. This is a tabulated value. 
 
Table 6.4: An overview of the process conditions in the preconditioner 
Preconditioner 
 Parameters Unit Run 1 Run 2 Run 3 Run 4 Control 
Meal 
Feed rate (dry 
mix) 
kg/h 106.00 104.00 106.00 108.00 104.00 
Temperature (dry 
mix) 
°C 22.20 24.70 23.09 25.20 26.00 
Water 
Water flow rate kg/h 21.20 23.00 20.00 21.00 20.80 
Water flow rate 
(dry mixture) 
% 20.06 22.02 18.86 19.55 19.98 
Water 
temperature 
°C 70.40 70.20 70.03 70.10 70.40 
Steam 
Steam flow rate  kg/h 2.60 2.30 12.60 11.60 11.60 
Steam flow rate 
(dry mixture) 
% 2.45 2.18 11.88 10.80 11.12 
Total 
Total liquid 
addition 
kg/h 60.00 60.00 68.00 67.00 67.00 
Total liquid 
addition  
% 56.60 57.30 64.10 62.20 64.20 
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Table 6.5: An overview of the process conditions in the extruder 
Extruder 
 Parameters Unit Run 1 Run 2 Run 3 Run 4 Control 
E
n
g
in
e
 
Extruder screw 
speed 
rpm 309 309 417 368 407 
Extruder motor 
load 
kW 11.30 11.80 9.10 8.20 8.60 
Current A 16.30 17,10 13.20 11.80 12.50 
Specific 
mechanical 
energy (SME) 
kW 
ton-1 
h-1 
83.04 88.21 63.98 56.46 60.63 
T
e
m
p
e
ra
tu
re
 
Zone 1 (precond. 
outlet temp.) 
°C 51.20 54.00 89.90 90.20 90.30 
Zone 2 °C 33.20 36.70 76.40 71.50 88.00 
Zone 3 °C 38.30 38.90 86.80 82.70 94.50 
Zone 4 °C 41.40 43.30 108.70 104.00 114.40 
Zone 5 °C 54.30 55.10 95.80 94.60 101.80 
Zone 6 °C 36.50 38.40 90.10 88.00 98.70 
Zone 7 °C 27.80 28.40 92.80 88.40 105.10 
Spacer  °C 77.10 81.80 94.10 91.10 87.10 
P
re
s
s
u
re
 (
g
a
u
g
e
) 
Zone 1 (precond. 
outlet temp.) 
bar 0 0 0 0 0 
Zone 2 bar 0.40 0.40 0.60 0.50 0.70 
Zone 3 bar 4.70 3.60 3.60 3.70 3.70 
Zone 4 bar 14,70 12,90 9,40 9,10 9.10 
Zone 5 bar 0.00 0.00 0.10 0.20 0.20 
Zone 6 bar 0.52 0.00 1.93 1.51 2.21 
Zone 7 bar 13.11 15.70 10.48 10.96 8.40 
spacer bar 17.88 22.94 19.36 18.72 14.42 
M
a
s
s
 
fl
o
w
 
Total die area mm2 34.02 34.02 34.02 34.02 34.02 
Total cylinder 
area 
mm2 250.70 250.70 250.70 250.70 250.70 
Extruder 
discharge rate 
kg/h 164.90 164.07 173.81 174.41 171.30 
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Table 6.6: An overview of the process conditions in the dryer 
Dryer 
 Parameters Unit Run 1 Run 2 Run 3 Run 4 Control 
T
e
m
p
. 
Zone 1 °C 78.10 76.10 75.00 77.80 70.20 
Zone 2 °C 75.30 74.60 75.00 75.00 64.50 
Zone 3 °C 74.10 75.50 75.00 75.20 60.10 
  
6.2.5 Sampling 
Sampling was performed at five different stages in the production process: 
mixing (dry mix, dm), conditioning (wet mix, wm), extrusion (extrudate, ext), 
drying (base pellet, bp) and coating (final feed, ff). It was taken five samples 
with 10 seconds time intervals at each point of production stage. 
6.2.6 Sample preparation 
Initially, pulverised feed sample (2.00 g) was dispersed in hexane (6.0 ml). 
Afterwards, this dispersion was span down (4000 rpm for 10 min) and then 
supernatant was transferred to 10 ml separation funnel. The formed 
precipitate was saved for later use. Subsequently, supernatant (hexane 
solution) was washed two times with saturated sodium bicarbonate (1 ml, 
Item S005, Table 2.4). The aqueous fraction was collected and then used to 
disperse the spared precipitate. The resulting dispersion was left overnight at 
4°C. The following day, dichloromethane (4.0 ml) was added and the sample 
container was shaken thoroughly. Thereafter, the content was span down 
(4000 rpm for 10 min) yielding supernatant consisting of two fractions 
(organic on the bottom and aqueous on the top). This new supernatant was 
transferred to a 10 ml separation funnel and combined with hexane (3.0 ml). 
This operation changed the order of the fractions.  
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Finally, the aqueous fraction was collected and stored at 4°C for the later 
ELISA assay. ELISA was performed as previously described by 
Munang’andu et al. (2012) with minor modifications at Norwegian School of 
Veterinary Science (Oslo, Norway). Statistical analysis was conducted 
according to the method described in the Section (2.2.6.4). 
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6.3 Results and Discussion 
6.3.1 Experimental conditions of the feed production runs 
From the results in the Table 6.7, it can be seen that the mean enthalpy of 
the first two runs is double as low as the enthalpy of the control run. 
Furthermore, there was no statistically significant difference between the 
standard runs and the control run at the 5% significance level. This also 
indicates that the enthalpy of the mild runs is approximately 50% lower than 
the enthalpy of the standard runs. In conclusion, the amount of heat added in 
the mild runs was only half of the amount of heat added per kilogram of feed 
material in the standard runs. This is also graphically illustrated in the Figure 
6.2.  
The enthalpy calculations were based only on the properties of water in the 
system. It was justified by the fact that the feed material was of constant 
composition. In addition, the changes in specific enthalpy of the experimental 
runs were expressed as the percent ratio to the specific enthalpy of the 
control run.   
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Table 6.7: Mean enthalpies with their upper and lower levels of the 95% 
confidence intervals in the antigen stability study. The mean values were 
calculated out of eight different measurements (preconditioner, zone 2-7 and 
spacer; Table 6.5). The measured quantities were gauge pressure and 
temperature. Calculations were performed using the Equations 6.1 and 6.2. 
The mean values of Runs 1-4 were compared to the mean value of the 
control run in the last column.  
Run Upper level Lower level Mean Enthalpy 
(kJ/kg) 
Ratio to 
Control 
(%) 
Controli, ii 446 370 408 100 
Run 1iii 244 136 190 47 
Run 2iii 256 137 196 48 
Run 3i 419 352 386 94 
Run 4i 411 342 377 92 
iStandard (hot) process conditions 
iiControl run is the same run as the Ctrl-negative (Table 6.1) 
iiiMild process conditions 
 
 
Figure 6.2: Average enthalpies of the four extruder runs along with one 
control run Enthalpies of the Runs 1 and 2 are significantly lower than the 
enthalpies of the Runs 3 and 4 and the control run at 5% significance level. It 
suggest that, the amount of heat applied per kilogram of feed material is 
approximately 50% lower in the first two runs (mild runs) than in the other 
runs performed under standard conditions (Table 6.7). Error bars represent 
95% confidence intervals.  
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6.3.2 Survival of the IPNV antigen throughout fish feed production 
process 
From the Figure 6.3, it can be concluded that IPNV was detected in all four 
groups of the final feed samples. This observation suggests that IPNV 
antigen may survive throughout fish feed production process conducted at 
temperature ≤109°C. There is also an indication for both un-encapsulated 
and encapsulated IPNV antigen surviving throughout extrusion, drying and 
infusion coating process. It suggest that IPN virus is relatively withstand 
temperature around 100°C in a short period of time (15 s).This observation is 
also consistent with the investigation by Dixon et al. (2012) where IPN virus 
was not completely inactivated within one hour at 60°C. 
 Low response of encapsulated antigen (Encap-Std and Encap-Mild) in both 
dry and wet mix could be due to ineffective antigen extraction method. In all, 
it seems easier to extract antigen from the samples after the extrusion. It 
could be explained by additional effect of moisture, temperature and shear 
force on dissolution of alginate matrix. However, the maximum achieved 
temperature in the standard extrusion process is much lower than the 
operating extrusion temperature (>150°C) at the factories. Due to this 
difference, capability of IPNV antigen to retain its viability and integrity could 
be assessed throughout more extreme process conditions. 
From the results it can be seen that the encapsulation has rather negative 
effect on antigen survival at all stages of production process except form the 
final feed where it is insignificant (Figure 6.4). This could also be due to an 
ineffective antigen extraction method. Dissolution of alginate beads requires 
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alkaline conditions but too high pH may hydrolyse antigen. Another challenge 
is the high buffer capacity of feed material which may in turn consume 
hydroxide anions needed for dissolution of alginate matrix. 
Responses of samples 1 to 5 were decreasing towards the higher sample 
number on 96-well plate. We tried to relate position of the samples on ELISA 
plate to this variability but it proved to be unsupported by data.  
 
Figure 6.3:  Observed responses by treatments at different steps in the feed 
production process. dm – dry mix (initial meal mix), wm – wet mix (after 
preconditioning), ext – extrudate (after extruding), bp – base pellet (after 
drying), ff – final feed (after applying oil), response – optical density. 
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Figure 6.4: Estimated coefficients for process factors, encapsulation factors 
and their interaction. The coefficients are shown in the same order on the 
horizontal axes. The actual effect is twice the coefficients because coding [-1, 
+1] was used. All coefficients are on the logarithmic scale because 
logarithmic transformation was applied before analysis. 
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Chapter Seven:General Discussion and Conclusion 
This chapter summarises major findings of the thesis and presents an overall 
conclusion. The conclusion was drawn on the basis of all work carried out. 
This work includes: in vitro trials (dissolutions tests), in vivo trial (A. salmon), 
in situ trials (fish feed production trial) and several benchtop experiments 
(optimisation of encapsulation process).  A great number of samples were 
taken in these trials. In sample analysis, large variety of methods was 
applied. Data were processed by diverse statistical software generating large 
amount of results.  
The results suggest that protein antigens can be entrapped into alginate 
beads that are sufficiently small for being effectively incorporated into feed 
pellets. The antigen will most likely be released in the mid and distal 
compartment of A. salmon intestine. The results also indicate that the antigen 
can be absorbed in those compartments. Furthermore, there is evidence to 
suggest that the absorbed antigen is able to induce specific immune 
response in A. salmon.   
According to the results of study on antigen stability in fish feed production 
process, we could purpose pre-extrusional addition of IPNV antigen to be 
considered under mild process conditions.  
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7.1 Major findings 
7.1.1 Very fine alginate beads 
Optimisation of encapsulation process air pressure-assisted energised 
jetting) resulted in very fine alginate beads (dmedian= 8 µm). In comparison to 
previous studies the current results were amongst the smallest reported sizes 
of alginate beads generated by an extrusion method (Table 5.8). The 
optimised encapsulation process could be used to produce alginate particles 
which can readily be integrated into the feed pellet with a size of 10 mm and 
probably smaller. In short, the achieved mean particle size of 10 µm with a 
half of the particles smaller than 8 µm meets the objectives of producing 
suitably sized alginate beads for effective association with feed pellet. Finally, 
it can be said that the outcome of this study improves understanding of the 
issues regarding incorporation of delivery systems into fish feed in the current 
manufacturing process. 
7.1.2 A new dissolution test strategy 
This study developed a new dissolution test strategy with respect to chemical 
properties of alginate and physiological conditions for A. salmon. The new 
strategy is based on one single dissolution test combining pH 3.0 for 15 min 
with pH 8.0 for 50 min performed at two different  temperatures (4°C and 
18°C). This is in contrast to common practice were release of an active 
pharmaceutical ingredient from a cross-linked alginate is assessed in a dual 
dissolution test. The dual dissolution test applies one acidic dissolution 
medium (pH 1 – 2) and another nearly neutral medium (pH 6.8 – 7.4). The 
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test temperature, which is adapted to humans, is normally maintained 
constant at 37°C (Azarmi et al., 2007). 
We demonstrated that the results generated in the redesigned dissolution 
test are in strong correlation with the results produced in the in vivo study. 
This is promising considering the previously reported difficulties experienced 
in dissolution testing of extended release products (Zahirul and Khan, 1996).  
Release from ethylenediammonium alginate was both pH- and temperature-
independent. Furthermore, encapsulation efficiency of protein antigens in the 
ethylenediammonium alginate matrix is very high (> 97%). In conclusion, 
ethylenediammonium alginate proved to be an excellent oral delivery system 
for macromolecular drugs to A. salmon. 
7.1.3 Oral vaccination strategy 
On the whole, this study shed light on the opportunities and issues related to 
i.p. priming/oral boost strategy involving an inactivated IPN virus. Oral 
delivery of the encapsulated antigens elicited the immune response in A. 
salmon in the first oral boost period. Although the OD values (ELISA) of the 
groups fed with oral boost feeds rose from the 1.OB to the 2.OB, there was 
no significant difference between them and control feed. According to qPCR 
results, this inefficiency was most likely caused by the immune tolerance 
which is a common issue in immunising via oral route (Jump and Levine, 
2004; Siewert et al., 2008; Weiner et al., 2011). 
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7.1.4 Survival of IPNV antigen through fish feed production 
From the trial related to stability of IPNV antigen in fish feed production 
process, it can be concluded that IPNV was present in all four groups of the 
samples. This suggests that IPNV antigen may survive throughout fish feed 
production process conducted at temperature ≤108°C. Survival of IPNV 
antigen at elevated temperatures was previously reported as well but this is 
most likely the harshest tested conditions so far (MacKelvie and Desautels, 
1975). Although the temperatures below 108°C are far lower than what 
commercial reality is, they are not unrealistic. There is also an indication for 
both un-encapsulated and encapsulated IPNV antigen surviving throughout 
extrusion, drying and infusion coating process. 
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7.2 Future directions 
Additional studies are required to optimise the alginate formulations further 
as well as to characterise release profiles of the relevant antigens from 
alginate matrices both in vitro and in vivo. Since the dose-response of the 
oral IPNV Ag in A. salmon is very little known, additional research should 
address this issue. There are also questions regarding duration of an oral 
IPNV antigen dose action which could be answered in a future study. Since 
the significance of voltage for minimising particle size remained unclear, 
future research should either assess the effect of voltage coupled with an 
increasing conductivity of alginate solution, or should assess the effect of 
liquid properties on particle size at stationary point. In future studies, efficacy 
of alginate-encapsulated antigens could be tested in a challenge trial. In 
addition to immunohistochemistry tools and ELISA, DNA microarray 
techniques and multiplex PCR could be used to measure the expression 
levels of relevant genes. 
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7.3 General conclusion 
According to the results in this study, ethylenediammonium alginate proved 
superior to calcium alginate in the encapsulation efficiency test. On the other 
hand, calcium alginate in return performed much better in immunising the 
fish. This was observed in the second oral boost interval where IPNV antigen 
entrapped in calcium alginate matrix demonstrated the ability to boost 
immune response. However, multi-boosting with high antigen doses was not 
advantageous for immune response. This inefficiency was most likely caused 
by the immune tolerance which is a common issue in immunising via oral 
route.  
In short, the findings of the present study can be summarised as follows: 1) 
Parenteral prime with the combination vaccine followed by an oral boost with 
encapsulated antigens results in a the augmentation of both the systemic and 
mucosal immune responses; 2) Mucosal (gut) immunity is not primed by 
parenteral but by oral administration of antigens and 3) Oral prime and 
subsequent boost with encapsulated antigens results in augmentation of 
mucosal immune responses. 
Furthermore, the findings in this study suggest that there is a delay in uptake 
of the encapsulated antigens compared to the un-encapsulated ones. This is 
logical given that antigens are less readily available when encapsulated than 
in solution.  
In conclusion, it can be said that differences do exist between differently 
cross-linked alginate matrices. Differences between the 
ethylenediammonium and calcium alginate are evident with respect to 
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dissolution rate at low temperatures. In order to recognise these 
characteristics of alginate beads, a new dissolution test strategy is 
developed. This new strategy makes dissolution test highly representative for 
gastrointestinal conditions found in fish with stomach. As a consequence, the 
results generated by the redesigned dissolution test are in strong correlation 
with the results obtained from the present in vivo study.  
On the whole, ethylenediammonium alginate is an excellent delivery system 
for macromolecular drug to ectothermic animal like salmon. There is 
evidence to suggest that this delivery system is temperature-independent 
within the temperature range of salmon’s life habitat. The practical implication 
of the results of the present study is that the amount of drug delivered is 
irrespective of the environmental temperature when using this novel oral 
delivery system. 
In addition, our data indicate that some IPNV antigen may survive through 
the current fish feed production process. Given this, it may be concluded that 
this antigen is a highly robust. Other antigen candidates for oral vaccination 
may be less robust. These and then can be delivered through the vacuum 
coating system. Because of the progress we have made with encapsulation 
technology in this study, vacuum infusion coating with alginate-encapsulated 
antigens can be performed with high yield. It is a result of optimising air 
pressure-assisted energised jetting to produce alginate beads with median 
size of 16 µm using DI water as alginate solvent. Sodium alginate 
concentration, pressure and distance were significant production variables 
whilst voltage and flow rate exerted little effect upon particle size.  
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However, it has been demonstrated that the median particle size dropped 
down to 8 µm when alginate solvent was changed to PBS, indicating a 
possible effect of conductivity. In comparison to previous studies the current 
results were amongst the smallest reported sizes of alginate beads 
generated by an extrusion method. Therefore, it can be concluded that, air 
pressure-assisted energised jetting could be used to produce alginate beads 
of a size which can readily be integrated into the fish feed pellet with a size of 
davg = 10 mm and smaller. In addition to associating very well within the feed 
pellet, oral delivery systems of the size d ≤ 10 µm are reported to be capable 
of crossing the intestinal epithelial layers.  
The results of the porosimetry and SEM image analysis suggest that the 
spherical particles should be at least four times smaller than the estimated 
pore size of a feed pellet. This is to ensure easy passage of a greater 
number of beads through the entry holes of the surface pores which appear 
to be rather irregular.  
From the outcome of the micro-CT scan it can be seen that micro-particles 
with dmedian = 25 µm are readily able to access the pellet with predominant 
pore sizes of 100 µm.  
In conclusion it can be said that protein antigens can be successfully 
delivered to A. salmon using the encapsulation technology developed in this 
study.  
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